Molecular and cellular studies of zoledronic acid : a potent inhibitor of multiple myeloma-induced osteolysis by Pan, Beiqing
Molecular and Cellular Studies of Zoledronic




Matthew Roberts Laboratory, Hanson Institute,
Institute of Medical and Veterinary Science
Department of Medicine, The University of Adelaide,
South Australia
A thesis submitted to the University of Adelaide





I.2 BONE REMODELLING 5










1.3.4 Parathyroid Hormone Related Protein.'........
1.3.5 RANKL/ ODF/TRANCE/OPGL: the Ligand
1.3.6 RANK: the Receptor..
7.3.1 OPG/OCIF: the DecoY RecePtor
1.3.8 The Relationship betweenRANKL, RANK and OPG inMM'........
1.3.9 The Relationship between RANKL/RANIIOPG and OAFs Secreted by MM
BISPHOSPHONATES ........161.4
1.4.1 General Properties.. t6
The Effect of Bisphosphonates on Osteoclasts'
The Effect of Bisphosphonates on Osteoblasts .
The Effect of Bisphosphonates on Myeloma Cells
The Effect of Bisphosphonates on Cell Adhesion.."'. ..24
,,26Zoledronic Acid.
1.5 HYPOTHESES.... 28
1.6 AIMS AND EXPERIMENTAL RATIONALE OF'THIS PROJECT 28
I.7 SIGNIF'ICANCEOT'PROJECT 29
CHAPTER 2 MATERIALS AND METHODS 30











2.1.2 2-Mercaptoethanol(2-ME)........... . ..'..'.'.'.".



















Fluorometric Caspase 3 Assay Buffer..........
Blocking Buffer for Flow Cytomehic Analysis
Flow Cytometry Fixative (FACS Fix).................
Double-Strength Iscove's Modified Dulbecco's Medium (2 xIMDM) .......
l\%(w lv) Bovine Serum Albumin (BSA).......
Dulbecco's Modifred Eagles Medium- I 0 (DMEM- 1 0)
Alpha Minimal Essential Medium-l0 (cr-MEM-lO) for Osteoblastlike Cell Culture .
Alpha Minimal Essential Medium-l0 (cr-MEM-l0) for Myeloma Cell Culture.'...'."'
CELL CTILTURE
Human Myeloma Cell Lines
Murine Cytokine-Dependent Myeloid Cell Line, FDC-Pl
Normal Human Bone Cells (NHBC)...
Normal Osteoblast Donor (NOD) .......
Enzymatic Digestion of Osteoblastlike Cell Cultures
Cryopreservation of Cells..
Thawing Cryopreserved Samples....
EF'F'ECT OX'ZOLEDRONIC ACID ON THE CELL GROWTH
Reagents Used in This Study.............
Cell Proliferation Assay
Time Course Experiment of Zoledronic Acid on Myeloma Cells..........
Analysis of Nuclear Morphology
Agarose Gel Analysis of Intranucleosomal Fragmentation....'.....'...'..
Cell Cycle Analysis......
Caspase Activity Assay
DETECTION OF'GENE EXPRESSION IN CELLS...... ..........38
TRIzolrM Isolation of Total RNA........
Determination of RNA Concentration. .39
Reverse Transcription (RT) Polyrnerase Chain Reaction (PCR) Amplification of DNA............39























2.5 IMMUNOF'LUORESCENCE STAINING AND FLOW CYTOMETRY.....................40
2.5.1 One-Colour Flow Cytometric Analysis
2.5.2 Intracellular AntigenDetection.....
Two-Colour Flow Cytometric Analysis
Analysis of Cell Cycling Status of STRO- 1* Cells byKi-67 Reactivity....
Three-Colour Flow Cytometric Analysis
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Labelling of Cells
Fluorescence-Activated Cell Sorting (FACS)



















Calciene Labelling of Non-Adherent Cells.




2.7 IN VITRO MINERALISATION AND MEASIIREMENT OF'CALCIUM
PHOSPHATE PRODUCTION...... .44
2.8 STATISTICAL ANALYSIS.......... .........45
CHAPTER 3 MYELOMA CELL LINES EXHISIT INHIBITION OF CELL
PROLIFERATION AND ENHANCED CELL DEATH IN
11
RESPONSE TO ZOLEDRONIC ACID 46
3.1 INTRODUCTION 46
3.2 RESULTS
3.2.1 Multiple Myeloma Cell Lines Display Differential Sensitivity to Zoledronic Acid ...................48
3.2.2 Zoledronic Acid Induces Cell Death by Inhibiting Cell Cycle Progression in RPMI 8226 ........48
3.2.3 Zoledronic Acid Does not Increase Caspase Activity
3.2.4 Gene Expression of Myeloma Cells Treated with Zoledronic Acid.
.49
.50
3.2.5 Zoledronic Acid Upregulates the Cell Surface Molecule Expression on the Myeloma
Cell Lines
3.2.6 Differential Sensitivity of Myeloma Cell Lines to TRAIL-Mediated Cell Death.......................51
3.2.1 TRAIL Enhanced the Effect of Zoledronic Acid When Used in Combination on the
Myeloma Cells ....................
3.2.8 The Effect of Zoledronic Acid on the Expression of TRAIL and TRAIL Receptors
on Myeloma Cell Lines.......... .52
CHAPTER 4 IN VITRO STUDIES EXAMINING THE EFFECT OF THE NITROGEN
CONTAINING BISPHOSPHONATE, ZOLEDRONIC ACID, ON
OSTEOBLAST-LIKE CELLS ..................64
4.2 RESULTS 66
The Effect of Zoledronic Acid on Osteoblast-Like Cell Proliferation and Survival ...................66
Zoledronic Acid Mediates the Differentiation of Osteoblast-Like Cells... ".'...'.'.'.67
STRO-1b'ishtOsteoblast-Like Cells Proliferate More Rapidly and Are More Sensitive
to Zoledronic Acid..
4.2.4 Zoledronic Acid Regulates the Expression of Osteoclast and Osteoblast-Related Genes ...........69
4.2.5 The Up Regulation in Gene Expression Mediated by Zoledronic Acid Was Not Related
to the Proportional Alteration of Osteoblast-Like Cell Subpopulations
Zoledronic Acid Decreased Protein Expression on the Osteoblast-Like Cells....'..."'..
Zoledronic Acid Upregulated TACE Gene Expression..............
TNF-cr and IL-1p Augmented STRO-I*/ALP* Subpopulation and Increased
Cell-Dividing Potential of Osteoblast-Like Cells

















This thesis contains no material that has been accepted for the award of any other degree or
diploma in any other university. To the best of my knowledge and belief, this thesis contains
no material previously published or written by another person, except where due reference has
been made in the text.
I give consent to this copy of my thesis, when deposited in the University Library, being




I would firstly like to thank my great supervisors. To Dr Andrew Zannettino, thank you for your
patience, kindness, enthusiasm and wisdom. Through your endless help, which was available at
anytime, you guided me gently to form scientific thoughts and equipped me with essential techniques.
Thank you for polishing my English and the meticulous scrutiny of my thesis. To Professor Luen Bik
To, I owe special gratitude for your kindness, warmth and invaluable encouragement. You have made
me feel like I am at home, and you have enabled me enjoy the life in Adelaide very much. I also wish
to thank you both for your generous support. To my mentor Professor Maofang Lin in China, thank
you for your discreet instructions over the past years of which I have always benefited.
I especially wish to thank to my best friend Ms Amanda Famrgia. Thanks for your consideration and
passion. I have a greattime working with you and enjoy our daily funny conversations. Thank you, my
language consultant and technical guider. I am very grateful to Ms Andrea Dewar, thanks for your
friendship and teaching me some special words. Thanks to both of you for energising me by kindly
teasing me. Thanks for your superb job of proof reading my manuscripts for which I am deeply
indebted. The friendship of my friends has been a perpetual source of encouragement. Thank you, Mr
Yan Hong, Ms Qinglan Wang, Dr Chunni Zhu,Dr Ping Gao, Dr Zhao Cai, Ms Qi Zhou and Ms Yang
Zhang...... I am also thankful to all those who have helped me in the Division of Haematology and
Department of Orthopaedics and Trauma: Mrs Kate Harrison, Mrs Panagiota Kostakis, Dr Petranel
Ferrao, Ms Silvana Niutta, Dr Sue lH:einzel, Mr Sam Randles, Dr Pak Reynolds, Mr Steve Bouralexis,
Ms Agatha Labrinidis, Ms Katie Welldon, Mrs Shelley Hay...... To all of them I am most grateful,
I greatly appreciate the insightful comments from Associate Professor David M Findlay, Dr Andreas
Evdokiou, Dr Gerald J Atkins and Dr Stan Gronthos. I would also like to acknowledge technical
assistance of Mr Michael Haywood for his help with the use of the atomic absorption
spectrophotometer. I also wish to thank }/lrs Zara Zanneltino, thank you for your fantastic job of proof
reading my thesis.
Finally, I wish to thank my family for their eternal love and support. You gave me many joyful
moments on the phone and I miss you very much. To mum and dad, thank you for everything you
have done for me. Thank you my dear brother and sister-in-law for your financial support, I am
eternally grateful. My dear cute little niece, your naivety and intelligence always make me laugh. I
miss you very much and thank you for giving me the sunshine in my life.
ABSTRACT
Myelomatosis (MM) is an incurable B cell malignancy, characterised by the presence of
osteolytic bone lesions, a major cause of morbidity and mortality. This study investigated the
effect of zoledronic acid, a potent nitrogen-containing bisphosphonate (BP), on myeloma cells
and osteoblasts-like cells to establish the molecular and cellular mechanism responsible for
the clinical effectiveness of BPs in the treatment of patients with MM.
These studies indicate that zoledronic acid induces apoptotic and non-apoptotic cell death in
myeloma cell lines bV (1) inducing S phase arrest in a time and dose dependent manner, (2)
inhibiting the mevalonate pathway, and (3) up regulating TRAIL expression and uncoupling
the regulated expression of TRAIL death and decoy receptors.
Using an established model of osteoblast differentiation, zoledronic acid was found to
increase the number of mature osteoblast/osteocyte-like cells, with a concomitant decrease in
the number of stromal precursor cells. In accordance with these findings, zoledronic acid was
found to enhance the osteoblast-like cells' ability to form a mineralised bone matrix, when
used at concentrations in the range of 5pM and 25 pM. Therefore, we conclude that
zoledronic acid mediates the differentiation of osteoblasts-like cells, which accounts for the
enhanced bone formation. Zoledronic acid also upregulates the gene expression of IL-l8 and
TNF-cr, which serve to increase the number of osteoprogenitors cells which in tum can
respond to zoledronic acid. Furthermore, zoledronic acid was found to decrease the
expression of membrane-associated RANKL by increasing TACE expression, a
metalloproteinase disintegrin. In conclusion, the studies presented herein show that zoledronic
acid enhances bone formation by directly acling on osteoblasts.
In conclusion, work reported in this thesis suggests that myeloma cell death, and proliferation
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Myelomatosis (multiple myeloma, MM) is an incurable B cell malignancy, chatacterised by
the presence of a monoclonal population of end-stage B cells (plasma cells), a monoclonal
immunoglobulin (Ig) protein (M-, or para-protein) and "punched out" lytic bone lesions.
Osteolytic bone destruction, a major cause of morbidity and mortality, is a striking clinical
feature for approximately 80% of patients with MM. It is generally accepted that the
osteolysis is related to the accumulation of the myeloma cell clone within the bone marrow
(BM), in close vicinity to the bone trabeculae. Although current evidence suggests that
myeloma cells cannot directly resorb bone, they produce a variety of osteoclast-activating
factors (OAFs) which lead to the recruitment and activation of osteoclasts (OC) (Michigami
et al., 2000 Roodman, 1997). The normal equilibrium between bone formation by
osteoblasts (OB), and bone resorption by multinucleated OC, is therefore disrupted leading to
localised bone loss (Hjorth-Hansen et al., 1999). It has been known for many years that
cultures of human myeloma cells in vitro prodttce several OAFs, including tumour necrosis
factor-cr (TNF-cr), Tl.tF-P (lymphotoxin), interleukin-lp (L-18), and IL-6, macrophage-
colony stimulating factor (M-CSF) and parathyroid hormone related protein (PTHTP) (Costes
et al., 1998; Filella et al., 1996; Pfeilschifter et al., 1989). However, most of the studies
identifying factors produced by myeloma cells in vivo are inconclusive due to the presence of
other contaminating cell t1pes, including stromal cells and macrophages. In the last three
years, a newly identified clokine system has provided us with a greatly improved
understanding of bone remodelling physiology. This system includes receptor activator of
nuclear factor-rcB ligand (RANKL), which is a member of the tumour necrosis factor (TNF)
ligand family, its receptor, termed receptor activator of nuclear factor-rB (RANK), and its
soluble decoy receptor, osteoprotegerin (OPG). Studies by our group (Famrgia et al',2002)
and others (Croucher et a1.,2001; Giuliani et a1.,2001; Hofbauer et a1.,2001; Sezer et al.,
2002) have demonstrated that this system plays a vety important role in myeloma-induced
osteolysis.
Understanding the molecular mechanisms, by which MM cells induce osteolysis is essential
for the development of new drugs to cure bone disease. To this end, the discovery of
bisphosphonates (BPs), which are stable analogues of naturally occurring pyrophosphate-
containing compounds, represents a significant milestone in the history of treatment of bone
disease. BPs inhibit resorption of bone predominantly through an effect on OC, and have
provided us with an expectation of improved treatment for the skeletal complications of
myeloma. Several double blind, placebo-controlled randomised trials have demonstrated that
BPs reduce the skeletal complications of multiple myeloma, decrease the associated
morbidity (Berenson et al., 1996; McCloskey et al., 1998) and improve the survival
outcomes in some patients (Berenson et al., 1998). The underlying mechanisms, by which
these compounds act on the tumour cells and OB, require further elucidation.
In this project, we investigated the role of the most potent BP, zoledronic acid (formerly
referred to as zoledronate), on myeloma cells and OB, to clarify the underlying molecular
mechanism of clinical effectiveness.
1.1 MYELOMATOSIS
1.1.1 Generøl Description
Myelomatosis is a differentiated B cell neoplasm characterised by the malignant clonal
expansion of plasma cells that accumulate in the BM. It accounts for 2.9Yo of all
malignancies in black people and 1 .0o/o in white people. The median age of diagnosis is 69
and 7l years for males and females, respectively. The diagnosis of MM depends on the
demonstration of increased numbers of marrow plasma cells (>10%) which present as
atlpical and immature forms, the presence of monoclonal paraprotein (M-protein, >3/d1) in
serum, Bence-Jones protein in urine, and osteolytic skeletal lesions. Extensive bone disease is
a hallmark of MM and contributes to most of the debilitating morbidity and mortality
associated with this disease (Roodman, 1995). Multiple myeloma induced osteolytic bone
lesions or osteoporosis cause intractable bone pain and other distressing symptoms such as
pathological fractures after trivial injury, spinal cord compression, and disturbance in calcium
homeostasis. At diagnosis, approximately 50o/" of patients have vertebral fractures, and
approximately 30%o have non-vertebral fractures (Lahtinen et al., 1992). Valuable adjunct
therapies for bony complications in addition to chemotherapy and BM transplantation, are
therefore necessary for improving the quality of life for MM patients.
1"1"2 Myeloma ønd Drug Resistance
Despite initial responses to chemotherapy, myeloma patients ultimately develop drug
resistance and become uffesponsive to a wide spectrum of anti-cancer agents. This
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phenomenon is termed multi-drug resistance (MDR). MDR presents a major obstacle to
curing myeloma, and understanding factors that determine drug response and the
development of drug resistance aÍe essential in developing means of preventing or
overcoming this problem (Dalton, 1997).
The development of intrinsic cellular resistance to front-line chemotherapeutic drugs, such as
melphalan (an alkylating agent) and doxorubicin (an anthracycline), is a major factor
responsible for treatment failure of MM. Classically, investigators of MDR have focused on
the drug resistant single cells, selected by exposing cells to cytotoxic agents. In summary,
these studies have revealed a number of potential mechanisms including: (1) Reduction of
intracellular drug concentration due to the overexpression of membrane pump proteins such
as P-glycoprotein, MRP, and LRP, (2) Altered drug metabolism or enhanced drug
detoxification (changes in glutathione and glutathione-associated enzyrnes), (3) Alterations in
the drug target that reduce drug efficacy (alterations in topoisomerase II), (4) Enhanced
cellular repair of drug-induced damage (Dalton, 1997), and (5) Cell adhesion-mediated drug-
resistance (for review see Dalton and Jove, 1999; Damiano and Dalton, 2000).
The integrin family of cellular adhesion molecules represents a major family of cell-surface
receptors that mediate both cell-cell and cell-extracellular matrix (ECM) interactions. They
are transmembrane heterodimers composed of noncovalently bound u- and þ-subunits' To
date, 16 different g subunits have been identified, which associate with as many as nine
known p-subunits (for review see (Hynes,7992; H¡mes and Zhao,2000)). The u4B1 (Very
Late Activation Antigen 4, or VLA-4), cr5B1 (VLA-5) and u4þ7 heterodimers are the major
ñbronectin (FN) receptors of the integrin family (Clark and Brugge, 1995; Hynes, 1992)'
cr4B1 is unique among the integrins as it is the only heterodimer that has conclusively been
shown to mediate cell-ECM as well as cell-cell interaction (Pulido et a1.,1991). cr4B1 is one
of the main adhesion receptors involved in the homing and localization of myeloma cells to
the BM microenvironment. A better understanding of its regulatory adhesive mechanisms
might contribute to a greater knowledge of the pathology of MM (Sanz-Rodriguez et al',
r99e).
It is well recognised that cell-cell andlor cell-ECM adhesion may regulate apoptosis and cell
survival in a wide variety of tumour types (Clark and Brugge, 1995). It was demonstrated
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that myeloma cell lines and patient-derived myeloma cells express the FN receptors cr4B1
and cr5Bl (Damiano et al., 1999), which facilitate the attachment and communication
between the myeloma cells and the BM microenvironment (Barker et a|.,1992; Jensen et al.,
1993). Fibronectin, as well as VCAM-L, are expressed on the surface of MM stromal
monolayers (Faid et al., 1996; Lokhorst et al., 7994), and antibodies to VCAM-I partially
inhibit myeloma cell adhesion to MM stroma (Kim et al., 1994; Robledo et al., 1998). In
addition, anti-a4 and anti-Bl antibodies have been reported to inhibit the adhesion of
myeloma cells to total FN and intact MM stroma, which indicates that o4B1 has an important
role in this adhesion (Lokhorst et al., 1994; Uchiyama et al., 1992; Uchiyama et al., 1993;
van Riet et a1.,1994).
Damiano and colleagues (1999) recently presented data suggesting that integrin receptors on
myeloma cells may be responsible for cell adhesion-mediated drug resistance (CAM-DR)
following attachment to FN (Damiano et al., 1999). These investigators showed that the
drug-sensitive myeloma cell line RPMI 8226, known to express both u4B1 and cr,5B1 integrin
FN receptors, were relatively resistant to the apoptotic effects of doxorubicin and melphalan,
when cells were pre-adhered to FN, compared to cells exposed to the drug while in
suspension culture. Consistent with previous studies, which demonstrated that o4B1
mediated adhesion decreased the proliferation of haemopoietic progenitor cells (Hurley et al.,
1995), Damiano and co-workers reported that chronic exposure of the myeloma cell line,
RPMI 8226, to either doxorubicin or melphalan, prolonged cell doubling times by over-
expressing a4 integrin (Damiano et al., 1999). This suggested that integrin-mediated
adhesion decreased the response of RPMI8226 cells to chemotherapeutic drugs. Clinically,
elevated FN receptor expression or function in myeloma cells within the BM may be an
indicator of a more aggressive tumour cell that has a survival advantage against the cytotoxic
effects of anti-cancer drugs. In vivo alterations in FN receptor expression or function may
have a magnified effect on myeloma cell survival when they are in direct association with
stromal cells and ECM component of the BM. The CAM-DR mediated by FN adhesion may
be sufficient to allow the eventual emergence of drug resistance mechanism such as the up-
regulation of P-glycoprotein, MRP, and topoisomerase II, which then become the
predominant cytoprotective processes.
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Blocking intercellular communications by blocking cell adhesion may represent a new
approach for the treatment of myeloma. These findings provide evidence that antagonists of
cellular adhesion, or signaling events related to adhesion, ffiày serve as a means of inducing
myeloma cell apoptosis or improving the effrcacy of anti-cancer therapy for myeloma.
IL-6 is a potent growth factor for myeloma cells. It is secreted from both tumour and stromal
cells in response to co-adhesion and a4Bl ligation (Uchiyama et al., 1993), where it is
thought to play a role in drug resistance in MM patients. Autocrine IL-6 reflects a highly
malignant phenotype of myeloma cells, and autocrine IL-6 production and deregulated
apoptosis may induce expansion of IL-6+ myeloma cells resistant to spontaneous and drug-
induced cell death (Frassanito et a1.,2001).
1.2 BONE REMODELLING
1.2.1 Physíological Bone Remodelling
Bone is a highly organised structure composed of a calcified connective tissue matrix
(hydroxyapatite) formed by OB, bone lining cells and osteocytes. Bone remodelling
represents the predominant form of bone tumover in the adult human skeleton and serves to
prevent the accumulation of micro-damage and allow the skeleton to respond appropriately to
changes in mechanical loading. Although trabecular bone represents 20o/o of the skeletal
mass, it accounts for up to 80% of the bone tumover. The process of bone remodelling, is
mediated by the highly coordinated activities of two cell types, namely the bone resorbing
OC and the bone forming OB (Parfitt, 1984). Osteoclastic bone resorption is preceded by a
cascade of events that starts with the activation of haemopoietic stem cells and is followed by
proliferation, differentiation, chemotaxis, attachment, and subsequent terminal differentiation
and fusion of the OC precursors into functioning multinucleated OC. After activation, OC
start to erode and form a cavity (lacuna) on the bone surface. This process occurs for
approximately two weeks. After completion of resorption, the OC disappear and OB
subsequently differentiate and form new bone at the same site. Newly formed sites then
remain quiescent, normally for 2-3 years, until a new activation stimulus event occurs at this
site.
1.2.2 Osteoblasts
Osteoblasts represent a heterogeneous population of cells, which are derived from the stromal
or mesench¡rmal cell system. This family includes mature OB, the bone lining cells, which
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cover bone surfaces, and osteocytes, which are buried within bone and communicate with
each other via the canalicular system.
Mature OB line the bone surface, and have a single eccentric nucleus and a well-developed
endoplasmic reticulum and Golgi apparatus (for review see Mundy, 1995). They are
identified morphologically by their cuboidal appearance and their association with newly
synthesized mineralized bone matrix (hydroxyap atite) at sites of active bone formation. This
may be mediated in part by subcellular particles known as matrix vesicles, which are
generated from the OB cytoplasm, are enriched in alkaline phosphatase. Osteoblasts also
produce other bone matrix constituents that may be important in the mineralisation process
such as phospholipids and proteoglycans. These committed osteogenic cells afe
characterised histologically by the synthesis of certain bone-associated matrix proteins, such
as collagen type I (COLI), osteocalcin (OCN), bone sialoprotein (BSP), osteonectin (ON),
and osteopontin (OP). Approximately 95o/o of the organic bone matrix is comprised of COLI,
with the remainder consisting of various other molecules such as proteoglycans, other
collagen tlpes and non-collagenous proteins (Robey, 1996). Osteoblasts secrete the growth
factors that are stored in the bone matrix, such as transforming growth factor B, bone
morphogenic proteins, platelet-derived and the insulin-like growth factors (Hauschka et al.,
1986). Expression of the membrane-bound ectoenzyme alkaline phosphotase (ALP) is one of
the earliest, and most widely accepted indicators that a cell has initiated a program of
osteogenic differentiation. ALP probably plays an essential role in bone mineralisation and is
frequently used by bone cell biologists as a marker of cells with an OB phenotype, and by
clinicians as a serum marker of OB activity. The majority of OB die by apoptosis, and those
remaining have two alternative fates: to become lining cells or osteocytes (Jilka et a1.,1998).
The fact that bone remodelling process continues throughout adult life, and both OB and OC
have a limited functional lifespan, points to the existence of precursor cell populations with
the potential for extensive proliferation and further differentiation. The osteogenic cell
lineage belongs to the stromal fibroblastic system of the BM, which includes other stromal
tissue, such as cartllage, smooth muscle, and fat (Beresford, 1989; Owen and Friedenstein,
1988). Although there is heterogeneity within the OB lineage with regard to their
proliferative capacity and functional state, these cells have a common stromal cell precursor
capable of differentiation into a number of mature lineages, including adipocytes, reticular
cells, fibroblasts and chondrocfes (Liu et al., 1997). Although the factors involved in
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controlling the differentiation of precursors into cells of the OB lineage have not yet been
fully determined, a number of growth regulatory factors such as transforming growth factor
B (TGFB), fibroblast growth factors, bone morphogenetic proteins (BMPs), and platelet-
derived growth factor (PDGF), have been implicated (as reviewed by Mundy,1995).
The exact location of BM stromal precursor cells in the marrow spaces is still a matter of
conjecture. Histological evidence suggests that multipotential stromal progenitors may reside
in the soft fibrous tissue of the marrow stroma. The osteogenic potential of the marrow
stroma was attributed to the presence of a small population of highly adherent, clonogenic
cells, termed colony-forming units fibroblastic (CFU-F) (Owen and Friedenstein, 1988). A
monoclonal antibody (-Ab) STRO-I has been used to recognize a trypsin-resistant cell
surface antigen present on a osteoprogenitor stem cell subpopulation of BM cells, including
essentially all detectable CFU-F (Simmons and Torok-Storb, 1991). BM mononuclear cells
sorted on the basis of STRO-I expression are capable of establishing an adherent stromal
layer in vitro, consisting of a number of phenotl,pically distinct stromal cell types, including
fibroblasts, smooth muscle cells, adipocfes, and OB (Gronthos et al., 1994).In addition, it
has been demonstrated that the STRO-I* population of human BM cells is capable of
osteogenic differentiation and that osteoprogenitors are present in the STRO-1+ population
(Gronthos et a1.,1994). The growth factors required for the expansion of the maffow CFU-F
population have also been characterised (Gronthos and Simmons, 1995).
Using two independent cell surface markers, STRO-I and ALP, cells of the OB lineage at
different stages of maturation have also been identified (Gronthos et al., 1999; Stewart et al.,
19gg). The bone/liver/kidney isoform of ALP is broadly used as a general marker of
committed OB, and STRO-I is used as a marker representiative of a preosteoprogenitor
phenotype. Gronthos et al (1999) showed that the majority of normal human bone cells
(NHBCs), which express the STRO-I-/ALP* and STRO-I7ALP- phenotypes, appear to
represent fully differentiated OB, while the cells that express the STRO-I*/ALP* phenotype
are considered as osteoprogenitors, and cells which express the STRO-I antigen are stromal
precursors (Gronthos et al., 1999). This observation is based on the expression of bone-
associated matrix proteins and the ability of each subpopulation to form a mineralised bone
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matrrx in vitro
Studies on human bone have shown that cells of the OB lineage express arange of integrin cr
and p subunits, bothin situ andin culture (Clover et al.,1992; Gronthos et a|.,1997; Grzesik
and Robey,1994; Saito e¡ al., 1994). pl integrins appear to be the predominant adhesion
receptor subfamily used by stromal precursor cells to adhere to matrix glycoproteins
commonly found in the BM microenvironment and bone surfaces (Gronthos et aL.,2001). In
addition, the ability of human BM stromal cells (BMSC) to initiate matrix mineralisation was
found to be significantly diminished in the presence of a functional blocking monoclonal
antibody to the B1 integrin subunit, demonstrating a role for this integrin subfamily during
bone formation (Gronthos et a\.,2001). Collectively, these studies suggest that the resorption
of bone by OC may be mediated through integrins such as crvp3 and perhaps crvB5, while
OB development and bone formation may be more dependent on B1 integrin interactions.
1.2,3 Osteocløsts
Osteoclasts are derived from pluripotent precursors of the monocyte macrophage lineage in
the BM (for review see Mundy, 1995). They are seen frequently at active sites of bone
remodelling, such as the metaphyses of growing bones or adjacent to collections of tumour
ce|ls. Usually the large multinucleated cells have less than 10 nuclei, and have primary
lysosomes, numerous and pleomorphic mitochondria, and a specific area of the cell
membrane that forms adjacent to the bone surface, known as the ruffled border. This area of
the cell membrane comprises folds and invaginations, which facilitates intimate contact with
bone resorption sites and the formation of resorption pits (also known as the Howship's
lacuna or resorption bay). The ruffled border is surrounded by a cleat zone, which contains
actin filaments, and appears to anchor the ruffled border area to the bone surface undergoing
resorption. This structure may be critical to the polarisation of the OC, which occurs
immediately when the cell is activated prior to bone resorption'
Osteoclasts are produced in the BM where they are in physical contact with stromal cells.
Experimental data suggest that OB and their progeny (bone lining cells) may act as accessory
cells for osteoclastic resorption. Interactions may occur by either direct cell-cell contact or by
the production of soluble mediators that are critical for the proliferation and differentiation of
haemopoietic OC precursors. Using the mononuclear fraction of peripheral blood of adults as
a source of precursors, terminally differentiated OC capable of extensive resorption pit
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formation can be cultured in vitro either in the presence of OB or essential mediators (Azuma
et a1.,2000; Fujikawa et a1.,1996; Matayoshi et a1.,1996).
1.3 MECHANISM OF INCREASED OSTEOCLAST ACTIVITY IN MM
It is widely accepted that the underlying mechanism of osteolysis in MM patients is increased
osteoclastic bone resorption. Myeloma cells are found in the close vicinity of bone
trabeculae, suggesting a strong relationship between tumour cells and their environment (for
review see Van Fiiet et al., 1993). Recent studies suggest that there is considerable
interdependence between malignant myeloma cells and BM stromal cells present within the
bone environment, through the interaction of different adhesion receptors with their ligands.
The BM microenviroment itself is a site of synthesis of numerous cytokines which may be
important in the proliferation and/or survival of myeloma cells (Bataille et al., 1996). The
adhesion of myeloma cells to MM stroma triggers s¡mthesis of cytokines, including IL-6,
which augments myeloma cell growth and survival and confers drug resistance. IL-6, a
potent growth factor for myeloma cells, is secreted from both tumour and stromal cells in
response to co-adhesion and a4p I ligation (Uchiyama et al., 1993).In addition, the important
OAFs secreted by myeloma cells and OB, such as IL-6, IL-1P, TNF-o, TNF-P, and PTHTP,
are also increased (Bataille et al., 1992b; Caligaris-Cappio et al., 1992) (figure 1.1). It has
been showed that MM patients with advanced aggressive disease, secrete significantly higher
levels of IL-6, TNF-ø, and IL-1 than normal controls (Filella et al.,1996; Lichtenstein et al.,
1e8e).
1.3.1 Interleukin-6
Interleukin-6 (IL-6), a pleiotropic cytokine produced by a variety of cells, is a critical growth
factor for normal B-cell growth and development and represents a major tumour survival and
proliferation factor for MM cells (Klein et al., 1995; Nilsson et al., 1990; Ohtake et al.,
1990). Although the origin of IL-6 is controversial, some primary plasma cells have been
shown to produce, or can be induced to produce,IL-6. This is thought to mediate autocrine
growth of human myeloma cells by modulating IL-6 signalling and IL-6 receptor expression
in myeloma cells (Hirano et al., 1990; Jernberg-Wiklund et al., 1992; Kang et al., 1996).
Autocrine IL-6 production reflects a highly malignant phenotype of myeloma cells, and
together with deregulated apoptosis, may induce expansion of selective IL-6* myeloma cells
resistant to spontaneous and drug-induced cell death (Frassanito et a|.,2001).
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Bone resorption Bone formation
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Figure 1.1.Increased osteoclastic bone resorption is an underlying mechanism of
osteolysis in MM. A number of OAFs including IL-6, IL-1P, TNF-ct, TNF-8, and
PTIkP, have been implicated in the pathogenesis of the ostelytic bone






The development of MM is a multistep transformation process and Hallek et al supported
that several oncogenic events result in the selection and malignant expansion of a single IL-
6* clone (Hallek et a1.,1998). On the other hand, some studies show that IL-6 is produced by
stromal components grown from myeloma BM, suggesting a paracrine regulation of tumour
growth, which implies that the proliferation of myeloma cells is dependent upon close contact
with stromal cells (Lichtenstein et a1.,1989; Lokhorst et al., 1994). The importance of the IL-
6/IL-6R interaction in MM was demonstrated by de Hon et al. (1.994), who showed that the
growth of MM cell line XG-l could be inhibited by the addition of mutant form of IL-6,
which displayed a 5-fold enhanced affinity for IL-6R, but was incapable of signalling through
the IL-6R (de Hon et al., 1994). Although IL-6 can stimulate osteoclast-like cell formation
(Kurihara et al., 1990), the role of IL-6 in osteoclastic bone resorption is complex and
remains unclear.
1.3.2 Interleukin-l
Serum interleukin-l (L-1) level in myeloma BM cells was found to be significantly higher
than that found in similarly processed BM cells from control individuals (Filella et al., 1996;
Lichtenstein et a1.,19S9). IL-l was shown to be mainly responsible for IL-6 production in the
tumoral BM environment of patients with MM through a prostaglandin E2 (PGE2) loop
(Costes et al., 1998; Lu et al., 1995).Inhibition of PGE2 slmthesis using an IL-1 receptor
antagonist (IL-1RA) and indomethacin, an inhibitor of cyclooxygenase which can block
PGE} synthesis, was found to inhibit myeloma cell proliferation by reducing IL-l-induced
endogenous IL-6 production invitro andin vlvo (Costes et al., 1998). In addition, IL-l8 is
also a principal bone resorption agent present in the supernatants of myeloma cell cultures
that enhances destructive bone lesions in the patients with MM (Cozzolino et al., 1989;
Yamamoto et al., 1939). This bone-resorbing activity can be neutralised by an antibody
directed against IL-lP (Cozzolino et al., 1989; Kawano et al., 1989). Thus, IL-1 can promote
the secretion of IL-6, and both IL-l and IL-6 enhance the bone lysis in MM'
1.3.3 Tumour Necrosis Factor
Tumour necrosis factor-o (TNF-cr), is found at higher levels in supernatants from BM
cultures of MM patients, and is capable of markedly stimulating osteoclast-like
multinucleated cell formation in human marrow cultures (Filella et al., 1996; Lichtenstein er
al., 1989; Pfeilschifter et al., 1989). The role of TNF-B in myeloma bone disease has been
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downplayed by more recent studies, which failed to find significant differences in the amount
of this cytokine in supematants derived from fresh BM plasma cultures from myeloma
patients, compared to controls. In addition, antibodies to TNF-p do not reduce the bone
resorbing activity of fresh BM plasma from myeloma patients. Interestingly, TNF-a has a
more potent effect than IL-6 in stimulating the growth of primary myeloma cultures from the
same patient, indicating that TNF-o in selected myeloma patients has a growth-promoting
effect equal to that of IL-6 (Borset et al.,1994)'
1.3.4 Parathyroìd Hormone Related Protein
Parathyroid hormone related protein (PTHTP) is a widely expressed hormone that is a major
mediator of malignancy-associated hypercalcemia and shows 70o/o homology to parathyroid
hormone (PTH). The binding of PTHrP to the PTH receptor activates cyclic adenosine
monophosphate (cAMP) and enhances osteoclastic bone resorption (Kaji et al., 1993). The
elevated PTHrP can be measured in the plasma of patients with myeloma (Horiuchí et al.,
1997; Schneider et a1.,1998). PTHrP released by myeloma cells acts in a paracrine manner
by binding to the PTH receptor expressed by OC to produce local bone resorption. When
secreted in large amounts by malignant cells, PTHrP may act in a humoral manner to cause
systemic hypercalcemia (Firkin et a1.,1996). Thus, PTHrP might be an important contributor
to the skeletal complications in MM.
Although several OAFs have been implicated in the enhanced OC activity, the precise role of
any of these factors in osteolytic bone disease in patients with myeloma has not been clearly
demonstrated in vivo. Recently, a new cytokine system RANKL/RANIIOPG was identified
and provides us with a novel paradigm as to the mechanisms of osteoclastogenesis and bone
resorption in physiological and pathological bone remodelling.
1.3.5 R,INKL/ ODF/TRANCE/OPGL: the Ligønd
Receptor activator of nuclear factor-rB ligand (RANKL) is a member of the TNF ligand
family, variously termed TNF-related activation-induced clokine (TRANCE),
osteoprotegerin ligand (OPGL), or OC differentiation factor (ODF) (Anderson et al., 1997;
Lacey et a1.,1998). It is secreted by BM OB/stromal cells, chondrocytes, mesenchymal cells
of the periosteum, OC, endothelial cells and T cells (Anderson et al., 1997; Lacey et al.,
1998; Yasuda et a1.,1998b). RANKL is a type II membrane-anchored polypeptide, which is
released from the plasma membrane by a metalloprotease-disintegrin TNF-alpha convertase
l1
(TACE) (Lum et a1.,1999). Truncated RANKL is an important component of the function of
transmembrane RANKL in bone and immune homeostasis (Lum et a1.,1999).
The development of OC comprises several stages: recruitment, proliferation, differentiation
of the progenitors into mononuclear OC, and fusion of mononuclear OC to form activated
multinucleated OC capable of resorbing bone. Numerous studies demonstrate that RANKL
provides an essential signal to OC progenitors, enabling their differentiation into OC (Yasuda
et al.,199Sb). RANKl-deficient mice show severe osteopetrosis, defects in tooth eruption,
and completely lack OC as a result of the inability of OB to support osteoclastogenesis (Kong
et al., 1999a; Kong et al., 1999b). Soluble RANKL (sRANKL) causes murine as well as
human OC differentiation when co-stimulated with macrophage-colony stimulating factor
(M-CSF) in vitro (Quinn et al., 1998; Udagawa et aL, 1999). This suggests that the RANKL-
mediated signals can be transduced not only by cell-to-cell contact between OB/stromal cells
and OC progenitors, but also by the cleaved or soluble form of RANKL in a paracrine
manner. The cell-to-cell interaction is essential for OC formation in the co-culture system,
suggesting a pivotal role for the membrane-bound RANKL in osteoclastogenesis. The
cleaved-form of RANKL may play a role in pathological bone resorption mediated by
abnormal osteoclastogenesis. Taken together, these results demonstrate that RANKL is an
essential OC differentiation factor in vivo and in vitro.
1.3.6 RANK: the Receptor
Receptor activator of nuclear factor-rB (RANK) is a member of the TNF receptor family and
represents the membrane-associated counter receptor for RANKL (Yasuda et al., 1999).
RANK is expressed by several cell types, including dentritic cells, B cells, and mainly by OC
precursor cells and is capable of initiating osteoclastogenic signal transduction after ligation
with RANKL or anti-RANKL agonist antibodies (Anderson et al., 1997; Hsu e/ a1.,7999).
RANK deficient mice show a profound defect in bone resorption and bone remodelling,
resulting from an apparent block in OC differentiation and an intrinsic defect in OC function
(Dougall et al., 1999; Li et a\.,2000). Severe osteopetrosis was observed in transgenic mice
expressing a soluble RANK-Fc fusion protein (Hsu e/ al., 1999). Recombinant RANK-Fo
bound with high affinity to RANKL in vitro and blocked OC differentiation and activation in
vitro and in vivo (Hsu e/ al., 1999). These results all indicate that RANK is an OC receptor
capable of mediating the biological activities of RANKL during normal bone homeostasis
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and in disease. The RANKL signalling pathway is the ultimate common mediator of humoral
signals that regulate bone resorption and calcium metabolism.
1.3.7 OPG/OCIF: the Decoy RecePtor
Osteoprotegerin (OPG), also called osteoclastogenesis inhibitory factor (OCIF), is a heparin-
binding, basic glycoprotein. It has been isolated as both a monomer and a disulfide-linked
homodimer, with a molecular weight of 60 kD and 120 kD, respectively. OPG is a secreted
member of the TNF receptor family, containing four cysteine-rich domains and two regions
which exhibit homology to death domains (Simonet et a1.,1997; Yamaguchí et a1.,1998). It
acts as a naturally occurring decoy receptor for RANKL by disrupting the interaction
between RANKI and RANK (Yasuda et al., 1999). OPG inhibits osteoclastogenesis by
blocking cell-to-cell signalling between stromal cells and OC progenitors (Yasuda et al.,
1998a). A mouse co-culture system using calvarial OB and BM cells prepared from OPG-
deficient mice suggested that OPG produced by OB/stromal cells is a physiologically
important regulator in OC differentiation and function (Udagawa et a|.,2000)'
1.3.8 The Retationshíp between RANKL, RANK and OPG in MM
As discussed previously, RANKL promotes the differentiation of OC precursor cells to OC
through the RANK receptor expressed on the OC precursor cells. OPG acts as a decoy
receptor that regulates the signalling between RANKL and RANK. The over-expression of
OPG in transgenic mice results in a muted osteopetrotic phenotype (Simonet et al., 1997).
Conversely, targeted ablation of OPG in knockout mice leads to severe osteoporosis (Bucay
et al., 1998). These results demonstrate that OPG is a key factor acting as a negative
regulator of osteoclastogenesis. It has been demonstrated that the bone resorbing agents 1
alpha, 25-dihydroxyvitamin D3 (1,25-(OH)2D3), PTH, and PGE2 can upregulate RANKL
expression, and stimulate OB-induced pit-forming activity of OC (Udagawa et al., 1999)'
Other investigators also reported that anumber of osteotropic agents including 1,25-(OH)2D3,
PTH or IL-l1, could increase the ratio of RANKL:OPG (Horwood et al., 1998). Thus, OC
formation may be determined principally by the relative ratio of RANKL to OPG in the BM
microenvironment. Alterations in this ratio may be a major cause of bone loss in many
osteolytic neoplasms including MM. It has been demonstrated that myeloma cells affect the
RANKI/OPG ratio in the BM environment by stimulating OB to overexpress RANKL
(Giuliani et al.,2O0l), and OPG could inhibit the development of osteolytic bone disease in
myeloma-beanngmice (Croucher et a|.,2001). Furthermore, freshmyeloma cells (as defined
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by their high expression of the CD38 cell surface molecule) isolated from patients with MM,
express RANKL and can facilitate bone pit formation in co-culture system in the absence of
OB (Famrgia et a1.,2002). These observations confirm that the RANKL/OPG system is
involved in the pathogenesis of MM induced osteolysis.
1.3.9 The Relationship between RANKL/RANI{/OPG ønd OAFs Secreted by MM.
As previously discussed, recent in vitro studies suggest that MM cell-derived OAFs may play
a central role in the pathogenesis of MM induced osteolysis. In terms of IL-6, Dai et al
reported that alcohol ingestion induced osteoclastogenesis and bone loss through an lL-6
mediated mechanism in mice, and that IL-6 achieved this effect by inducing RANKL to
promote osteoclastogenesis (Dai et at.,2000). However, the data from another group showed
IL-18 and TNF-cr, but not IL-6, could stimulate RANKL gene expression in human
osteoblastic cells (Hofbauer et al., 1999). These studies demonstrate that IL-6 induced
stimulation of OC activity remains controversial. In addition, IL-6 also appears to have a
complex interaction with IL-l, TNF and PTHrP in MM. Therefore, determining which of
these molecules represent the key factor in this complicated cytokine network remains to be
investigated.
1.3.10 Other Molecules That Affect RANKL/RANI(/OPG System in MM
(ø) TRAIL
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also called Apo2L) is a
member of a superfamily of cell death-inducing ligands that also includes TNF-a and Fas
ligand (FasL or CD95L). TRAIL induces apoptosis of malignant cells by interacting with a
complex system of cell surface receptors, including the two death-signalling receptors DR4
(also known as TRAIL-RI) and DR5 (TRAIL-R2) (Pan et al., 1997; Sheridan et a1.,1997).
These 2 receptors transmit a pro-apoptotic signal via interaction of their intracellular death
domains with adaptor proteins, which are not well characterised. The death domains of these
adaptors constitutively bind to caspases, initiating a cascade of proteolytic activation of
downstream caspases and apoptosis (Schulze-Osthoff et al., 1993). Additional antagonist
decoy receptors have also been described and include DoRI/TRID/TRAIL-R3 and
DcR2/TRAIL-4. These receptors have aî extracellular TRAIL-binding domain and a
transmembrane domain, but lack an intracellular death signalling domain (Pan et al., 1997;
Sheridan et al.,I9g7). Thus, ectopic expression of DcRl and DcR2 protects mammalian cells
from TRAIL-induced apoptosis and inhibits TRAIL cytotoxicity (Degli-Esposti et a|.,1997;
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Sheridan et al.,lggT). However, one report showed that the expression of DcRl or DcR2 did
not appear to be a significant factor in determining the resistance or sensitivity of some
tumour targetcells to the effects of TRAIL (Griffith et al.,1999). Although non-toxic to most
normal human cells iz¡ vitro (Pitti et al., 1996; V/iley et al., 1995), TRAIL was found to
effectively induce extensive apoptosis in RPMI 8226 and ARP-I myeloma cell lines in a
time- and dose-dependent manner, and also induce substantial apoptosis in freshly isolated,
flow-sorted myeloma cells obtained from different MM patients (Gazitt, 1999). Furthermore,
TRAIL-induced apoptosis in MM cell lines was not blocked bybcl-2 (Gazitt,1999; Gazitt et
al., 1999), and not abrogatecl by IT,-6, a major growth and survival factor for MM cells
(Mitsiades et al., 2001). Preclinical studies also suggest that TRAIL can overcome
conventional drug resistance and provides the basis for clinical trials of TRAIL-based
treatment regimens to improve survival outcomes in patients with MM (Mitsiades et al.,
2001).
It was subsequently found that OPG, a secreted homologue of the TNF receptor, represented
a fifth TRAIL receptor (Emery et a1.,1998). OPG-Fc bound TRAIL with an affinity of 3.0
nM, which was marginally weaker than the interaction of DcRl-Fc or DR5-Fc with TRAIL.
It was reported that OPG could inhibit TRAIL-induced apoptosis of Jurkat cells, whilst in
contrast, TRAIL blocked the anti-osteoclastogenic activity of OPG (Emery et al., 1998).
These data suggest that the mechanisms of potential cross-regulation may be mediated by
OPG and TRAIL.
(b) Syndecan-l
Syndecan-1 (CD 138) is a heparin sulfate bearing integral membrane proteoglycan that is
expressed and actively shed from the surface of most myeloma cells (Dhodapkar et al',1998;
Saunders et al., 1939). Syndecan acts as a matrix receptor on human myeloma cells by
binding type I collagen viahepainsulfate chains, and it is thought to participate in regulating
myeloma cell adhesion to the BM stromal cell matrix (Ridley et al., 1993)' Therefore,
syndecan-l may play a dual role in inhibiting the metastasis of tumour cells by promoting
cell adhesion to the extracellular matrix and suppressing the proteolytic activity needed for
invasion (Kaushal et al., 1999; Liebersbach and Sanderson, 1994). It has been found that
elevated level of syndecan-1 in serum is a strong and independent negative prognostic factor
for patients with myeloma (Seidel et a1.,2000b). However, some studies show that syndecan-
1 could induce apoptosis and inhibit the growth of myeloma tumour cells. In addition,
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syndecan-l increased OB development and inhibited OC formation in murine BM
(Dhodapkar et a1.,1998). Since syndecan-1 can bind with heparin-binding proteins, like OPG
or hepatocyte growth factor, it has been suggested that it may also regulate the biological
activity of heparin-binding cytokines (Borset et a1.,2000). These data indicate that soluble
syndecan-l may participate in the pathology of myeloma induced osteolysis by modulating
RANKL/RANIIOPG activity within the BM (refer to section 1.3.8).
(c) HGF
Hepatocle growth factor (HGF) is a cytokine overproduced by myeloma cells and has
implications for the prognosis of patients (Borset et a1.,1999). The biological significance of
HGF overexpression in multiple myeloma is likely to include effects on bone turnover and
angiogenesis (Borset et al., 1999). HGF exists in a complex with soluble syndecan-l.
Washing myeloma cells with purified soluble s¡mdecan-l was found to effectively displace
HGF from the cell surface, suggesting that soluble syndecan-l could act as a catrier for HGF
in vivo (Seidel et al., 2000a). HGF is only one of several heparin-binding cytokines
associated with myeloma (Seidel et a\.,2000). The relationship between HGF and syndecan-
1 and the effects of HGF on bone turnover requires further investigation.
In summary, it appears that RANKL and OPG will be a key agonist and antagonist cytokine
system in regulating MM induced osteolysis (figure 1.2). Other molecules, such as IL-6,IL-
1B, TNF-g, PTHrP and syndecan-l, secreted by MM cells may play a complex role in the
RANKL/RANK/OPG system that regulates bone tumover in MM patients. The
understanding of precise mechanisms responsible for myeloma-induced bone loss may enable
us to understand how BPs may achieve clinical therapeutic effect in the patients with MM by
affecting the molecules involved in the osteoclastic bone resorption.
1.4 BISPHOSPHONATES
1.4.1 Generøl Properties
Bisphosphonates represent stable pyrophosphate analogues that differ from pyrophosphate by
replacement of the oxygen bridge with a carbon atom to form a P-C-P structure which has
various side chains (figure 1.3). These compounds were first slmthesised in 1865 (for review
see Rodan and Fleisch, 1996). In the early 1960s, Neuman and Fleisch discovered that








Figure 1.2. The role of the newly defined TNF-family members RANKL and OPG in
osteoclastogenesis. RANKL promotes the differentiation of osteoclast precursor cells
to osteoclasts via the RANK receptor expressed on osteoclast precursor cells. OPG acts
as a decoy receptor that regulates the signalling between RANKL and RANK by
binding ro RANKL.
and urine, and could prevent calcification by binding to newly forming crystals of
hydroxyapatite. BPs were found to be able to inhibit the dissolution of hydroxyapatite crystal
and bone resorption both in vitro and in vivo (for review see Russell and Rogers, 1999). As a
result, BPs have been developed and over the last three decades used in the treatment of a
number of bone diseases, including Paget's disease, metastatic, osteolytic bone disease and
hypercalcemia of mali gnancy.
BPs can be classified into at least two groups with different modes of action. BPs that closely
resembles pyrophosphate (such as clodronate and etidronate) can be metabolically
incorporated into nonhydrolysable analogues of adenosine triphosphate (ATP) that may
inhibit ATP-dependent intracellular enzymes (figure 1.4). In contrast the more potent,
nitrogen-containing BPs (such as pamidronate, alendronate, risedronate, ibandronate,
tiludronate, incadronate and zoledronic acid) are not metabolized in this way, but serve to
inhibit enzymes of the mevalonate pathway (figure 1.5), a bios¡mthetic pathway responsible
for the production of cholesterol and isoprenoid lipids. Therefore nitrogen-containing BPs
serve to prevent the biosynthesis of isoprenoid compounds that are essential for the
posttranslational modification of small GTPases (refer to section 1.4.2).
The BPs, like pyrophosphate, bind to the bone mineral hydroxyapatite with high affinity,by
virtue of the PCP structure, which accounts for their uptake in bone and their selective action
on the skeleton. For example, it was demonstrated that the BP, alendronate, 'was rapidly
eliminated from plasma and was not detectable 1 day after injection, whilst the concentration
in bone was much higher than that in plasma. Approximately 30-40%" of the dose was
excreted in urine in24hours, whilst 60o/o of the dose was localised to the bone tissue; BPs
that adsorbed to the bone remained as an unchanged compound for a long period of time (Lin
et a1.,1991). Moreover, studies have demonstrated that BPs do not distribute uniformly in
long bones (Azuma et a1.,1995; Sato et al.,l99l). The metaphysis of the tibia were found to
possess a greater concentration than the diaphysis. Indeed, BPs are found to deposit where
bone mineral is exposed to the surrounding fluids, especially where bone is formed and
resorbed. It was reported that the distal femoral metaphyses of mice contained -5%o bone
resorption surfaces, -48% active bone formation surfaces, and the other surfaces were
considered as resting and eroded surfaces (Sato e/ al., 1997). Sato et al. reported that
following injection of 0.4 mglkg [3H] alendronate to newborn rats,72%o of the osteoclastic
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surfaces, 2o/o of the bone forming surfaces and -73Yo of all other surfaces were densely
labelled at day 1. In contrast, -46Yo of the bone forming surfaces were found to be
moderately labelled at day 1. It was assumed that the amount of alendronate in the densely
labelled site was about five-fold higher than in the moderately labelled site. The lower level
of ¡3U1 alendronate uptake on bone formation surfaces was thought to be due to the lower
accessibility of alendronate to the hydroxyapatite embedded within the newly syrthesised
osteoid (Sato e/ al.,l99I). These observations suggest that bone is the specific binding organ
for BPs, and bone resorption as well as bone formation surfaces are the major deposit sites
for BPs. In addition, BPs hind to bone particles by strong pH dependence and 50 % of this
drug would be released at pH 3.5 by virtue of the interaction of phosphate with
hydroxyapatite (Sato et al., 1991). Several studies showed that dense distribution of BPs was
seen primarily under OC at day I following administration, but 5 days later, it was no longer
observed under OC and was shifted from the metaphysis to the diaphysis (Azuma et al.,
1995; Sato et at.,I99l). These results imply that BP binding is strongly influenced by bone
growth and, therefore, one may expect that BP treatment inhibits osteoclastic activity only at
the level of the existing resorption sites. When new bone is laid down at sites of previous
resorption, the BP remains buried and functionally excluded within the bone tissue.
Therefore, as soon as the treatment is withdrawn, new remodelling sites will appear and
hence a non inhibited bone turnover can be restored despite the extended physical presence of
BPs in the skeleton. These observations may explain the need for repeated BP administration.
1.4.2 The Elfect of Bísphosphonates on Osteocløsts
Since mature, multinucleated OC are formed by the fusion of mononuclear precursors of
haemopoietic origin, BPs can inhibit bone resorption in the following ways: (1) lnhibition of
OC recruitment to the bone surface (Hughes et a1.,1989; Schmidt et al.,1996); (2) Inhibition
of the excavation of resorption pits by mature OC directly (Murakami et al., 1995; Sato and
Grasser, 1990; van Beek et al., I99l); (3) Shortening of the OC life span (Hughes et al',
1995); (4) Secretion of an inhibitor of OC-mediated resorption by OB (Vitte et al., 1996);
and (5) Interfering with the attachment of OC to certain bone matrix proteins via cell-surface
integrins (Colucci et a1.,1998).
It is likely that BPs are selectively intemalised by OC because of their accumulation in bone
and the phagocytic nature of OC. The uptake of bisposphonate by OC in vivo has been
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Figure 1.3. Chemical structure of a generic bisphosphonate. (A) Inorganic
pyrophosphate (PPi). (B) Structure of a bone-active bisphosphonate, highlighting
functional domains.
Enzyme + am¡no ac¡d + ATP am¡no-acyl'AMP + PP¡
Amino-acyl-AMP + pCp am¡no ac¡d + AppOp
Figure 1.4. A BP that closely resembles pyrophosphate can be metabolically
incorporated into nonhydrolysable analogues of ATP that may inhibit ATP-
dependent intracellular enzymes.
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Figure 1.5. Schematic representation of the mevalonate pathway indicates sites of
action of BPs.
confirmed using radiolabeled alendronate. These studies demonstrate that following
intemalisation, aledronate was localised to the intracellular vacuoles, and other subcellular
compartments such as the cytoplasm, mitochondria, and nuclei (Masarachia et a1.,1996; Sato
et a1.,1991). After cellular uptake, a characteristic morphological feature of BP treated OC is
the lack of a ruffled border (Sato and Grasser, 1990). It was reported that the presence of
alendronate on the bone surface in vivo and in vitro interfered with ruffled border formation
in OC by causing an increase in the leakiness of ruffled border to ions that stopped bone
resorption (Sato e/ at.,l99l). During the resorption process the low concentration of BPs in
extracellular fluids can rise to a very much higher local concentration in the OC resorption
lacuna. Sato et ctl (1991) demonstrated that acidification (Zimolo et al., 1995) produced
during the initiation of resorption caused the local release of alendronate with the
concentration of 0.1-1.0 mM under the ruffled border of OC (Sato et al.,l99l). This is much
higher than the concentrations of BPs required to affect OC morphology and cause OC
apoptosis in vitro (Hughes et al., 1995; Sato and Grasser, 1990). Breuil et al (1998)
demonstrated that in a human model, inhibition of resorption by alendronate was mediated
primarily by reduction of OC activity and OC number at very high concentrations (Bireúl et
a|.,1998).
One possible molecular mechanism of BPs activity on OC is based on its ability to inhibit
some of the enzymes involved in the pathway for cholesterol synthesis' Two groups of
enzymes were shown to be inhibited by BPs: squalene synthetase, a lipid metabolism enzgme
which has farnesyl pyrophosphate as its substrate (Ciosek et al., 1993), and protein tyrosine
phosphatases (pTp), which control tyrosine phosphorylation involved in signal transduction
pathways (Schmidt et al.,1996;Endo et al.,1996).
Inhibition of geranylgeraniol PPi (GGPP) synthase has been implicated in the induction of
apoptosis following BP treatment. GGPP is required for the prenylation and subsequent
membrane localisation of proteins, particularly small GTP proteins of the Rho/Rac/Rab
family. The Rho/Rac/Rab family of proteins are involved in a number of cellular processes
including assembly of the actin cytoskeleton, vesicular trafficking, signal transduction and
cell adhesion (Hall, 1998; ZenaI and Stenmark, 1993). BPs inhibit the farnesylation and
geranylgeranylation of proteins, by inhibiting enzymes required for synthesis of
farnesyldiphosphate (FPP) and geranylgeranyldiphosphate (GGPP), and therby disrupt OC
function. Several studies have demonstrated that alendronate and tibudronate disrupt the
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formation of actin rings in polarised, resorbing OC (Murakami et al., 1995; Sato e/ al., l99l).
The ability to inhibit GGPP syntheses appears to be restricted to the nitrogen-containing BPs,
suggesting that different BPs may have distinct targets. Disruption of the cytoskeleton also
could be brought about indirectly by the inhibition of protein kinases or phosphatases that
regulate cytoskeletal structure. Indeed, several recent reports have shown that alendronate
can inhibit several protein tyosine phosphatases (PTP), which determine the level of tyrosine
phosphorylation and play an important role in the transduction of signals that control cell
growth and differentiation (Endo et al., 1996; Schmidt et al., 1996). It is likely that BPs
inhibit metabolic pathways that firstly affect OC function (eg. via disruption of the OC
cytoskeleton and ruffled border) and therefore cause OC cell death as a later effect (figure
1.6). Differences probably also exist between the ability of different BPs to cause apoptosis,
depending on their molecular mechanism of action.
Previous studies of direct actions of BPs on bone have been limited, mainly to their effects on
bone-resorbing OC cells. Although several studies have demonstrated that the inhibition of
osteoclastic bone resorption induced by BPs may be mediated indirectly through paracrine
factors produced by the bone-forming OB cells, little is known about the direct actions of
BPs on the important bone-forming OB.
1.4.3 The Effect of Bisphosphonates on Osteoblasts
It has been established that the osteoblastic cells are important in the formation of tartrate-
resistant acid phosphatase-positive multinucleated cell (TRAP* VfNC; induced by 1,25(OH)2
D3 and PTH in mouse maffow cultures (Takahashi et al., 198S) and in co-culture of spleen
cells with osteoblastic cells (Takahashi et a1.,1988a). Therefore, it is postulated that direct
cell-cell interaction is crucial in the process of osteoblastic cell-supported OC formation and
maturation (Kurihara et al.,1989). Thus, BPs may aclvia OB to inhibit bone resorption, by
stimulating OB to produce osteoclast-inhibitory factors, or by differentiating OB progenitor
cells into mature and functional OB'
It is now generally accepted that cells of osteoblastic lineage control the recruitment and
activity of OC under physiological and pathological conditions. The inhibitory effect of BPs
on osteoclastic bone resorption might be mediated, at least in part, through the regulation of
the production of cytokines secreted by OB. The first experimental evidence to support this
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Figure 1.6. The mechanism of bisphosphonates action on bone-resorbing
osteoclasts.
notion comes from studies which demonstrate that BPs can inhibit the synthesis of
prostaglandin Ez (Ohya et al., 1985) and osteocalcin (Stronski e/ al., 1988) in murine
osteoblastic cells. It was also reported that BPs could inhibit IL-6 secretion by human OB-
like cells in a dose-dependent manner (Giuliani et aL,1998b). Recently, it has been shown
that conditioned media taken from rat CRP 10/30 osteoblastic cells briefly (5min) (Sahni e/
al.,1993) or continuously (Nishikawa et al., 1996) exposed to low concentrations of potent
BPs contains a factor(s) that reduces osteoclastic bone resorption in culture. The decrease in
resorption was subsequently found to be due to the secretion from OB of a protein with a
molecular weight between 1 and 10 kD, which was able to inhibit OC recruitment and
survival (Nishikawa et al., 1996; YíIte et al., 1996). Another study has shown that the OB-
like cell line IIMR-106 signifrcantly reduces its PTH-induced pit formation when pre-treated
with BPs in co-culture with rat OC. Furthermore, conditioned media from UMR-106 cells
pretreated with ibandronate was found to reduce bone resorption when added to cultures of
rat OC. This effect however was abrogated by culturing ibandronate-pretreated UMR-106
cells in l0-8 M PTH before harvesting the conditioned media. It is apparent that osteoclastic
bone resorption can be affected independently by the ibandronate-induced osteoclast-
inhibiting factor and the PTH-induced osteoclast-stimulating factor, but the final level of
bone resorption depends on the relative concentration of these two factors (Yu et al., 1996).
However, a contradictory finding showed that a low concentration of the nitrogen-containing
BPs APD and MezAPD act synergistically with PTH and increase osteoclastic resorption,
possibly also through interference with factor(s) produced by osteogenic cells (van der Pluijm
et al.,I99Ia).
Further studies have demonstrated that BPs can inhibit the secretion of molecules such as
prostaglandin Ez, osteocalcin, andIL-6 by OB-like cells (Giuliani et al., L998b; Ohya et al.,
1985; Stronski et al., 1983). Pamidronate and zoledronic acid were found to inhibit the
production of IL-6 by HBSCs at concentration of 1 ¡rmol/L or less (Derenne et al., 1999). A
statistically significant increase of TNF-cr and a mild increase of IL-6 in serum are observed
in patients receiving BP treatment, with the greatest effects seen with the highest
concentration of both pamidronate and zoledronic acid. No changes in IL-l were observed
with any agents. These increased cytokine production, which are demonstrated to be
transiently produced by macrophages and monocytes, are considered as an acute-phase
response associated with BPs (Thiebaud et al.,1997).
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Like pyrophosphate, BPs can affect mineral dissolution. Previous data indicate that BPs have
a negative effect on the mineralisation of bone matrix at a very high dose, with osteomalacia
and defective mineralisation reported (Adamson et al., 1993). Impaired mineralisation
associated with the first generation BPs, etidronate, has led to the development of more
potent second and third generation compounds, in which anti-resorptive efficacy is
dissociated from mineralisation effects. It has now been demonstrated that the low
concentrations of BP, and especially the newer more potent ones necessary to produce a
pharmacological effect, have no significant impact on mineral dissolution. It is notable that
concentrations of BPs as low as 10-11 M have an effect on OB. Animal and clinical studies
show that BP treatment markedly decreases trabecular bone turnover with normal
mineralisation (Balena et al., 1993; Chavassieux et al., 19971' Storm et al., 1993).
Furthermore, other investigators have also described an enhancement of OB function with
BPs (Giuliani et al.,I998a; Tenenbaum et al.,1992; Toolan et al.,1992; Tsuchimoto et al.,
1994). In one study, the BP-induced formation of CFU-F did not show a clear dose
dependency but rather an "on-off effect". There was also a biphasic effect on the formation of
bone-like nodules, with a dose-dependent stimulation at lower concentrations and an
inhibitory effect at higher concentrations (Giuliani et a1.,1998a). The differences in efficacy
and in effects on mineralisation among different BPs require further investigation at a
molecular, cellular and physiological level.
It is not yet clear how BPs access the OB in vivo. One possibility is that they come directly
from the general circulation after their administration. A more likely explanation, consistent
with their stability and long duration of action, is that they are released from bone into the
microenvironment of OB, either by passive diffusion or during resotption. The actual
concentration ranges of the BPs that OB and other cells in the body are exposed to under
pharmacological conditions are unpredictable. In one study, at pharmacologically effective
doses, 3H-alendronate labelled eightfold more OC surface than OB surface. In contrast, 
3H-
etidronate labelled approximately equal fractions of OC and OB surface. Therefore,
alendronate, at pharmacological active doses, showed higher uptake on resorption versus
formation surfaces than etidronate. However, the extent of bone formation on surfaces
containing alendronate or etidronate was similar to that of controls (Masarachia et a1.,1996)'
Therefore, the differences in the distribution of these different drugs in the skeleton cannot
explain the differences in efficacy and effects on mineralisation among different BPs.
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Proliferation and differentiation of OB or preosteoblast are essential steps in bone formation.
It has been demonstrated that pamidronate and zoledronic acid decreased OB proliferation
but enhanced the differentiation and bone-forming activities of OB (Reinholz et a1.,2000)'
Furthermore, BPs also have been reported to inhibit apoptosis of the murine osteocyte cell
line MLO-Y4 and primary murine OB (Plotkin et al., 1,999). The underlining mechanisms
however remain unclear. It was known that agents such as prostaglandins, PDGF, FGF,
TGFp and bone morphogenetic proteins were shown to stimulate OB proliferation in vitro
and in vivo (Canalis et a1.,1993). The receptors for these proteins are all protein kinases.
Therefore, the finding that BPs inhibit the PTP activity of a novel receptor type protein
tyrosine phosphatase sigma (PTPo) and stimulate the proliferation of quiescent calvaria OB
(1-10 ¡rM) supports the notion that PTP activities play an important role in the regulation of
cellular proliferation (Endo et al., 1996). However, the concentrations of circulating BPs do
not reach the concentrations required to inhibit PTPo in OB. But it is possible that other
PTPs that are not yet identified or tested are more sensitive to BPs. The increase in bone mass
which is produced by BP treatment may not be fully explained by inhibition of bone
resorption. Therefore, the finding that BPs inhibit the activity of PTP expressed in OB and
stimulate the proliferation of these cells could provide additional clues regarding the action
and molecular targets of BPs.
1.4.4 The Effict of Bisphosphonates on Myeloma Cells
In a randomised, double blind, phase III study, the second-generation BP, pamidronate,
prevented bony complications in the patients with active Durie-Salmone stage III MM.
Skeletal-related events, including the incidence of pathologic fracture, the use of radiotherapy
to skeletal sties of disease, bone pain, episodes of hypercalcemia, and the need for narcotic
analgesia, were all signihcantly reduced in pamidronate-treated patients (Berenson et al.,
1996). Similar results were found with clodronate in MM patient in another clinical trial
(McCloskey et a1.,199S). There was also a significant prolongation of survival from 14 to 2I
months in the patients who were on salvage chemotherapy receiving pamidronate (Berenson
et a1.,1993). These survival advantages suggest that BPs not only decrease morbidity and
mortality associated with bone events but also may induce an anti-tumor effect resulting in a
longer survival rate. In support of these observations, several in vitro studies have shown that
BPs such as pamidronate and incandronate can decrease cell proliferation and induce
cytostasis and apoptosis in some human myeloma cells (Aparicio et a1.,1998; Shipman et al.,
1997). The third generation BP, YM529 at a concentration of 50 ¡rM, also induced inhibition
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of proliferation in all MM cell lines dose-dependently (Takahashi et a|.,2001). A slmergistic
induction of apoptosis was demonstrated when myeloma cell lines lvere exposed to a
combination of zoledronic acid and Dex (Tassone et a1.,2000). In addition, it was reported
that the BP, incadronate, caused apoptosis of myeloma cells in vitro by inhibiting the
mevalonate pathway (Shipman et a1.,1998). Bisphosphonate-induced apoptosis has also been
demonstrated in breast cancer cells. The osteolytic bone lesions induced by metastatic MDA-
231 breast carcinoma cells, as well as tumour burden in a mouse model of breast cancet)
could be reduced by risedronate (Sasaki et a1.,1995). These effects are considered to be the
results of both decreased osteoclastic bone resorption and inhibited release of bone-derived
tumour growth factors. However, although the potent BP ibandronate did not reduce tumor
burden, it significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing
mice (Cruz et al., 2001; Dallas et al., 1999; Shipman et a1.,2000). Despite these promising in
vitro and animal model studies, there is no direct evidence to support the notion that that BPs
induce apoptosis of myeloma cells in patients with MM.
Overall, these observations suggest that BPs might have some benefit not only on the
improvement of bone disease but also on the prolongation for survival in some myeloma
patients.
1.4.5 The Effect of Bísphosphonates on Cell Adhesion
There is also evolving evidence that BPs may act by inhibiting integrin-mediated adhesion.
As described in section 1.1.3, molecules that mediate cell adhesion molecules, such as
laminin and E-cadherin, play key roles in several important events involved in cancer cell
invasion and metastasis. Cell adhesion molecules (CAMs) mediate not only cell-to-cell but
also ce|l-to-substratum communications. The most abundant CAMs are integrins. Integrins
have been shown to mediate attachment of cancer cells to vascular endothelial cells and to
matrix proteins such as laminin and FN.
A large cohort of adhesion molecules modulating adhesion between myeloma cells and
stromal cells have been defined (Tricot, 2000; Uchiyama et al., 1993; Vidriales and
Anderson, 1996). Preliminary data suggest that BPs modulate adhesion molecule profile and
thereby overcome drug resistance (refer to Section 1rl.2). Adhesion assays using bone slices
pretreated with alendronate, at the established active concentration, showed that, although the
morphology of OC plated onto pretreated bone slices was not modified, the number of
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adherent OC was reduced about 50% compared with controls. The inhibitory effect of
alendronate on cell adhesion may be due to the interference with receptors specifically
recognising bone matrix proteins, such as crup3 integrins (Colucci et a1.,1998). For instance,
FN can be recognised not only by crsÞ¡ , but also by cruÊ¡, and bone sialoprotein (BSP) acts as
an adhesion molecule with which tumour cells establish contact with the bone matrix. Van
der Pluijm et al (van der Pluijm et al., 1996) showed that bone slices that were incubated
with BPs were resistant to the adhesion molecules of tumour cells. Another study showed
drastically reduced adhesion properties of breast and prostate carcinoma cell lines when the
cells were pretreated with BPs (Boissier et a|.,2000).
Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases with
proteolytic activity for a large range of components of the extracellular matrix, are also
known to play a critical role in bone remodelling and tumour invasion. Members of the MMP
family are divided into three classes based on their substrate specificity: collagenases,
gelatinases, and stromelysins. Interstitial collagenase (MMP-l) is the only protease beside
neutrophil collagenase that is known to initiate the degradation of types I collagen at neutral
pH. Collagen I is the major structural protein of bone and osteoid layer and the degradation
of collagen I is critical for the initiation of bone resorption. After fragmentation by MMP-I,
the denatured collagen I becomes a substrate for the gelatinases MMP-2 and MMP-9. It has
been reported that myeloma cells express MMP-9 and induce BM stromal cells to express
MMP-1 and MMP-2 (Barille et a\.,1997). An increase in MMP-1 levels reflects an enhanced
capacity to degrade collagen I. The conversion of proMMP-2 into its active form will
actively contribute to the final collagenolytic activity by achieving the degradation of
collagen I initiated by MMP-I. The beneficial effects of the BPs on the metastatic process
may be related to inhibition and downregulation of various genetically distinct MMPs
(MMp-2, MP-9, MMP-13, and membrane type MMPs (MT-MMPs)) that are obligatory for
successful tumor cel| invasion, and bone destruction at a metastatic site (Teronen et al.,
2000).
In bone metastases, it is conceivable that BPs released from resorbed bone inhibit the
proteolytic activity of MMPs secreted from tumor cells and stromal cells. It has been
demonstrated that the inhibitory activity of BPs on tumor cell invasion requires the R¿ chain
of the molecule, which is effective at low concentrations. Inhibition of MMP activity by BPs
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occurs however through the so-called "bone hook" of the molecule, which is effective only at
high concentrations (Boissier et al',2000)'
The many different actions of BPs suggest that inhibition of bone resorption can be due to the
overlap of several different actions ocurring together to exert their final effect.
More potent third-generation BPs are now available and have been shown to be 100-1000
times more potent than pamidronate, a commonly used BP in the treatment of MM. These
new BPs may therefore represent a better treatment option for patients with myeloma.
Bisphosphonates containing a hydroxyl group at the Rl side chain and a 1:ufüary nitrogen
within a ring structure in the R2 side chain appear to be the most potent anti-resorptive BPs
discovered to date, including zoledronic acid, which contains animidazole ring.
1.4.6 Zoledronic Acíd
Zoledronic acid (formerly referred to zoledronate), CGP 42' 446 l2-(imidazol-1-yl)-1-
hydroxyethylidene-l,1-bisphosphonate], is a heterocyclic imidazole, nitrogen-containing
third-generation Bp (figure 1.7). Among the clinically tested BP compounds, it is the most
potent amino-substituted BP, which appeares to be 850 times more active than pamidronate
in the thyroparathyroidectomized (TPTX) rats with hypercalcemia induced by 1, 25-(OH)2
vitamin D3, and 40-100 times more potent than pamidronate in inhibiting calcium release
induced by vitamin D3, parathyroid hormone, parathyroid hormone-related protein, or
recombinant human interleukin-1B from mouse calvaria in vitro (Green et al., 1994)' Unlike
the first generation Bps, zoledronic acid produces potent and specific inhibition of bone
resorption at low dose level without any significant detrimental effects on bone growth and
mineralization. Although both pamidronate and zoledronic acid cause a dose-dependent
suppression of cancellous bone tumover and resorption, and augment cancellous bone
formation in a rat model, zoledronic acid is 100 times more potent than pamidronate in vitro
and 850 times more active than pamidronate in vivo (Pataki et al., 1997). Recent clinical
trials show that very small doses of zoledronic acid can effectively normalise high calcium
levels in patients with tumour-induced hypercalcemia (Body et al., 1999)' In addition,
zoledronic acid has the largest therapeutic ratio of any BPs tested in terms of the desired
inhibition of bone resorption versus unwanted renal toxicity and inhibition of bone
mineralisation (Arden-Cordone et a1.,7997; Body, 1997; Buckler et al., 1999).It was also





Figure 1.7. Chemical structure of zoledronic acid. Zoledronic acid is a nitrogen-
containing heterocyclic imidazole bisphosphonate. It is 100 times more active than
pamidronate invitro and 850 times more active than pamidronate invivo.
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safe and well tolerated, and effectively suppressed bone resorption in cancer patients with
metastatic bone disease, in a phase I clinical study (Berenson et al.,200la; Berenson et al.,
2001b). Furthermore, a phase II trial demonstrated that zoledronic acid (4mg and 8mg) was
superior to pamidronate (90mg) in normalising serum calcium in cancer patients with
moderate to severe hlpercalcemia (Majot et a1.,2001)'
In addition to its highly potent effects on bone resorption, several preclinical studies suggest
that zoledronic acid exhibits anti-tumor activity. In vitro studies demonstrate that zoledronic
acid not only inhibits the proliferation of breast carcinoma cells (Fromigae et al., 2000) and
prostate cancer cells (Lee et a1.,2001), but also induces cytostasis and apoptosis of myeloma
cells (Apari cio et al., 1998). Zoledronic acid also may interfere with the process of metastasis
atvery low concentrations. It has been demonstrated that zoledronic acid at concentrations of
10-12-10-6 M, inhibits the ability of human prostate and breast carcinoma cells to invade the
extracellular matrix in vitro, without inducing apoptosis and inhibiting tumour cell migration.
However, apoptosis is induced at a higher concentration (10-a M) (Boissier et at., 2000).
These preliminary results suggest that zoledronic acid may prove to be a powerful drug in





BPs and TRAIL act synergistically to enhance myeloma cell death'
BPs disrupt the integrin-mediated cell adhesion of myeloma cells to Stromal/OB cells
leading to myeloma cell death.
BPs act via OB to inhibit bone resorption, by stimulating or inhibiting OB to produce
osteoclast-inhibitory or osteoclast-activating factors, respectively.
BPs possess anabolic activity and are capable of differentiating OB progenitor cells into
mature and functional OB.
1.6 AIMS AND EXPERIMENTAL RATIONALE OF THIS PROJECT





a To examine if BPs reduce bone resorption by acling on OB cells as well as OC cells
o To examine if BPs can induce new bone formation.
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1.7 SIGNIFICANCE OF PROJECT
The osteolytic lesions in MM represent one of the major clinical manifestations of the
disease. The new RANKL/RANIIOPG cytokine system and OC activating factors play an
important role in the normal bone remodelling and pathological bone resorption including
MM induced osteolysis. Numerous studies have shown that BPs provide gteat benefits to
MM patients including improved life quality and prolonged life expectation. Better
undcrstanding of the mechanism of actions of these compounds on osteolysis in cancer
patients provides a new means by which the mechanism of tumour metastasis can be
understood. Furthermore, it also enables us to obtain a greater understanding of normal bone
remodeling biology as well as its precise mechanisms of action'
This project is centred on investigating two aspects of BP activity, and include (1) finding a
new drug combination to overcome multiple drug resistance in MM patients, and (2)
understanding the normal biology of OB and the underlying mechanism of BPs on
osteoblastic bone formation.
V/e anticip a1e thatthis study will provide some novel and valuable insights into the molecular
and cellular mechanisms responsible for the clinical effectiveness of BPs on the skeletal




2.1. SOL(ITIONS, BUFFERS AND MEDIA
2.1,1 Sodíum þruvøte
Stock solutions of 100 mM sodium pyruvate (100x) were prepared by dissolving 1.1 g of
sodium pynrvate powder (cr-Ketopropionic Acid; 2-Oxopropanoic Acid, Sigma, USA, Cat.
No. P-5280) in 100 ml Milli-Q water. The solution v/as filter sterilised and stored at 4C.
2.1.2 2-Mercøptoethanol (2-ME)
A lM stock solution of 2-ME was prepared by diluting 0.7 ml of 14.27 M p-mercaptoethanol
(Sigma, St. Louis, MO, USA,Cat. No. M-3148) into 9.3 ml Hank's Balanced salt Solution
(HBSS, Infectious Diseases Laboratories, IMVS) and was stored at -20"C. The 1 M stock
solution was further diluted 1:10 (in HBSS) to prepare a 0.1 M working solution. This was
filter sterilised and stored as 500 ¡rl aliquots aI -20oC.
2.1.3 PI/Trìton X-100 Støining Solution v,ith RNAse A
The solution was prepared freshly by adding 0.2 mglml of DNAse-free RNAse A (Roche
Diagnostics, Castle Hill, NSW, Australia, Cat. No. C 109169),20 pglml of propidium iodide
(PI, Sigma Chemical Co. Ltd, St Louis, MO, USA), and 0.1% (vlv) Triton X-100 (ICN
Biomedicals Inc, Ohio, USA, Cat. No. 807423) to PBS.
2.1,4 Fluorometríc Caspase 3 Assøy Buffir
The fluorometric caspase 3 assay buffer @H 7.4) was prepared by adding 1.2% (wlv)
HEPES, l0% (wlv) sucrose (BDH AnalaR@, Victoria, Australia), and O.lYo (w/v) CHAPS (3-
[(3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonate (Pierce, IJkkinios, USA) to
MilliQ-water.
2.1.5 Btocking Bufferfor Flow Cytometric Anølysis
HBSS was supplemented with 0.4o/o (w/v) bovine serum albumin, 4%(vlv) normal human
serum (NHS; Red Cross, Adelaide, South Australia), 5%(v/v) foetal calf serum (FCS; CSL
Limited, Victoria, Australia, Cat. No. 09102301) and penicillin (50 i.u./ml)/streptomycin
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sulphate (50 pglml)(Csl Biosciences, Victoria, Australia, CaL No. 05081901). The buffer
was filter sterilised through a0.22 pm bottle filter (Nalge Nunc International Corp, USA) and
stored at 4C.
2.1.6 Flow Cytometry Fixative (FACS Fix)
To 1 litre of PBS, 10 ml of formaldehyde (40% w/v, ACE Chemical Company, Adelaide,
Australia), 20 g of D-glucose (BDH AnalaR@, CoHrzOo, Victoria, Australia), and 0.2 g of
sodium azide (Sigma, USA, Cat.No. 5-8032) were added.
2.1.7 Double-Strength Iscove's Modifted Dulbecco's Medium (2xIMDM)
To prepare 500 ml of 2xIMDM (Cytosystems, Castle Hill, NSW, Australia, Cat. No. 50-016-
PA), one sachet (17.67g) of IMDM powder was dissolved in Milli-Q water. To this, sterile
stocks of penicillin, streptomycin, DEAE-Dextran (Pharmacia-LKB Biotechnology AB,
Uppsala, Sweden, Cat. No. 170350-01) and L-asparagine (Sigma, Cat. No. A-0884) were
added at concentrations of 200 i.u./ml, 200 pglm|5.2 mglml and 0.4 mglml, respectively.
Filter sterilised medium was stored as 50 ml aliquots at -20oC or used immediately.
2.1.8 10%(w/v) Bovine Serum Albumin (BSA)
To prepare l}%(wlv) BSA, 20 g BSA (CSL Limited, Victoria, Australia, Cat. No. 06711701)
was carefully overlayed on the surface of Milli-Q water (88.4 ml), and was allowed to sit at
4.C for 24 hours. Once dissolved, 3 g of AG@ 501-X8 (D) Resin (Bio-Rad Laboratories, CA,
USA, Cat. No. 142-6425) was used to deionise the BSA and to remove trace elements and
contaminants. The beads were removed by filtration through Whatman No. I paper
(Whatman Laboratory Division, England) when beads had changed colour from green to
yellow. The procedure was repeated 3 times. An equal volume (100 ml) of 2x IMDM (or
2xPBS) was added to the BSA and sterilised by filtration through a 0.22 pm bottle filter,
prior to storage at -20"C.
2.1.9 Dulbecco's Modified Eøgles Medium-I0 (DMEM-I0)
To prepare 500 ml of DMEM-I0, Dulbecco' Modified Eagles Medium (JRH Biosciences,
USA, Cat. No. 51444-500M) was supplemented with penicillin (50 i.u./ml)/streptomycin
sulphate (50 pglml), l0o/o (v/v) foetal calf serum (FCS, CSL Limited, Victoria, Australia,
Cat. No. 09702301),2 mM of glutamine (JRH Biosciences, USA, Cat. No. 59202-I00M), 1
mM of sodium pyruvate, 15 mM of HEPES buffer (JRH Biosciences, USA, Cat. No' 59205-
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100M / TRACE Scientific LTD, Melbourne, Australia, Cat. No. 21-115-0100V), and was
buffered with 1 g of sodium bicarbonate (Infectious Diseases Laboratories, IMVS)' The
medium was subsequently filter sterilised and stored at 4"C. The medium was replenished
with 2mM L-glutamine at weekly intervals.
2.1.10 Alpha Mínimøl Essentiøl Medium-I| (a-MEM-LL) for Osteobløst-like Cell Culture
To prepare 500 ml of single strength o-MEM-1O,410 ml of cr-MEM (JRH Biosciences,
USA, Cat. No. 51451-500M) was supplemented with penicillin (50 i.u./ml)/streptomycin
sulphate (50 pg lml), l0o/o (v/v) FCS, 2 mM of glutamine, 1 mM of sodium pyruvate, 15 mM
of HEPES buffer, 100 pM L-ascorbate-2-phosphate (V/AKO pure chemical industries, LTD,
Japan, Cat. No. 013-12061), and buffered with 1 g of sodium bicarbonate. The medium was
subsequently filter sterilised and stored at 4"C. The medium was replenished with2 mM L-
glutamine at weekly intervals.
2.1.11 Alpha Minimal Essential Medium-L| (a-MEM-LL) for Myeloma Cell Culture
To prepare 500 ml of single strength o-MEM-10, 415 ml of a-MEM was supplemented with
penicillin (50 i.u./ml)/streptomycin sulphate (50 ¡rg lml),I0o/o (v/v) FCS, 2 r'rlNI of glutamine,
1 mM of sodium pyruvate, 15 mM of HEPES buffer, 0.45% (w/v) D-glucose (BDH
AnalaR@, CoHrzOo, Victoria, Australia) and buffered with 1 g of sodium bicarbonate. The
medium was subsequently filter sterilised and stored at 4"C'
2.2 CELL CULTURE
2.2.1 Humøn Myeloma Cell Lines
Myeloma cell lines RPMI 8226, ARH-77, and tJ266 were purchased from the American
Tlpe Culture Collection.WL2 was kindly provided by Dr. Doug Joshua, Royal Prince Alfred
Hospital, Sydney). All the myeloma cell lines were cultured in cr-MEM-lO supplemented
with glucose. The cells were cultured at a cell density of 2x10s cells/ml and the medium was
changed every 2 to 3 days. Cells were cultur ed at 37"C in the presence of 5%o COz'
2.2.2 Murine Cytokine-Dependent Myeloid Cell Line, FDC-PI
The murine cytokine-dependent myeloid cell line, FDC-PI, was cultured in DMEM-IO
supplemented with 100 U/ml of murine granulocyte macrophage-colony stimulating factor
32
(GM-CSF; which was kindly provided by Dr. Thomas J. Gonda, Hanson Institute). Cells
were culturedat3T"C inthepresence of 5YoCOz.
The cells were washed with DMEM-10 thrice and cultured in DMEM-I0 without GM-CSF'
Following starvation for 24 hrs, the cells were harvested and prepared as a positive control
for apoptosis and intranucleosomal fragmentation analysis (refer to section 2.3.5).
2,2.3 Normal Human Bone Cells (NHBC)
Trabecular bone specimens were obtained from osteoarthritis patients, during routine knee
and hip replacements, from the Department of Orthopaedic Surgery and Trauma at the Royal
Adelaide Hospital. Bone chips were cultured in T-75 tissue-culture flasks in c¿-MEM-1O
supplemented with 100 pM L-ascorbate-2-phosphate. Medium was changed two times per
week for 5-6 weeks, and cultures were incubated at 37" C in the presence of 5o/o COz until
confluent.
2.2.4 Normal Osteoblast Donor (NOD)
Normal OB-like cells (NOD's) were derived from young healthy donors as part of an
institutional ethics approved Normal Bone Marrow Donor Program. Briefly, the donated
bone marroìw was strained using a cell strainer (Becton Dickinson, USA) and the small bone
chips were washed through with HHF (HBSS supplement wíth 5o/o FCS) and cultured in cr-
MEM-10 supplemented with 100 ¡rM L-ascorbate-2-phosphate. Medium was changed twice
weekly for 5-6 weeks, and cultures were incubated at 37" C in the presence of 5o/o COz until
confluent.
2.2.5 Enzymatic Digestíon of Osteobløst-like Cell Cultures
Single-cell suspensions were obtained from confluent primary osteoblast-like cell cultures by
enzymatic digestion. The cells were washed twice in PBS, and then digested in a 2 ml
mixture of collagenase (1 mg/ml, Worthington Biochemical Corporation, NJ, USA) and
dispase (l mglml, Boehringer Mannheim, Cat. No. 165859) for 45 mins at 37"C. The
detached cells were transferred to a 50 ml Falcon tube, following a wash in 10 ml PBS. The
remaining adherent cells were treated with Trypsin-EDTA (0.05% trlpsin, 0.53 mM EDTA-4
Na, GIBCO Invitrogen Corporation, Canada, Cat. No. 15400-054) for 5 mins at 37' C. After
washing with HHF, cells were mixed and pelleted by centrifugation at 1.,400 rpm for 5 mins
and used in experiments outlined below.
JJ
2.2.6 Cryopreservation of Cells
Cells were cryopreserved in FCS containing 70o/o (v/v) of the cryoprotectant, dimethyl
sulphoxide (DMSO, BDH AnalaR@ Merck Pty Limited, Victoria, Australia). Immediately
prior to freezing,0.5 ml of sterile freeze mix (20o/o (v/v) DMSO in FCS) was added dropwise
with mixing, to 0.5 ml of FCS containing 5-10 x 106 cells. The cell mixture was kept on ice
and immediately transferred to cryoampoules (Greiner Labortechnik) for liquid nitrogen
storage (-196' C).
2.2.7 Thcrwing Cryopreserved Samples
Following removal from liquid nitrogen storage, cryoampoules were rapidly thawed at 37"C,
and the cells were transferred to a 14 ml pollpropylene round-bottom tube (Becton
Dickinson, NJ, USA), Dropwise, 3 ml of appropriate medium was added, and then the
sample was made up to a final volume of 10 ml. Cells were pelleted by centrifugation at
1,400 rpm for 5 minutes, and subsequently washed twice in medium to remove residual
DMSO. Finally, cells were resuspended in appropriate growth medium and cultured in T75
flask (Greiner Bio-one, Germany) at37"C in the presence of 5%o COz'
2.3 EFFECT OF ZOLEDRONIC ACID ON THE CELL GROWTH
2.3.1 Reøgents Used in Thís StudY
Zoledronic acid was kindly provided by Dr Kevin Lynch (Novartis Pharmaceuticals).
Recombinant soluble human TRAIL (Peprotech, Rocky Hill, NJ, USA) and TNFcr were
kindly provided by Drs. Andreas Evdokiou and Pu Xia, respectively (Hanson Institute).
2.3.2 Cell Proliferation AssøY
2.3.2.1 Dose Dependent Effects of Zoledronic Acid on Myeloma Cells
Different myeloma cell lines were seeded in 96-we11 plates (Nalgene Nunc International,
Denmark), at a density of 1x104 cells per well in 100 ¡rl of cr-MEM-lO. Cells were cutured
with zoledronate at different concentrations for 3 days. The relative number of viable cells in
each well was determined on day 3 using the colorimetric assay reagent WST-I (Roche
Molecular Biochemicals, Cat. No. 1644807). Briefly, 10 pl of WST-1 was added to each
well, including three wells containing only medium, to enable background subtraction. WST-
1 is a tetrazolium salt that is cleaved to formazan by cellular enzyrnes. An expansion in the
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number of viable cells results in an increase in the overall activity of mitochondrial
dehydrogenase in the sample that leads to an increase in the amount of formazan dye' After a
2.5-hour incubation at 37"C in the dark, the colour of the medium turned to orange, which
was proportionate to the degree of cell viability and cell number. The absorbance of dye
solution was measured directly with a plate reader (BIO-RAD Model 3550 microplate reader,
CA, USA) using the test wavelength of 450 nm. Different treatment groups were performed
in triplicate and the results were compared against controls using the Student's /-test'
2.3.2.2 Dose Dependent Assay of TRAIL on Myeloma Cells
Myeloma cell lines v/ere seeded in 96-well plates as described in section 2.3.2.1.
Alternatively, the cells were treated with recombinant soluble human TRAIL at different




2.3.2.3 Cell Proliferation Assay of Osteoblast-like cells Treated with Zoledronic Acid
Osteoblast-like cells from three different donors (two NHBCs and one NOD) were seeded
into 96-we11 plates using the ACDU facility of the FACStar cell sorter at a cell density of
4000 cells/well and incubated at 37oC for 24 hrs in a-MEM culture medium. The medium
was then replaced with 100 pllwell fresh medium containing various concentrations of
zoledronic acid. The cell number was assessed using WST-I on day 3, as described before'
Altematively, when exploring the effect of zoledronic acid on the growth of osteoblast-like
cells, STRO-I* and STRO-I- cells were sorted directly into the 96-well plates at a cell
density of 4000 cells/well, and cell proliferation assay was performed as discribed above'
2.3.2.4 Cetl Proliferation Assay Examing the Effects of Zoledronic Acid and TRAIL on
Myeloma Cells
Myeloma cell lines were seeded into 96-well plates as described in section2.3.2.l. The cells
were exposed to both TRAIL and zoledronic acid. The RPMI 8226 cell line was treated with
zoledronic acid at concentrations from 0.01 to 25 ¡rM and TRAIL at constant concentration
of 30 nglml. The concentration of zoledronic acid used for the ARH-77, WL2 andU266 cell
lines was from 0.1 to 50 ¡.rM with 100 nglml of TRAIL. The cell number was assessed on day
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3 and day 5 by using WST-I, as described previously. The experiment was performed twice
with triplicate well samples.
2.3.3 Time Course Experiment of Zoledronic Acid on Myeloma Cells
Myeloma cells in exponentially grown phase were seeded into 48-well plates at an initial
concentration of 5x104/ml. Zoledronic acid was added at the specified concentrations (10 ¡rM
for ARH-77, RPMI 8226 and Balm, 50 pM lor WL2 andU266). At each time point after
treatment, the cells were harvested and counted in triplicate using a haemocytometer. The
viability was determined by trypan blue dye exclusion. Two separate counts were performed
on each sample and the results were compared against controls using Student's /-test.
2.3.4 Analysis of Nuclear Morphology
To assess the effect of zoledronic acid on cell apoptosis, myeloma cells were seeded into 96-
well plates at the cell density of 1x104 cells per well and treated with 0, 5 and 25 ¡t'ld
zoledronic acid for 48 hrs, respectively. The cells were cytospun onto slides using a Shandon
cytospin 2 (500 rpm for 5 min), air dried over night and fixed in FACS fix for 10 mins at
room temperature. The cells were stained with 1 ¡tglml DAPI (4'-6-diamidino-2-phenyl-
indole, Sigma, USA) in PBS lor l-2 mins and examined with the fluorescence microscope.
Apoptotic cells were defined on the basis of the characteristic changes in nuclear
morphology, including condensation of chromatin to produce crescent shapes around the
periphery of the nucleus and apoptotic bodies'
Alternatively, osteoblast-like cells \Mere cultured in 8-chamber slides (Nalge Nunc
International, Denmark) and treated with 5 ¡rM zoledronic acid. The cells were centrifuged
before being fixed with FACS fix for 10 mins. The cells were stained with DAPI and
assessed using fluorescence microscopy as described above.
2.3.5 Agørose Gel Analysis of Intrønucleosomøl Fragmentatíon
The osteoblast-like cells from different donors were detached by trypsin and washed once
with cold PBS. The cell viability was determined using typan blue exclusion. The cell pellets
were treated with lysis buffer (10 ¡rl/106 cells with a minimum of 50 ¡.rl) for 10 seconds: 1olo
(v/v) NP 40 (Nonidet@P 40, Fluka, BioChemika),20 mM EDTA, 50mM Tris-HCl(pH 7.5) in
MilliQ-water. The nuclei were pelleted by centrifugation at 1,600 xg for 5 mins. The
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supernatant was collected and the nuclei were resuspended in 50¡rl of lysis buffer. The
suspension was brought up to final concentration of 1% SDS (5pl of 10% SDS for 50 ¡rl) and
treated for 2 hrs with RNAse A (5¡rg/pl) at 56oC, and subsequently digested with Proteinase
K (PK, 2.5 pgl¡;J, Sigma, Cat. No. P 2308) for 2 hrs at 37"C. This was followed by the
addition of 0.5 volumes of 10 M ammonium acetate, and the DNA was precipitated with 2.5
volumes of absolute ethanol. The reaction was incubated on ice for 10 mins, and centrifuged
at 12,000x g at 4"C for 15 mins. The DNA pellet was air dried and then dissolved in loading
buffer. The DNA ladder was separated by electrophoresis on I% (wlv) agarose gel and
visualised with SYBR Gold (Quantum Scientific, Cat. No. S-11494) staining.
2.3.6 Cell Cycle Analysis
Untreated and zoledronate-treated myeloma cells (10 pM for RPMI 8226 and 25 pM for
WL2) were harvested and washed twice with PBS, and then fixed in 70% (vlv) cold ethanol
for at least2 hrs at 4oC. After fixation, the cells were pelleted by centrifugation at 1100 rpm
for 5 mins. The cells were washed once with PBS and stained with 1 ml of PVTriton X-100
staining solution (containing RNAse) for 30 mins at room temperature (or at 37'C for 15
mins) in the dark. Cell cycle distribution was determined by analysing 10,000 events on a
Excel flow cytometer (Beckman Coulter) using the red fluorescence of excited propidium
iodide-stained nuclei as a measure of DNA content. Linear displays of fluorescence
emissions were fitted to cell cycle distribution analysis by use of the MODFIT program for
MAC Y2.0. The degraded sub- Go/Gr DNA content was quantitated and considered
characteristic of an apoptotic cell.
2.3.7 Cøspase Activity Assay
Caspase-3 activity was measured by determining the degradation of the fluorometric
substrate DEVD (Ac-Asp-Glu-Val-Asp-AFC), which contains the amino acid sequence of
the caspase-3 cleavage site in poly (ADP-ribose) polyrnerase (PARP), conjugated with AFC.
Cells were lysed in caspase lysis buffer (5 mM Tris-HCl lpIl7.4l, 5 mM EDTA lp}J 7.61,
0.5% NP a0) by incubating on ice for 20 mins with shaking. Protein concentration \¡/as
measured using Bicinchoninic Acid (Pierce, Illinios, USA). Lysates (15 pg protein) were
incubated with 200 ¡rl of caspase activity assay mixture (Fluorometric caspase 3 assay buffer
þIJ7.al supplemented with 10 mM DTT and 9 pM caspase-3/ CPP 32 substrate IAo-DEVD-
AFC, Kamiya biomedical company]) for 4 hours at room temperature in the dark. The
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released fluorescent molecule AFC (7-amino-4-trifluoromethyl coumarin) was measured in a
microplate fluorescence reader FL 500 (Bio Tek Instruments, 
'Winooski, Vermont USA) with
emission wavelength of 505 nm.
2.4 DETECTION OF GENE EXPRESSION IN CELLS
2.4.1 TRlzolrvlsolation of Total RNA
Total RNA was extracted from 5-10x106 cells by adding 1 ml of TRIzolrM (Life
Technologies, Catl No. 15596-026). Washing cells before addition of TRIzol reagent was
avoided as this increases the possibility of mRNA degradation. RNA was solubilised by
passing the lysate through a pipette several times. The homogenized samples were incubated
for 5 minutes at room temperature to permit the complete dissociation of nucleoprotein
complexes. To each tube, 0.2 ml of chloroform (APS Finechem, A division of Asia Pacific
Specialty Chemicals Limited CAN, NS'W, Australia) was added per I ml of TRIzol Reagent.
The tubes were shaken vigorously by hand for 15 seconds and then incubated at room
temperaturefor2 to 3 mins. The samples were centrifuged at 12,000xg for 15 minutes at 4o
C to separate the mixture into a lower red phenol-chloroform phase, an interphase, and a
colourless upper aqueous phase. RNA that remained exclusively in the aqueous phase was
carefully removed and transferred to a fresh 1.5 ml eppendorf tube (Scientific Specialties
Incorporated Life Technologies Australasia, Cat. No. 1220-00). The total RNA was then
precipitated by the addition of 0.5 ml of isopropyl alcohol (BDH Chemicals, Victoria,
Australia, Cat. No. 10224) per 1 ml of TRIzol Reagent used for the initial homogenization'
Following incubation for 10 mins at room temperature, the RNA was pelleted by
centrifugation at 12,000 x g for 10 mins at 4"C. The RNA pellet was washed once withT5o/o
(v/v) ethanol by adding at least 1 ml of 7 5o/o ethanol per 1 ml of TRIzol Reagent used for the
initial homogenization. The samples were mixed by vortexing and were centrifuged at 7,500
x g for 5 mins at4" C. At the end of the procedure, the RNA pellet was briefly air-dried at
37" C for 5-10 mins. RNA was resuspended in RNase free diethylpyrocarbonate (DEPC,
Sigma Aldrich Ltd, Cat. No. D 5768)-treated Milli-Q water, and to facilitate RNA solubility,
the samples were incubated for 10 minutes at 55 to 60o C. The concentration of RNA was
determined by spectrophotometry, and the integrity of the RNA was determined by l% (w/v)
agarose gel electrophoresis. RNA was stored at -80'C or used immediately for cDNA
synthesis.
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2.4.2 Determínation of RNA Concentrøtion
The concentration of RNA in solution was determined by measuring the absorption at 260
nm on a Beckman UV spectrophotometer (Beckman Instruments, Mt. Waverley, Victoria,
Australia), assuming that an A¿oo of 1.0 represents 40 pglml of RNA. Alternatively, the
sample was electrophoresed in agarose gels and the intensity of the sample's ethidium
bromide-stained bands was compared with the intensities of bands containing RNA standards
of known concentration.
2.4.3 Reverse Trønscríption (RT) Polymerase Chain Reaction (PCR) Amplificøtion of
DNA
2.4.3.1 Synthesis of Complementary DNA (cDNA)
Total cellullar RNA from cell lines or tissues was prepared with TRIzol, as described in
section 2.4.1. The following components were added to a nuclease-free microcentrifuge tube:
1 pl random hexamers (Geneworks, Cat. No. RP-6) at the concentration of 250 nÚþ1,1¡rg of
total RNA and RNase free DEPC-treated Milli-Q water to 12 p"l. The mixture \¡/as heated at
70oC for 10 mins and quickly chilled on ice. The contents of the tube was collected by brief
centrifugation and was then added to a mixture containing 4 þl of 5x first strand buffer, 2 pl
of 0.1M DTT, and 2 ¡rl of 5 mM dNTP Mix (5 mM each dATP, dGTP, dCTP and dTTP at
neutral pH). The contents of the tube were mixed gently and incubated at room temperature
for 10 mins. One ¡rl (200 units) of Suppnscrupr II (Gibco Life Tech, Cat. No. 18064-014) was
added and mixed by pipetting gently up and down. The mixture was incubated at 42"C for 50
mins and the reaction was inactivated by heating at 70"C for 10 mins. The cDNA was then
used as a template for amplification in PCR.
2.4.3.2 Polymerase Chain Reaction (PCR) Amplification of cDNA
gDNA was amplified by PCR to generate products corresponding to mRNA encoding the
gene products. One pl of each oDNA synthesis reaction was ustilised as template DNA in
each PCR reaction. Routinely, the cDNA mixture was added to a 200 ¡.rl microcentrifuge
tube, to which 2 ¡i of 10 x PCR amplification buffer (10 x PCR buffer: 670 mM Tris HCI pH
8.8, 166 mM (NH+)zSO+, 4.5%oTnton-X 100, 2 mglml gelatin), 1.2 ¡i of 25 mM MgCl2,2 ¡l
of 2 mM dNTP mixture, 100 ng each of the appropriate sense and antisense primers (table
7),0.2 pl (1 Unit) of Amplitaq DNA Polymerase (Applied Biosystems, Roche, Switzerland),
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and DEPc-treated water were added to a final volume of 20 ¡r1. Amplitaq Gold is a "hot
start" DNA polymerase that has an inactivating protein modification that only allows the
enzyme to become active at high temperatures. Amplification was achieved by incubation in
a Corbett Research thermal cycler. DNA was amplified under the following typical cycling
conditions: denaturation at 94"C for 1 minute, annealing at the temperatures suitable for
different primers for 1 minute, extension at 72"C for 1 minute for 20-40 cycles, with a final
10 minutes extension performed at 72"C, such that all products were assayed in the
exponential phase of the amplification curve. Following amplification, the PCR products (10
¡rl of each reaction mixture) were separated on 2% (wlv) agarose gel according to molecular
weight, and visualised by SYBR Gold staining under UV light at 570 nm.
2.4.4 Primers Used in This Study
All the primers used in these studies are displayed in table 1. The cycle numbers were
determined by cycle course analysis, and annealing temperatures were determined
empirically using AmpliTaq Gold in a gradient thermal cycler.
2.5 IMMUNOFLI]ORESCENCE STAINING AND FLOW CYTOMETRY
Flow cytometry was performed using an Epics@-XL-MCL analyser (Beckman Coulter).
Cells to be analysed were immunostained with primary antibodies that recognise specific
antigens of interest. Cell populations were analysed on the basis of their forward and side
light scattering properties, which is indicater of cell size and cell density, respectively'
2.5.1 One-Colour Flow Cytometric Analysis
Cells were harvested from culture (2xl0s cells per condition), and pelleted by centrifugation
at 1,400 rpm for 5 mins at 4C. Prior to immunolabelling, cells were incubated in blocking
buffer at a concentration of 5x106 cells/ml, and were incubated on ice for 30 mins. For each
condition, aliquots of 2x10s cells were incubated with 50 ¡rl of antibody or isotype-matched
control (used as culture supernatants or purified mAbs al a final concentration of 10 ¡rg/ml).
After a 45 minute incubation at 4oC, the cells were washed twice in chilled HHF to remove
unbound antibody, and the pellets were resuspended in 50 ¡rl HHF containing 1:50 dilution of
fluorescein isothiocyanate (FlTC)-conjugated or phycoerythrin (PE) conjugated goat anti-
mouse Ig (Southern Biotechnology Associates Inc. Birmingham, AL, USA). Following
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Table 1: RT-PCR primers and conditions for the specific amplification of human mRNA.
Target
Gene






































































































































* Osteoblastlike cells ** Myeloma cell lines
1. Atkins et a1.,2000b
2. Atkins et a1.,2000a
3. Gronthos et al.,1999
4. Genebank accession number NM 000963
5. Evdokiou et a1.,2002
6. Genebank accession number XM 015606
incubation with secondary antibody for a further 45 mins at 4"C, cells were washed as above
and fixed in FACS fix. Tlpically, for each sample 10,000 events were analysed on the flow
cytometer, and stored as list mode data for further analysis using WinMDI software
(Windows Multiple Document Interface Flow Cytometry Application, 1993-1998 Joseph
Trotter).
Altematively, when cells were stained with rabbit anti human antibodies (OCN and
RANKL), a l:200 dilution of RDF (Sheep Anti-Rabbit Immunoglobulin F (ab)z Fraction
Fluorescein conjugated, AMRAD Biotech, Victoria, Australia, Cat. No. 984141020) was
used as a secondary antibody.
2.5.2 Intracellular Antigen Detection
Single cells were blocked in blocking buffer for 30 mins on ice and then washed twice in
PBS. After fixing in lo/" (w/v) paraformaldehyde (BDH Chemical Ltd, England) in PBS for
20 mins at room temperature, cells were washed twice by HHF containing 0.1olo saponin
(w/v, Sigma Cat. No. 5-4521). The cells were resuspended with 50 pl of culture supernatant
or purified mAbs at a final concentration of 10 ¡rglml (diluted in HHF containing 0.1%
saponin). Following a 60 min incubation at 4"C, the cells were washed twice in HHF
(containing 0.1% saponin), and resuspended in wash medium containing a 1:50 dilution of
goat anti-mouse IgG (y-chain specific)-FlTC and a goat anti-mouse IgM (p-chain-specific)-
PE. After a further incubation at 4oC for 45 mins, the cells were washed as described above
and then fixed in FACS fix prior to analysis.
2.5.3 Two-Colour Flow Cytometric Analysis
The single cells were incubated in blocking buffer for 30 mins. For each condition, aliquots
of 2x105 cells were incubated with 100 pl of STRO-1 mAb supernatant and 100 ¡rl of B4-78
at the concentration of 10 ¡rglml for t hour on ice. The isotype matched negative control
antibodies, IgGr (1B5) and IgM (146.12) were used under identical conditions. The cells
were then washed in HHF and incubated with a goat anti-mouse IgG-FITC (l:50) and a goat
anti-mouse IgM-PE (1:50) for 45 mins on ice. The cells were then washed twice and
resuspended in 300 pl of FACS fix prior to analysis.
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2.5.4 Anølysis of cetl cycling status of sTRo-I* ceus hy Ki-67 Reactivity
Single cell suspension of osteoblast-like cells was stained with STRO-I using a goat anti-
mouse IgM-PE conjugated second label as described in section 2.5.1. After staining, the cells
were washed twice with ice cold PBS and then fixed with cold ethanol (70%) for 10 mins on
ice. Following this, the cells were washed thrice with PBS and then incubated in blocking
buffer for 15 mins. The monoclonal antibody FlTC-conjugated Ki-67 (DAKOPATTS a/s,
Denmarþ was added directly to the cells (1/10 dilution in blocking buffer) for 45 mins on
ice. The FITC conjugated mouse IgGl negative control antibody was used under the same
conditions. After washing and fixation, the cells were analysed by dual-colour flow
cytometric analysis.
2.5.5 Three-Colour Flow Cytometríc Analysis
Single cell suspension of osteoblast-like cells were dual stained with ALP and STRO-1 using
a goat anti-mouse IgG-FITC and IgM-PE conjugated second label as described in section
2.5.3. After staining, the cells were fixed in 0.5Yo (wv) paraformaldehyde in PBS (2x106
cells/ml) for 30 mins at 4oC. Then cells were washed once in TPBA (PBS supplement with
0.lo/o Tnxton 100, 0.1% BSA and 0.\o/o sodium azide) and resuspended in 500 pl TPBA
containing 5pg RNAse. The cells were incubated at 37" C for 20 mins and washed once by
TpBA. The cells were resuspended in 500 ¡rl PBA (PBS supplement with 0.1% BSA and
0.1% sodium azide) containing 5 pglml 7-aminoactinomycin D (7-AAD, Molecular Probes,
Netherlands, Cat. No. A-1310) and stored in dark at 4"C until ready to analyse (at least t hr
after staining).
2.5.6 Carboxyfluoresceín Diøcetate Succinimidyl Ester (CFSE) Løbelling of Cells
The cell-permeant fluorescein-based dye CFSE covalently attaches to cytoplasmic
components of cells, resulting in uniform bright fluorescence. Upon cell division, the dye is
distributed equally between daughter cells, allowing the resolution of up to eight cycles of
cell division by flow cflometry. This technique was used to determine division-related
phenotypic and functional change during differentiation of osteoblast-like cells.
The osteoblast-like cells were detached as described previously. The cells were washed once
and resuspended in I ml of PBS/0.1% BSA, and2 pl of 5 mM CFSE (final 10 ¡^tM) was
added to the cells and incubated at 37oC for 10 mins. The staining was quenched by adding 5
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volumes of ice cold culture media (u-MEM supplemented with 10% FCS), followed by
incubation on ice for 5 mins. The cells were washed three times in the culture medium and in
vitro cultures were established as described below.
At appropriate time points, the cells were detached by Trypsin-EDTA and were stained with
STRO-I or ALP mAbs coupled with PE as described above. Dual-colour flow cytometric
analysis was performed to analyse samples.
2,5.7 Fluorescence-Activated Cell Sorting (FACS)
After detachment, approximately 1x107 osteoblast-like cells were pelleted in 14 ml
polypropylene tubes and resuspended in 2 ml (100 pl/ 5x10s cells) of a saturating
concentration of STRO-1 supernatant for 60 minutes on ice. The monoclonal mouse isotype
control Ig M (146.12) was used under identical conditions. The cells were then washed in
HHF and incubated with a goat anti-mouse IgM-PE (1/50) in a final volume of 1 ml (50 pV
5x10s cells) for 45 minutes on ice. The cells were resuspended to approximately 106 cells/ml
and passed through a cell strainer to obtain a single cell suspension prior to analysis using
FACStarPLus flow cytometer (Becton Dickinson, Mountain View, CA, USA). Positive
fluorescence for STRO-1 stainingwas defined as the level of fluorescence greater than99o/o
of the corresponding isotype-matched control antibody.
STRO-I positive and negative cells were collected and cultured in the presence/absence of
different treatments. Single cell deposition was performed using the ACDU facility of the
FACStaTPLUS cell sorter and 4000 single cells were sorted directly into the appropriate
medium in 96-well plates for cell proliferation assays.
2.5.8 Antibodies Used ín Thís Study
All the antibodies used in this study are listed in the table 2
2.6 CELL ADTIESION ASSAYS
2.6.1 Cølciene Labelling of Non-Adherent Cells.
Untreated and zoledronate (5 pM) treated myeloma cells were washed twice and resuspended
in 500 pl cell adhesion buffer (IMDM-0.2%BSA). Ten pM calciene-AM (stock 1 mM in
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Table 2: List of Antibodies Used in This StudY










anti-human bone/liver/kidney isoform of ALP mlgGl DSHB
Erythroid, Stromal cells, CFU-F, Endothelial cells mIgM DSHB
Osteoclacin (OCN), Bone-associated matrix protein rlg G Dr. L' Fisher2
Cell cycle antigen (Gr, S, M, &G2) mIg G, DAKO3
TNF-related activation induced cytokine dgGro R&D4
Receptor activator of nuclear factor-rB ligand tnlg G Santa Cruz5
vascular cell adhesion molecule-l (VCAM-l), CD106 mlg G1 Dr. B.
Masinovski6
R&DTumour necrosis factor-related apoptosis-inducing
ligand
h TRAIL-RI, Death-signalling receptor of TRAIL
mlg G1
dgGru R&D
h TRAIL-R2, Death-signalling receptor of TRAIL rnlg Gt R&D
h TRAIL-R3, Antagonist decoy receptors of TRAIL mlg Gt R&D
h TRAIL-R4, Antagonist decoy receptors of TRAIL dg Gt R&D
B2 microglobulin (MHC class I o subunit) mIg Gt Dr. 
L.
AshmanT
DAKOMembrane-bound glycoproteins expressed on the
surface ofnearly all nucleated cells
Subunit of HLA Class I
mlgG2u
mlg M PharMingen8







8A2 (p1) CD2g,Úrtegrin Blsubunit(mAb shown to activate B1
integrin function)








1992 (u3þl) CD49clCD29, VLA-3ct, integrin cr3 mlg G1 Chemicon
Table 2: List of Antibodies Used in This Study, Continued.
Antibody Name Specificity Isotype Source
P4C2 (a4) CD49í/CD29,YLA-4a, integrin a 4
1999 (crsÞ1) CD49elCD29, VLA-5cr, integrin cr 5
PHM2 (cr5Bl) CD49elCD29, VLA-5o, integrin cr 5
aF10 (cr6B1) CD49flCD29, VLA-6cr, integrin a 6
1997 (crvp3) Integrin ovB3
23 C6 Úrtegrin ovB3
Leucocyte Function Associated- 1 antigen (LFA- 1 ),
alpha chains
Phagocytic glycoproteìn-1 (Pgp-1), CD44
Leucocyte Common Antigen (LCA)
Intracellular Cell Adhesion Molecule-1 (ICAM-1),
CD54
Natural killer cell, N-CAM, NKH1
mlg G1 Dr. L. Ashman
dgGru Chemicon




mlg G1 Dr. L. Ashman
mlg G, Immunotechra























Syndecan-1, a heparin sulfate bearing integral membrane mlg G1
proteoglycan
Isotype-matched negative control/ o-Giardia mlg Gt
Mayrhoferr
Isotype-matched negative control/cr-Salmonella dgGru Dr. L. Ashman
Isotype-matched negative control/cr-S almonella mlgGro Dr. L. Ashman
Multiple antigenic peptide(MAP, HBV 2I-47 pre S) rlg G Dr. G. Atkinsl8
7
tA6.t2 Isotype-matched negative control/a-Salmonella mlg M Dr. L. Ashman
DSHBT: Developmental Studies Hybridoma Bank, University of Iowa, IA, USA
Dr. L. Fisher2: Craniofacial and Skeletal Disease Branch, National Institute of Dental and
Craniofacial Research, National [rstitute of Health, bethesda, maryland, USA
DAKO3 : DAKAOPATTS A/S, Glostrup, Denmark
R&Da: R&D Systems Inc. Minneapolis, MN, USA
Sants Cruzs: Santa Cruz Biotechnology, Inc. Santa Cruz, California, 95060, USA
Dr. B. Masinovski6: FCOS Cotp., Seattle, WA, USA
Dr. L. AshmanT: School of Biomedical Science, The University of Newcastle, NSW, Australia
PharMingens: BD Biosciences, San Diego, California, USA
Dr. J. Gamblee: Dept. Human Immunology, Hanson Lrstitute, I.M.V.S, Adelaide, South Aushalia
Drs. J. Harlan and N. Kovachl0: University of Washington, Seattle, USA
Chemicon,CArr: Chemlcon Inc. Pittsburgh, PA, USA
Prof. R. A. Atkinsr2: Monash Medical Centre, Melbourne, Victoria, Australia
Serotecl3: Serotec, Oxford, England
Immunotechla: Bio Online,Inc. Berkeley, CA, USA
Dr. P. Simmonsl5: Stem Cell Biology Laboratory, Peter MacCallum Cancer Institute, Melboume,
Victoria, Australia
Becton Dickinsonl6: Becton, Dickinson and Company, NJ, USA
Dr. G. MayrhoferlT: Molecular Lifescience, University of Adelaide, South Australia, Australia
Dr. G. Atkinsls: Department of Orfhopaedics and Trauma, University of Adelaide, South Australia
DMSO) were added to the cells and incubated at37oC for 60 mins. Cells were washed twice
in adhesion buffer and resuspended at an appropriate density (l-2x 104 cells/ well). The assay
was performed in triplicate.
2.6.2 Cell Adhesion Assøys of Myelomø Cells on Fibronectin or VCAM-I
After labelling with calciene, myeloma cells were washed twice with adhesion assay buffer,
resuspende d in 25 pl of adhesion buffer at a concentration of 8x 10s cells/ml, and chilled on
ice for 10 minutes prior to assay. The same volume of different test antibodies was added to
the cells and 50 ¡rl of the labelled cell suspension was placed, in triplicate into 96 wells
previously coated with Fibronectin or VCAM-I (10 ¡rglml, 50 prl/well). The entire procedure
was carried out on ice. Plates were centrifuged at 1,000 rpm for 5 mins at 4"C to sediment
cells into direct, uniform contact with treated surfaces. Plates were incubated in a humidified
(100%) incubator at 37"C for the indicated periods (usually 90 mins). Assay medium was
removed by aspiration and wells were washed three times by adding 150 pl of the adhesion
assay medium and flicking it off. After the last wash, cell adhesion was examined using an
inverted-contrast microscope before adding 150 ¡rl of lo/o (w/v) sodium dodecyl sulphate
(SDS) in HzO. Plates v/ere scanned using the Fluorimag"rtt 595 (Sunnyvale, CA, USA)
using the 530 nm filter.
2.7 IN VITRO MINERALISATION AND MEASUREMENT OF CALCIUM
PTIOSPHATE PRODUCTION
The conditions for the induction of human bone marrow stromal cells to develop mineralised
bone matrix in vitro have been reported by Gronthos et al (Gronthos et al., 1994). Briefly,
primary BM stromal cells were seeded into 96-well plates (8x103 cells/well), in cr-MEM
supplemented with 10% FCS, B-mercaptoethanol (5x10-5 M), dexamethasone sodium
phosphate (10-8 M), and KHzPOo (1.8 mM) at 37"C in the presence of 5Yo COz. The medium
was supplemented with zoledronic acid at the different concentrations. Culture medium
(200p1) was changed at weekly intervals for a period of 5 weeks. Alternatively, cells were
only treated with zoledronic acid at day 0 (d0). Calcium levels were determined as described
below at weekly intervals. The cultures were washed three times with Ca+ and Mg* free PBS
and then solublized in 0.6 N HCI (100 ¡rl per well) ovemight. Samples from each well were
then reacted with o-cresol-phthalein-complexone, and the colorimetric reaction was read at
570 nm. The absolute calcium concentration was determined by a standard curve for calcium
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according to the manufacturer's recommendations. The method used here is based on the
cresolphthalein complexone (CPC) method of Moorehead and Briggs (Moorehead and Biggs,
lg74). CPC reacts with calcium and magnesium in alkaline solution to form a deeply
coloured complex. The intensity of the purple colour formed is proportional to the calcium
concentration and can be measured photometrically between 540 and 600 nm with maximum
absorbance at 575 nm. Alternatively, the calcium levels were also detected using AAnalyst
300 Atomic Absorption Spectrometer (Perkin Elmer intruments). Statistical significance
(p<0.05) in the level of calcium detected between the zoledronic acid-treated BM stromal cell
cultures and the untreated cells was determined using the paired /-test.
2.8 STATISTICALANALYSIS
Results are expressed as the mean +the standard error of the mean (SEM). Student's /-test
was used to determine the statistical significance of differences between the means of several
experiments for normal distribution data. Wilcoxon test was used for non-parametric data.
Spearman's test was used for correlation analysis. A probability value < 0.05 was considered




MYELOMA CELL LINES EXHISIT INHIBITION OF CELL PROLIFERATION AND
ENHANCED CELL DEATH IN RESPONSE TO ZOLEDRONIC ACID
3.1 INTRODUCTION
It has been demonstrated that BPs prevent bony complication and prolong the survival of
myeloma patients in clinical trials (Berenson e/ a1.,1998; Berenson et al.,1996; McCloskey
et a1.,1998). This survival advantage has been attributed to anti-tumour effects mediated by
the BP family of drugs. In vitro studies have demonstrated that BP such as pamidronate and
incandronate, can decrease cell proliferation and induce cytostasis and apoptosis in some
human myeloma cells (Aparicio et a\.,1998; Shipman et a\.,1,997; Takahashi et a|.,2001). A
synergistic induction of apoptosis was also observed when myeloma cell lines were exposed
to a combination of zoledronic acid and dexamethasone (Tassone et a|.,2000).
Simultaneously, it was found that TRAIL can effectively induce extensive apoptosis in some
myeloma cell lines in a time- and dose-dependent manner, and also induce substantial
apoptosis in myeloma cells freshly isolated from MM patients (Gazitt, 1999).Importantly, it
is not toxic to most normal human cells in vitro (Pitti et al., 1996; Wiley et al., 1995)'
Furthermore, TRAIL-induced apoptosis in MM cell lines is not abrogated by IL-6, a major
growth and survival factor for MM cells (Mitsiades et a1.,2001). Preclinical studies also
suggest that TRAIL can overcome conventional drug resistance and provides the basis for
clinical trials of TRAIL-based treatment regimens to improve outcome in patients with MM
(Mitsiades et al., 2001).
It is generally accepted that cultures of human myeloma cells, in vitro, ptoduce several
OAFs, including TNFcr, IL-1P, IL-6, M-CSF (Costes et al., 1998; Filella et al., 1996;
Pfeilschifter et a\.,1989). It has been recently demonstrated that myeloma cells, also express
RANKL, an important molecule involved in the pathogenesis of MM induced osteolysis
(Famrgia et a1.,2002).In addition, the anti-resorptive effects of BPs are considered, at least
partially, to be the result of inhibited release of some OAFs from OB (Derenne et al., 1999;
Giuliani et a1.,1998b; Ohya et a1.,1985; Stronski et a1.,1938). However, to date, it is still
unknown whether or not BPs inhibit the secretion of OAFs and RANKL from myeloma cells.
In this study, we have investigated the effect of zoledronic acid on cultures of human
myeloma cell lines. In addition, we have investigated if zoledronic acid in combination with
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TRAIL can mediate a synergistic anti-tumour effect. Finally, we have investigated whether
zoledronic acid treatment of myeloma cells, leads to an inhibition of OAF syrthesis.
4l
3.2 RESULTS
3.2.1 Multìple Myeloma Cell Línes Display Differentíal Sensitivity to Zoledtoníc Acid
Initial experiments monitored possible cytotoxic effects of zoledronic acid on the myeloma
cell lines using the colorimetric reagent WST-I. The WST-I assay is a measure of the
combined effects of cytostasis (inhibition of proliferation) and cytolysis (induction of target
cell death). As shown in Figure 3.1, a significant reduction in cell number was observed
when the RPMI 8226 cell line was exposed to zoledronic acid for 72 hours. At a
concentration of lpM, zoledronic acid induced a significant reduction in cell number
(p<0.005). A classical dose-dependent sigmoid response curye was evident and a plateau was
achieved at concentrations greater than 5 ¡rM. In contrast, this drug had little or no effect on
the myeloma cell lines V/L2 and 1J266. The ARH-77 cell line was less responsive to
zoledronic acid treatment than RPMI 8226, and a significant reduction in cell number was
only observed when more than 10pM of zoledronic acid was used (p<0.05).
To investigate whether zoledronic acid was mediating its effect by inducing clostasis or cell
death, a time course study was performed by counting viable cells using trypan blue
exclusion. In agreement with the above findings, a significant reduction in cell number was
achieved at day I (p<0.005) in RPMI 8226 cells treated with zoledronic acid (figure 3.2).
Zoledronic acid induced a significant reduction in cell number over the period of 5 days in
RPMI 8226 cells (p<0.005). ARH-77 cell proliferation was also inhibited in the presence of
zoledronic acid (B) (p:0.025), however, no effects were observed with theWL2 andU266
(p>0.05) cell lines. Interestingly, the proliferation rate of RPMI 8226 cells in the normal
culture media was significantly greater than that of the other three myeloma cell lines.
3.2.2 Zoledronic Acid Induces Cell Death by Inhibiting Cell Cycle Progression ín RPMI
8226
To identify the mechanisms of the cytoreductive effect of zoledronic acid on the myeloma
cell line RPMI 8226, flow cytometric cell cycle analysis was performed (figure 3.3). There
was a 2-fold increase in the number of cells, which accumulated in S-phase of the cell cycle
after exposure to zoledronic acid for 24I'ns. After 48 hrs culture in zoledronic acid, there was
an increase in the proportion of hypo-diploid cells in the sub-Go/Gr peak consistent with the
onset of apoptosis. This increase in the sub-Go/Gr peak was time dependent. In contrast, no
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Figure 3.1. Multiple myeloma cell lines display differential sensitivity to zoledronic
acid. Four myeloma cell lines, ARH77, RPMI-8226,WL2 andU266 were seeded in 96-
well plates at a cell density of 10,000 cells/ well. The cells were cultured in the presence
or absence of zoledronic acid and the cell number and viability was quantitated at d3
using WST-I, as described in the methods (refer to section 2.3.2.I). Zoledronic acid
induced a significant decrease (p<0.005, Êtest) in cell number at a concentration of I
pM in RPMI 8226 cell lines. A classical dose-dependent sigmoid response curve was
evident and a plateau was achieved at concentrations greater than 5 pM (A). ARH-77
was less responsive to zoledronic acid treatment and the decrease in cell number was
observed when more than 10pM of zoledronic acid was used (8, p<0.05, t-test)' In
contrast, myeloma cell lines V/L2 (C) and 1J266 (D) were resistant to the effects of
zoledronic acid treatment. Values represent means +SEM of triplicate cultures of each






















































Figure 3.2. F,ffects of zoledronic acid on the proliferation of myeloma cell lines. The
myeloma cell lines were cultured in 48-well plates at a density of 5 x 104 cells/well'
ARH-77 and RPMI 8226 cell lines were cultured in the presence of 10 pM zoledronic
acid, whilstIJ266 andWL2 cell lines were treated with 50 ¡rM zoledronic acid. Using
trypan blue exclusion, viable cells were counted each day for the period of 5 days' The
results showed that the proliferation rate of RPMI 8226 (A) was greater than the other
three cell lines. The significant reduction in cell number was achieved at day I
þ<0.005, /-test) in RPMI 8226 fieated with zoledronic acid. Zoledronic acid induced a
significant reduction in cell number over the period of 5 days in RPMI 8226 cells
þ<0.005, Wilcoxon test). ARH-77 cell proliferation was also inhibited in the presence
of zoledronic acid (B) (p:0.025, Wilcoxon test), however, no effects were observed in







































































Figure 3.3. Zoledronic acid induces cell death by inhibiting cell cycle progression rn
RPMI 8226 cells. The myeloma cell line RPMI 8226 was treated with zoledronic acid at
concentrations of 10 ¡rM. Cells were harvested at different time points over a period of
5 days and stained with the DNA fluorochrome, propidium iodide (PI), as described in
the methods. The samples were subsequently analysed by flow cytometry and ModFit
LT for win 32 (version 2.0). There was a 2-fold increase in the number of cells, which
accumulated in S-phase of the cell cycle after exposure to zoledronic acid fot 24 hts.
After 48-hr culture there is an increase in the proportion of hlrpo-diploid cells in the
sub-Go/Gr peak, consistent with the onset of apoptosis. This increase in the sub-Go/Gr
















































































































alteration of cell cycle was observed in the zoledronic acid-resistant cell line V/L2 (data not
shown).
The changes in nuclear morphology of myeloma cell lines induced by zoledronic acid were
also examined by fluorescence microscopy. As shown in figure 3.4, morphological changes
characteristic of apoptosis (Wyllie et a1.,1980) including condensation and the formation of
dense, rounded apoptotic bodies are clearly evident in a small percentage of all four myeloma
cell lines when compared with untreated cells. Consistent with the cell proliferation results
(ftg 3.113.2), fewer apoptotic nuclei were noted in ARH-77 , WL2 and U266 compared with
RPMI 8226. However, the proportion of cells with apoptotic nuclei was not proportional to
the reduction in cell numbers. Therefore, the most profound effect mediated by zoledronic
acid is the induction of cytostasis.
3.2.3 Zoledronic Acid Does not Increase Cøspøse Activíty
It is generally acknowledged that apoptotic cell death can be triggered by caspase activation.
Therefore, the caspase activity of myeloma cell lines RPMI8226 andWL2 was investigated
(figure 3.5). Consistent with previous observations, zoledronic acid significantly inhibited
cell proliferation of RPMI 8226 G)<0.001) and ARH-77 cells (p<0.05) at the indicated
concentrations. However, caspase inhibitor I did not prevent the zoledronic acid-mediated
reduction in cell numbers. Interestingly, untreated myeloma cells displayed a relatively high
caspase activity, and zoledronic acid did not enhance caspase activity in both of these
myeloma cell lines. The caspase inhibitor I, z-VAD-FMK (50 ¡rM) successfully inhibited the
basal caspase activity.
The nitrogen-containing BPs inhibit the mevalonate pathway by inhibiting
geranylgeranylation of small GTP-binding proteins such as Ras, Rho, Rac and Rab
(Murakami et al., 1995; Sato e/ al., l99l), which is important for many cellular processes,
including proliferation, cytoskeletal organisation and intracellular signalling (Hall, 1998;
Zenal and Stenmark, 1993). To examine the involvement of the mevalonate pathway on the
zoledronic acid-mediated apoptosis of myeloma cells, \rye assessed the ability of
geranylgeraniol (GGO), an intermediate product in mevalonate pathway, to protect myeloma
cell lines from zoledronic acid-induced apoptosis. Consistent with the findings of others
(Miquel et al., 1996; Ohizumi et al., 1995; Ohizumi et al., 7997), this study (figure 3.513.6)
also showed that GGO alone induced cytostasis and cell death in RPMI 8226 cells in a dose-
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Figure 3.4. Zoledronic acid induces apoptosis in myeloma cell lines. Myeloma cell lines
were treated with 10 pM zoledronate for 72 hrs, stained with DAPI, and examined by
fluorescence microscopy as described in the methods (refer to section 2.3.4).
Morphological changes characteristic of apoptosis including condensation and the
formation of dense, rounded apoptotic bodies are clearly evident in a small percentage
of all four myeloma cell lines (8, D, F & H) when compared with untreated cells (4, C,
E & G). Consistent with the cell proliferation results (figure 3.113.2), fewer apoptotic
nuclei were noted in ARH-77 (D), WL2 (F) and U266 (H) compared with RPMI 8226
(B). The affows display the apoptotic cells.

Figure 3.5. Zoledronic acid does not enhance caspase activity in myeloma cell lines.
Myeloma cell lines RPMI 8226 and ARH-77 were seeded in 96-well plates under the
different treatment conditions and the cell proliferation was assessed at day 3 using
WST-I. At the same time, cells were also cultured in24-well plates under the same
treatment condition. Caspase-3 activity was measured at day 3 by measuring the
caspase-3 dependent degradation of the fluorogenic substrate DEVAFC, as described in
the methods. Consistent with the previous observations, zoledronic acid significantly
inhibited cell proliferation of RPMI 8226 (A, p<0.001, Êtest) and ARH-77 (8, p<0'05,
/{est) cells at the indicated concentrations. Geranylgeraniol (GGO) alone, also
decreased cell number in both cell lines (A&8, condition 3, p<0.05, Êtest). However,
caspase inhibitor I did not prevent the cells from a zoledronic acid-mediated reduction
in cell number (A&B, 4tn, 6tn condition). Similarly, GGO at a concentration of 50 ¡rM
did not have a protective effect on the myeloma cell lines treated with zoledronic acid
(A&8, condition 5&6). Interestingly, untreated myeloma cells displayed a relatively
high caspase activity, and zoledronic acid and GGO did not enhance caspass activity in
both of myeloma cell lines (C&D, condition 2eÐ. The caspase inhibitor I, z-VAD-
FMK (50 pM) successfully inhibited the basal caspase activity (C&D, condition 4e,q.
The data represent means + SEM of triplicate cultures of each condition.
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dependent manner (p<0.05) at both d3 and d5. However, GGO did not enhance caspase
activity in either myeloma cell lines ARH-77 or RPMI 8226 (figwe 3.5). The results also
show that GGO protects myeloma cells against the effects of zoledronic acid, in a dose-
dependent manner at high concentrations (figure 3.6). Notably, this protection was observed
when GGO was used at concentrations greatt than 300 ¡rM (p<0.01). The protective effect
of GGO suggests that zoledronic acid, in part, mediates its effects by inhibiting the
mevalonate pathway.
3.2.4 Gene Expressíon of Myelomø Cells Treøted wíth Zoledroníc Acid
The effect of zoledronic acid on the gene expression of the myeloma cell lines RPMI8226
and WL2 was examined using semi-quantitative RT-PCR, as described in the methods. As
seen in figure 3.7, TNF ø, IL-IB and COX-2 gene expression was upregulated in RPMI 8226
cells following zoledronic acid treatment þ<0.005). In contrast, the WL2 cell line, which is
resistant to zoledronic acid, showed no changes in gene expression.
3.2.5 Zoledronic Acid Upreguløtes the Cell Surface Molecule Expression on the
Myelomø Cell Lines
Cell-cell and/or cell-ECM adhesion plays an important role in regulating apoptosis and cell
survival in tumour cells (Clark and Brugge, 1995). Previous studies demonstrate that
myeloma cells overexpress a vaÅety of cell surface molecules (Leo et al., 1992; Damiano,
1999 #59; Van Driel et a1.,2002), which may be responsible for cell adhesion-mediated drug
resistance (Barker et al., 1992; Damiano et al., 1999; Jensen et al., 1993). Therefore, the
expression of various cell surface molecules by myeloma cells was examined using single
colour flow cytometric analysis (figure 3.8). One interesting finding is that RPMI 8226 cells
express high levels of HLA class I, B2 microglobulin and CD138. In contrast,WLz, which is
resistant to zoledronic acid, did not express any of these antigens. However, zoledronic acid
had no effect on the expression of these molecules þ>0.05) at dl or d3. Consistent with other
studies (Clark and Brugge, 7995; Damiano et al., 1999), both cell lines expressed c¿¿Fr
integrin (61.2C4,P4C2), whilst the expression by the zoledronic acid-resistant cell line WL2
was greater when compared to the zoledronic acid-sensitive cell line RPMI 8226. Zoledronic
acid marginally increased the expression of oaBl integrin in both cell lines (p<0.05).
Moreover, zoledronic acid was also found to marginally increase the expression of CD44,
CD45, CD54 and CD56 in both cell lines (p<0.01).
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Figure 3.6. GGO pafüal|y protects against zoledronic acid-mediated cell death in a
dose-dependent manner. RPMI 8226 cells were seeded in 96-well plates and cultured
for 3 and 5 days in the presence of GGO alone or GGO in combination with zoledronic
acid, at the indicated concentrations. The cell number and viability were quantitated
using WST-I. The results show that GGO alone induced cytostasis and cell death of
RPMI 8226 ín a dose-dependent manner (p<0.05, /-test) at both d3 (A) and d5 (B).
GGO was found to protect zoledronic acid-induced cytostasis and cell death at a
concentration of 300 pM (p<0.01, Êtest). The data represent means t SEM of trþlicate
cultures of each condition. The cell morphology ìwas assessed at d5 and representative
examples are shown in C (negative control), D (zole, 10 pM), E (zole, 10 pM and GGO
25 ¡tM),F (zole, 10 prM and GGO 100 ¡rM), G (zole, 10 ¡rM and GGO 300 pM), and H
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Figure 3.7. The effect of zoledronic acid on the gene expression of myeloma cell lines.
Myeloma cell lines RPMI 8226 and WL2 were treated with zoledronic acid at a
concentration of 10 ¡rM and the cells were harvested at three different time points over a
period of 5 days. Total RNA was isolated and semi-quantitative RT-PCR was
performed as described in the methods. The house-keeping gene, GAPDH was used as
an internal control for mRNA integrity and enabled relative gene expression to be
determined. PCR products were subjected to electrophoresis on l%o agatose gel, stained
with SyBR gold and visualised using a Fluorimager. The product bands were semi-
quantitated and plotted as a histogram of the ratio of specific gene expression relative to
the expression of GAPDH. The experiments were performed twice and the Wilcoxon
test was employed for statistical analysis. The data shows that zoledronic acid
upregulates IL-IB (A), TNF-cr (B) and COX-2 (C) gene expression in RPMI 8226 cells
0<0.005, Wilcoxon test), which is sensitive to zoledronic acid treatment. However, no
alteration was noted in the WL2 cell line.
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Figure 3.8. Zoledronic acid upregulates the expression of cell surface molecules on the
myeloma cells. Myeloma cell lines RPMI8226 andWL2 were treated with zoledronic
acid and harvested at dl and d3 for single-colour immunofluorescence staining of each
of the different cell surface molecules, as described in the methods. Data arc displayed
as the mean fluorescence of each protein, from which the mean fluorescence value of
the isotype-matched negative control has been subtracted. RPMI 8226 cells were found
to express high levels of HLA class I, p2 microglobulin and CD138 (A&B). However,
zoledronic acid had no effect on the expression of these molecules (p>0.05, 
'Wilcoxon
test) at dl or d3. In contrast, V/L2 did not express any of these antigens (A&B).
Consistent with other studies (Clark and Brugge,1995; Damiano et a1.,1999), both cell
lines expressed aaBl integrin (61.2C4,P4C2), whilst the expression by the zoledronic
acid-resistant cell line WL2 was greater contrast to zoledronic acid-sensitive cell line
8226 çeD). Zoledronic acid marginally increased the expression of aapl integrin in
both cell lines (p<0.05, Wilcoxon test). Furthermore, it was also found to marginally
increase the expression of CD44, CD45, CD54 and CD56 expression in the both cell
lines (E&F) þ<0.01, Wilcoxon test).
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To investigate if zoledronic acid altered the functional status of the adheston mo
expressed by myeloma cell lines, adhesion to FN and VCAM-I was examined using a
quantitative adhesion assay. The results show that myeloma cells adhere preferentially to
VCAM-I and not FN. RPMI 8226 cells use craBl to adhere to VCAM-I and CD44 to adhere
to FN. V/L2 cells use both craBl and CD44 to adhere to FN, and use oaBl adhere to VCAM-I.
This data also shows that zoledronic acid does not augment adhesion of myeloma cells to two
important ligands (frgure 3.9).
3.2.6 Dffirentiøl Sensitivity of Myelomø Cell Línes to TRAIL-Mediated Cell Death
As shown in figure 3.10, myeloma cells are differentially sensitive to the cytotoxic effects of
TRAIL. Interestingly, the response amongst the different cell lines was similar to the
response seen following zoledronic acid treatment. In brief, TRAIL mediated a significant
reduction in RPMI 8226 cell number in a dose-dependent manner. A significant decrease in
cell number was found when the cells were treated with TRAIL at concentrations greater than
100 nglml (p<0.05). In contrast, TRAIL had no effect on the other cell lines, ARH-77,WL2
andU266.
3.2.7 TRAIL Enhønced the Efþct of Zoledroníc Acid When Used in Combinøtion on the
Myelomø Cells
The culture of myeloma cell lines with zoledronic acid in combination with TRAIL resulted
in a decrease in the cell number and viability that was consistently greater than that observed
in cultures treated with either drug alone in the four cell lines tested (figure 3.11). Of note,
there is no significant difference between d3 and d5, indicating that prolonged exposure of
drugs did not enhance the effect. TRAIL rendered the cells more sensitive to zoledronic acid
(p<0.05) at concentrations previously shown to have no significant effect on cell
proliferation. When the concentration of TRAIL was increased to 100 nglml in RPMI 8226,
zoledronic acid was only effective when used at a concentration greater than 5 pM (p<0.05).
These results indicated that zoledronic acid might affect the cells through the TRAIL and
TRAIL receptor pathway. The expression of TRAIL and TRAIL receptors in response to
zoledronic acid treatment was therefore investigated using semi-quantitative RT-PCR and
flow cflometry.
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Figure 3.9. Zoledronic acid does not regulate integrin-mediated adhesion of myeloma
cells to FN and VCAM-I. Calciene labelled suspensions of myeloma cell lines RPMI-
8226 and WL2 were incubated with function-blocking antibodies directed against the
various adhesion molecules. The cells were seeded into plates, previously coated with
either FN or VCAM-I as described in the methods. The data present the mean values *
SEM of trþlicate wells, expressed as a percentage of the input population (2 x I}a
cells). The level of significance for the percentage of attached cell in all conditions was
compared between with zoledronic acid treated and untreated groups. The results show
that myeloma cells adhere preferentially to VCAM-I and not FN. RPMI 8226 cells use
a+Þr b adhere to VCAM-I and CD44 to adhere to FN. V/L2 cells use both oaBl and
CD44 to adhere to FN, and use crapl to adhere to VCAM-I. Futhermore, these data
indicate that zoledronic acid does not augement adhesion.
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Figure 3.10. Differential sensitivity of myeloma cell lines to TRAll-mediated cell
death. The myeloma cell lines were seeded in 96-well plates at a cell density of 10,000
cells/well. The cell number and viability were assessed by WST-I at d3. The results
showed that TRAIL mediated a significant reduction in RPMI 8226 cellnumber (A) in a
dose-dependent manner. A significant decrease in cell number was found when the cells
were treated with TRAIL at concentrations more than 100 nglml (p<0.05). In contrast,
TRAIL had no effect on the other cell lines, ARH-77 (B), WL2 (C) and U266 (D).
Values represent means +SEM of trþlicate cultures of each concentration. The results













3 10 30 100 300
TRAIL concentratlons (ng/ml)
wL2













3 10 30 100 300
TRAIL concentratlons (ng/ml)
u266
3 10 30 100 300
























Figure 3.11. TRAIL enhanced the effect of zoledronic acid when used in combination
on the myeloma cells. The myeloma cell lines were seeded in 96-well plates and treated
with either zoledronic acid alone, or zoledronic acid and TRAIL at the concentrations as
indicated. The cell number and viability were assessed at d3 and d5 using V/ST-l.
Values represent means tSEM of triplicate cultures of each concentration. The results
displayed are a representative example of 2 independent experiments. Of note, there is
no difference between d3 (A) and d5 (B) data, indicating that prolonged exposure of
drugs did not enhance the effect. TRAIL rendered the cells more sensitive to zoledronic
acid þ<0.05, Wilcoxon test) at concentrations previously shown to have no significant
effects on cell proliferation [30 nglml for RPMI 8226 (C of d3 &C' of d5) and 100
nglml for other cell lines (E, F, G of d3 &E', F', G' of d5)]. When the concentration of
TRAIL was increased to 100 nglml in RPMI 8226 (D&D'), zoledronic acid was only
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3,2.8 The Effect of Zoledronic Acíd on the Expressíon of TRAIL and TRAIL Receptots
on Myeloma Cell Lines
TRAIL and its receptors were investigated at both the transcriptional and protein levels, using
semi-quantitative RT-pCR and flow cytometry. Gene expression analysis showed that the
TRAIL transcript was increased in response to zoledronic acid treatment in both cell lines
(figure 3.I2). The protein expression study indicated that the zoledronic acid sensitive cell
line RpMI g226 had increased TRAIL receptors DR4 and DR5 with a decreased or
unchanged level of expression of decoy receptors (DcR1 and DcR2) in permeablised staining
(figure 3.13). However, an increased DR4 and DR5 expression, coupled with increased DcRl
and DcR2 expression respectively, were noted in the resistant cell line WL2 when the cells
were exposed to the zoledronic acid.
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Figure 3.I2. The effect of zoledronic acid on the TRAIL and TRAIL receptor gene
expression in myeloma cell lines. Myeloma cell lines RPMI 8226 and WL2 were
cultured in 6-well plates in the presence or absence of zoledronic acid at a concentration
of 10 pM. The cells were collected at day 3, total RNA was isolated and semi-
quantitative RT-PCR were performed as described in the methods. The results revealed
increased TRAIL gene expression in rosponse to zoledronic acid treatment in both cell
lines (A&B). Values represent means +SEM of the ratio of TRAIL gene expression
relative to the expression of GAPDH.
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Figure 3.13. The effect of zoledronic acid on the protein expression of TRAIL and
TRAIL receptors. The myeloma cell lines RPMI 8226 and WL2 were treated with
zoledronic acid and both membrane and cytoplasmic protein expression of TRAIL and
its receptors were detected as described in the methods. Data of d3 are displayed as the
mean fluorescence of each protein from which the mean fluorescence value of the
isotype-matched negative control has been subtracted. The results indicated that the
zoledronic acid-sensitive cell line RPMI 8226had increased TRAIL receptors DR4 and
DR5 with the decreased or unchanged level of decoy receptor DcRl and DcR2 when
cytoplasmic protein expression was examined (C). However, the increased DR4 and
DR5 expression, coupled with increased DcRl and DcR2 expression respectively, were
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The prolonged survival benefit seen in the patients with MM treated with BPs (Berenson e/
al., 1998; Berenson et al., 1996; McCloskey et al., 1998) has initiated numerous in vitro
studies in an attempt to determine the mechanisms of the anti-tumour effect of BPs. The anti-
tumour effects of BPs have been demonstrated in different cell lines, including human
myeloma cells (Aparicio et al., 1998; Shipman et al., 1997; Takahashi et a1.,2001), breast
carcinoma cells (Fromigae et a1.,2000; Sasaki et al., 1995) as well as prostate cancer cells
(Lee et a1.,2001). The studies reported herein, also demonstrate that zoledronic acid had a
dose- and time-dependent cytotoxic effects on myeloma cell lines RPMI8226 and ARH 77.
Both dye exclusion (refer to figure 3.2) and V/ST-I assays (refer to figure 3.1) revealed that
zoledronic acidhad aprofound cytoreductive effect inthe sensitive cell line RPMI 8226.11
contrast, the myeloma cell lines, 
'WL2 andtJ266 (which is an Il-6-autocrine MM cell line),
were completely unaffected by zoledronic acid. Given the apparent difference in sensitivity
between cell lines, it ',¡/ill be of interest to examine the underlying mechanism, for the
differential sensitivity seen in myeloma cells.
As described in the results, zoledronic acid at concentrations greater than 5 pM induced a
classical dose-dependent sigmoid response curve of cell number reduction. Therefore, in
these in vitro studies, the concentrations of zoledronic acid used were generally over 5 pM.
These doses are high relative to the peak serum concentrations achieved in the patients
undergoing treatment with bisphosphonates. Thus, it remains to be determined whether
sufficiently high levels of zoledronic acid could readily be attained in the patients for this
anti-tumour activity. The peak serum concentrations of ibandroante achieved in the murine
model were approximately 5 pM. This concentration did not affect the growth or viability of
the mouse myeloma cell line 5TGM1 in vitro, and cytotoxic effects were seen only at doses
of 50 ¡rM and higher (Dallas et al., 1999). Therefore, it is possible that BPs with different
chemical structures may have different effects on tumour cell growth and apoptosis. Thus,
the cytotoxic effects of Bps on myeloma cells may be limited to particular BPs with specific
structural features. The concentration required to inhibit the growth of myeloma cells in the
present study was far higher than the peak serum concentrations in vlvo. However, owing to
the singular skeletal distribution of administered BPs, maffow concentration may be
sufficient to inhibit growth of myeloma cells. It was demonstrated that the pharmacological
doses of BP required to inhibit bone resorption could lead to even higher concentrations, up
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to 1000 ¡rM, in the space beneath the ruffled border of osteoclasts in vivo, due to osteoclast-
induced acidification (Sato et a\.,1991). Since the areas of active bone resorption have been
described as specific homing sites of tumour cells in the patients with MM (BataiTle et al.,
1,995; Khan et al., 1997; Mundy et al., 1914), it is possible that the tumour cells may be
exposed to relatively high concentrations of BPs, which are sufficient to induce cell death.
However, the actual concentration of BPs encountered by cells other than osteoclasts remains
unknown. Moreover, it is unclear as to the period of time that high concentrations in these
areas are maintained.
The studies described here show that the zoledronic acid mediates its effect through a
combination of cytostasis and cytolysis. Flow cytometric analysis of DNA content (refer to
figure 3.3) demonstrated that following zoledronic acid treatment, there was an accumulation
of cells in S-phase of the cell cycle. This may be due to slowing of progression through S
phase or a block between S and G2M phase, and hence inhibition of cell proliferation. These
observations are consistent with reports that nitrogen-containing BPs can inhibit cell
proliferation in other cell types (Fromigue et a\.,2000;Lee et a|.,2001; Sasaki et al., 1995).
The accumulation of RPMI 8226 cells in S phase was observed following treatment with
zoledronic acid for 5 hours. After 48 hrs, there was a signifcant increase in the number of
cells in the sub-Go/G1 phase of the cell cycle. The sub-Go/Gr hypodiploid population, is a
characteristic of cells undergoing apoptosis, which have lost DNA owing to nuclear
fragmentation. Apoptosis was also confirmed by morphologic analysis. Although only few
apoptotic nuclei were observed, at least part of the cytoreductive effect induced by zoledronic
acid could be attributed to the induction of apoptotic death. In contrast, the WL2 myeloma
cell line was resistant to the effects of zoledronic acid. Of interest, RPMI 8226 was found to
possess a greater proliferativ e rate thanWL2 (refer to figure 3.2), which may account for the
different sensitivity. Myeloma cells typically show a very low rate of proliferation in patients
with MM. Therefore, the studies using myeloma cell lines are subject to limitations and
myeloma cells isolated from the patient with MM should be used in the future studies.
Howeve , it should be emphasised that in our study, treatment of tumour cells with
zoledronic acid was performed in the presence of serum, which is a survival factor for these
cells. Therefore, it is conceivable that serum counteracts some pro-apoptotic effect of
zoledronic acid.
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Interestingly, zoledronic acid did not enhance the caspase activity in either RPMI 8226 or
ARH-77 (refer to figure 3.5) although it induced apoptosis in a proportion of cells, which was
confirmed by morphologic observation (refer to figure 3.4). Furtherrnore, caspase inhibitor I,
which inhibits caspase activity, could not protect against cell death induced by zoledronic
acid. This indicated that zoledronic acid may induce cell death in RPMI 8226 tn a caspase
independent pathway (via non-apoptotic programmed cell death with necrotic-like
appearance, or via the mitochondrial pathway), which has also been reported (Mochizuki et
a1.,2002;Daugas et a1.,2000; Kroemer, 1999)
We next examined whether zoledronic acid induces myeloma cell death via inhlbition of the
mevalonate pathway (refer to figure 3.6), a biosynthetic pathway responsible for the
production of cholesterol and isoprenoid lipids. Consistent with previous reports (Shipman er
al., 1998; for review see Russell and Rogers, 1999), we have shown that the effects of
zoledronic acid on myeloma cells is mediated, in part, through the inhibition of the
mevalonate pathway. The cell death induced by zoledronic acid was reversed in the presence
of GGO, an intermediate of the mevalonate pathway, at a concentration greater than 300 pM.
However, the cell number was still lower than that in negative controls, suggesting that GGO
could not fully overcome the inhibitive effect of zoledronic acid on myeloma cell
proliferation. These results suggest lhat zoledronic acid induces its cytoreductive effect on
drug sensitive myeloma cell lines partially through the mevalonate pathway. Consistent with
the findings of others (Miquel et al., 1996; Ohizumi et al., 1995; Ohizumi et al., 1997), out
study also demonstrated that GGO caused a degree of cell death in RPMI 8226, in a dose-
dependent manner, without activating caspases.
Human myeloma cells were reported to produce several OAFs, including TNFcr, IL-lp, IL-6,
M-CSF and RANKL et al (Costes et a\.,1998; Filella et a\.,1996; Pfeilschifter et a1.,1989),
which play an important role in the pathogenesis of MM induced osteolysis' In addition, the
anti-resorptive effects of BPs, at least partially, are considered to be the result of inhibited
release of some OAFs from OB (Derenne et al., 1999; Giuliani et al', 1998b; Ohya et al.,
1985; Stronski et a1.,1988). To investigate whether BPs inhibit the secretion of OAFs from
myeloma cells, gene expression was examined using semi-quantitative RT-PCR.
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Surprisingly, zoledronic acid significantly upregulated gene expression of TNFa in the
sensitive myeloma cell line RPMI 8226 (refer to figure 3.7). TNF was initially recognised
and named for its ability to cause necrosis of tumour masses. It has been shown to also have
dramatic systemic effects. At the cellular level, TNF-o has widespread pleiotropic actions
and has been shown to modulate the fundamental processes associated with cell proliferation,
differentiation, and apoptosis or necrotic cell death in a number of different cell t1pes. TNF-
a is a survival and proliferation factor for human myeloma cells (Borset et al.,1994; Jourdan
et al.,l9gg), and a high level of TNF-a was found in supernatant from bone marrow cultures
of MM patients, which was capable of markedly stimulating formation of OC-like
multinucleated cells in human maffow cultures (Filella et al.,1996; Lichtenstein et a1.,1989;
pfeilschifter et al., 1989). In our study, TNF-cr was upregulated in the zoledronic acid
sensitive myeloma cell lines, whilst it remained unchanged in drug resistant cell line WLz,
suggesting it may represent a rescue mechanism in response to zoledronic acid treatment'
Horilever, TNF-c¿ was found to mediate apoptotic cell death in a mitotically active human
erythroleukemic cell line, and to induce cell proliferation in mitotically quiescent cells
(Baxter et al., Iggg). As we have shown in the results that the RPMI 8226 cell line had
greater proliferative potential thanWL2 cells (refer to figure 3.2), it is also possible that
zoledronic acid induces cell death by up regulating TNF-a gene expression. To differentiate
these two possibilities, blocking antibodies to TNF-cr could be used to examine whether they
can protect from zoledronic acid-mediated cell death in the myeloma cell line RPMI 8226.
Zoledronic acid also significantly upregulated gene expression of IL-lp and COX-Z in the
sensitive myeloma cell line RPMI 8226 Qefer to figure 3.7). IL-lp is a principal bone
resorption agentpresent in the supernatant of myeloma cell cultures that enhances destructive
bone lesions in the patients with MM (Cozzolino et a\.,1989; Yamamoto et al',1989). TNF-
cx, and IL-1p produced by MM or accessory cells are also able to stimulate IL-6 production by
OB, through a prostaglandinE2 (PGE2) loop and show additive effects (Costes et a|.,1998;
Lu et al., 1995; Thomas et a1.,1998), while IL-6 is a growth factor for MM. In addition,
TNF-a and IL-1p are also able to increase the adhesion of MM cells to stromal cells (Thomas
et al., 1998). Thus, IL-18 can promote the secretion of IL-6, and both IL-18 and IL-6
enhance the bone lytic lesions in MM. Furthermore, both TNF-o and IL-1p can induce COX-
2 expression. Cyclooxygenase (COX) is a family of enzyrnes that catalyse the conversion of
arachidonic acid to prostaglandins (for review see (Hinz and Brune, 2002)). Two COX
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isoforms have been identified: COX-I and COX-2. COX-1 is constitutively expressed as a
"housekeeping" enzyme and is ubiquitous in its distribution. COX-2 is inducible and it can
be upregulated by various pro-inflammatory agents, including lipopolysaccharide, cytokines,
and growth factors. The induction of COX-2 has been shown to promote cell growth, inhibit
apoptosis, and enhance cell motility and adhesion in a number of cell and animal models.
Expression of COX-2 appears to be important in tumour promotion, growth, metastasis and
angiogenesis (Cianchi et al., 2001; V/illiams et al., 1999), which is a key step in
carcinogenesis. Therefore, the upregulation of COX-2 may be in response to the increased
expression of IL-l B and TNF-ø, or induced directly by zoledronic acid. It is our contention,
however, that the upregulation of transcripts represent a rescue reaction of cell lines to the
zoledronic acid treatment since COX-2, ILI p, and TNF-cr are able to promote cell
proliferation.
Cells have the capability of responding to a multitude of signals that they encounter in the
extracellular environment. Therefote, an additional anti-tumour effect of BPs might occur
secondary to effects on MM cell growth factors, which can be secreted by both myeloma
cells and the bone ma¡¡ow environment. In contrast, our study demonstrates that zoledronic
acid does not inhibit the secretion of TNF-a,IL-lp and COX-2, at least atthe transcriptional
level. Although BPs were reported to potentially inhibit the production/release of IL-6 and
MMP-1 from myeloma cells and myeloma bone malrow stoma cells (Dereme et al.,1999),
we did not detect a significant change in the IL-6 gene expression when the cells were
exposed to zoledronic acid. It is well accepted that IL-6 is a potent myeloma growth factor
which acts via an autocrine and paracrine mechanism (Kawano et al., 1988; Klein et al.,
1989), and can be upregulated by TNF-a and IL-IB (Costes et al., 1998; Lt¿. et al', 1995;
Thomas et a1.,1998). In addition, zoledronic acid increased the expression of TNF-cr and IL-
1B in RPMI 8226, however, no upregulation of IL-6 gene expression was observed. The
detection of protein levels of IL-6 should be considered in future studies. In contrast to breast
cancer cells, myeloma cells are derived from haemopoietic cell lineages, which normally
reside in the bone marrow. Thus, the marrow microenvironment may already be favourable
for growth of the myeloma cells independent of local rates of bone resorption, or of the
production of cytokines secreted by OB such as IL-6. This may explain why myeloma cells
appear to be able to gtow in the marrov/ cavity and completely replace the normal maffow
cells even when osteoclastic activity is inhibited by BPs. Thus myeloma cells may be less
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dependent than breast cancer cells on factors released by resorbing osteoclasts, for their
growth in the bone marrow cavitY.
Cell-cell and/or cell-ECM adhesion not only play important roles in regulating apoptosis and
cell survival in tumour cells (Clark and Brugge,1995), but are also involved in the migration
of the MM cells into the extravascular compartment of the bone marrow, a process referred to
as "homing". Therefore, an additional anti-myeloma mechanism mediated by zoledronic
acid was considered to be the inhibition of the adhesiveness to bony matrix of circulation
myeloma cells, preventing further myeloma tumour deposits within the skeleton, thereby
overcoming the adhesion-mediated drug resistance (Boissier et a1.,2000; van der Pluijm e/
at., 1996). The cell surface molecules of interest which are expressed by myeloma cell lines
include p2-microglobulin, integrin o+Þr, CD44, CD45, CD54, CD56. The expression of these
molecules was examined using single-colour flow cytometric analysis in our study (refer to
figure 3.8).
One interesting finding is that RPMI 8226 cells express high levels of HLA class I' its
subunit B2 microglobulin, and CD138. In contrast,WLz,which is resistant to zoledronic acid,
did not express any of these antigens. It is generally accepted that the serum level of pz-
microglobulin is a reliable prognostic marker in the patient with MM (Bataille et al', 1992;
Bataille et al., 1984; Durie et al., 1990; Greipp et al',1988; Greipp et al., 1993)' A low B2-
microglobulin level is associated with a significantly better complete response rate among the
patients undergoing transplantation for myeloma (Rajkumar et al., 1999). The relationship
between the serum level of B2-microglobulin and cell surface expression on myeloma cells is
unknown. It is possible that zoledronic acid-resistant cells secrete more soluble þr-
microglobulin, or this molecule is cleaved from the cell surface into serum' It would be
interesting to investigate the relationship between drug resistance and B2-microglobulin
expression on myeloma cells derived from the patients' in future studies.
Consistent with other studies (Clark and Brugge,1995; Damiano et a1.,1999), both cell lines
were found to express c¿¿Þr integrin (61.2C4, P4C2), which allows attachment and
communication between the myeloma cells and the bone marrow microenvironment (Barker
et al.,1992; Jensen et a1.,1993). Our study found that the expression of ctaBl integrin by the
zoledronic acid resistant cell line WL2 was greater in contrast to zoledronic acid sensitive
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cell line RPMI 8226, suggesting that differential sensitivity to zoledronic acid between the
two cell lines may be partially attributed to the extent of u+Þr integrin expression.
Our results also showed that the zoledronic acid-resistant cell line WL2 strongly expressed
CD44 and CD45. CD44 is a transmembrane glycoprotein expressed by wide variety of cell
types. It functions in cell-cell adhesion and binds to components of the extracellular matrix,
including fibronectin, collagen, hyaluronan (HA), and osteopontin. The many isoforms of
these cell surface glycoproteins are encoded by a single gene that consists of standard exons
(1s to 10s) and variant exons (lv to 10v). The standard exons encode the common part of the
CD44 family members (CD44s, which is widely distributed), and the variant exons are
alternatively spliced, giving rise to the different members of the family (Gunthert, 1993). It
was demonstrated that CD44v10 mediates murine MM cells binding to bone marrow
endothelium (Asosingh et a1.,2001). CD44v9 was involved in binding to bone marrow
stromal cells which resulted in a significant induction of IL-6 secretion by bone marrow
stromal cells, which may account for correlation between CD44v9 expression and adverse
prognosis in MM (Stauder et al.,1996 van Driel et a\.,1998; Van Driel et a|.,2002). CD45
antigen was initially characterised as leucocle coÍtmon antigen expressed on all
haemopoietic cells except for mature erythrocytes and platelets, It has been reported to
identify subpopulations of myeloma cells with higher proliferative capacily (Joshua et al.,
1996; Kawano et al., 1993). The CD45* subpopulation of myeloma cells proliferate in
response to IL-6 (Fujii et al., 1999) and CD45 expression also can be induced by IL-6
stimulation (Mahmoud et al., 1998). The activities of src family protein tyrosine kinases
(PTKs) associated with the CD45 protein tyrosine phosphatase (PTP), seem to be a
prerequisite for the myeloma cell proliferation. The activation of signal transducer and
activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK1/2) by
IL-6 were further required (Ishikawa et a1.,2002). Therefore, CD44 and CD45 are two other
key molecules regulating myeloma cell adhesion, which may contribute to the resistance of
WL2to zoledronic acid treatment.
In contrast, the zoledronic acid sensitive myeloma cell line RPMI 8226 was found to strongly
express CD54, and CD56. CD54, an intercellular adhesion molecule-l (ICAM-l), was also
expressed by myeloma cells (Leo et a|.,7992; Van Riet et a\.,1991) and anti-CD54 antibody
had anti{umour activity without inhibiting adhesion and cell proliferation (Huang et al.,
1995). This suggests that CD54 may not be a key molecule in the adhesion of myeloma cells'
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CD56 antigen, a 140 kD isoform of the neural cell adhesion molecule (N-CAM), is a
membrane glycoprotein and belongs to the immunoglobulin superfamily. It is also known as
a differentiation antigen of natural killer (NK) cells and has been described as a prognostic
marker in MM (Kaiser et al., 1996). Down regulation of CD56 and upregulation of CD44
were found in extramedullary myeloma (Dahl et a1.,2002). The lack or weak expression of
CD56 is a characteristic feature of plasma cell leukemia (PCL) (Pellat-Deceunlmck et al.,
1998). It is difficult to compare myeloma cell lines and the myeloma cells isolated freshly
from patients with MM since the cell lines were immortalised and cultured in vitro for a long
time.
Our in vitro studies also showed that zoledronic acid marginally increased the expression of
craBl integrin, CD44, CD45, CD54 and CD56 expression in both cell lines, which could be
considered as a rescue response of myeloma cells to drug treatment. The up regulation of
CD54 may be a response to the upregulated IL-18 and TNF-c¿ expression, since it was found
that IL-IB and TNF-cr can upregulate CD54 expression (Thomas et al., 1998). It has been
reported that during the course of initial or chronic drug exposure, myeloma cells
overexpressing aapr mayhave a selection advantage over cells expressing low levels of this
protein. Selection pressure is required for cqBl upregulation in drug-resistant cells (Damiano
et al., 1999) and cells under selection pressure may then use soluble or cell-bound integrin
ligands as a protective mechanism. Furtherrnore, myeloma cells in patients are suffounded by
other cell types in the bone marrow microenvironment and they are exposed to the numerous
cytokines secreted by both myeloma cells and OB, and as such, myeloma cells may react to
zoledronic acid differently in an in vivo setting.
Our functional assays examining the adhesion of myeloma cell lines showed that both
rnyeloma cells adhere preferentially to VCAM-I and not FN. Both RPMI 8226 and WL2
cells use a4Bl to adhere to VCAM-1. RPMI 8226 use CD44, whilst WL2 cells use both
u4Bland CD44 to adhere to FN. Surprisingly, zoledronic acid does not change adhesion of
myeloma cells (refer to figure 3.9). This may be due to the relatively low concentration or
short exposure time of the drug. Breast cancer cells were found to adhere rapidly to
extracellular bone matrix, which can be inhibited by pre-treating of cortical or trabecular
bone with BPs (van der Pluijm et al.,1996). Moreover, the anti-adhesive effect of nitrogen-
containing BPs was bone specific since pre-treatment of non-mineralised tissues with BPs did
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not affect adhesion of the breast cancer cells (van der Pluijm et al., 1996). The one
underlying mechanism is that BPs, like pyrophosphate, specifically bind strongly to the bone
mineral, hydroxyapatite, thereby non-mineralised tissue cannot retain BPs to affect breast cell
adhesion. In addition, human bone cells express high levels of integrins (Hughes et al.,1993)
and BPs might affect the integrin expression on the bone instead of cancer cells. Thus, we
postulate that zoledronic acid may inhibit the adhesiveness of circulating myeloma cell to
bony matrix, and prevent further myeloma tumour deposits within the skeleton by inhibiting
the integrin expression on the OB. As we have known, FN and VCAM-1. arc expressed on
the surface of MM stromal monolayers (Faid et al., 1996; Lokhorst et al., 1994), and
antibodies to VCAM-I partially inhibit myeloma cell adhesion to MM stroma (Kim et al.,
1994; Robledo et al., 1993). Our preliminary experiments showed that zoledronic acid
decreased VCAM-I protein expression on the OB-like cells (data not shown), further
confirming that zoledronic acid might affect the adhesion of cells by acting on OB.
TRAIL is a TNF superfamily member that is capable of inducing apoptosis. It interacts with
five distinct receptors: DR4, DR5 (Pan et aL, l99l; Sheridan et al., 1.997), DcRl, DcR2
(Degli-Esposti e/ al., 1997; Sheridan et al., 1991) and OPG (Emery et al., 1998). DR4 and
DR5 are necessary and sufficient to mediate cell death, while DcRl, DcR2 and OPG may be
protective receptors by acting either as membrane-bound or soluble antagonistic receptors
(Degli-Esposti et al., 1997; Emery et al., 1998; Pan et al., 1997; Sheridan et al., 1997).
Consistent with the findings of others (Gazitt,1999), we found that TRAIL induced apoptosis
in a dose-dependent manner in one of four myeloma cell lines we used in this study (refer to
figure 3.10). Of note, our experiments showed that TRAIL and zoledronic acid had a similar
pattern of effect on the myeloma cell lines. RPMI 8226 cells are sensitive to both TRAIL and
zoledronic acid in a dose-dependent manner. TRAIL had no effect on the other myeloma cell
lines, WL2 andlJ266. Although TRAIL had no significant effect on ARH-77, it may produce
an effect if the dose was increased, since ARH -77 was only sensitive to zoledronic acid at
high doses. Zoledronic acid-induced reduction in cell number was significantly enhanced by
the addition of TRAIL in all four myeloma cell lines (refer to figure 3.11). However, when
the concentration of TRAIL was increased to 100 ng/ml in RPMI 8226 cells, which alone can
induce a significant reduction in cell number, zoledronic acid had limited effects on cells,
suggesting zoledronic acid may partially act on the myeloma cells through the upregulation
of TRAIL expression.
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At the 6RNA level, both RPMI8226 andWL2 cells expressed TRAIL, DR4 and DR5 (refer
to figure 3.I2). At the protein level, although zoledronic acid-resistant cell line, WL2, hardly
expressed cytoplasmic DR4 and DR5 receptors, both cell lines expressed membrane death
receptors (refer to figure 3.13). Therefore, the level of surface expression of either DR4 or
DR5 correlates with TRAll-sensitivity in our panel of MM cell lines. It has been reported
that some TRAll-resistant cells have very strong expression of both receptors, in comparison
to some TRAll-sensitive cells (Mitsiades et a1.,2001). DcRl and DcR2 expression has been
suggested as another potential mechanism for protection of cells against TRAIL. DcR2 was
uniformly expressed by both TRAIL sensitive and resistant cells by either RT-PCR or flow
cytometric analysis. In contrast, DcRl was hardly expressed at the mRNA level and
membrane protein levels on both MM cell lines, but cytoplasmic DcRl was strongly
expressed on both cell lines. Therefore, TRAIL receptor status alone cannot serve as a
reliable predictor of TRAIL sensitivity in MM cells, with the exception of the lack of both
DR4 and DR5 expression. This lack of correlation of TRAIL decoy receptor expression with
TRAIL sensitivity in MM cells observed in this study is consistent with another report
(Mitsiades et a1.,2001). It should be emphasised that it is not known how the different
TRAIL receptors interact with one another on the cell surface. Neither is it known how much
DcRl and DcR2 must be present on the surface of normal cells to prevent the formation of
DR4 or DR5 signalling complexes to provide protection from the cytotoxic effects of TRAIL'
After exposure of myeloma cells to zoledronic acid, the TRAIL transcript was increased in
both zoledronic acid-sensitive and resistant cell lines. Of interest, the flow cytometric
analysis indicated that the zoledronic acid-sensitive cell line RPMI 8226 had increased
TRAIL receptors DR4 and DR5 with the decreased or unchanged level of decoy receptor
DcRl and DcR2. However, the increased DR4 and DR5 coupled with the increased DcRl
and DcR2 respectively, were noted in resistant cell line, WL2, when the cells were exposed
to zoledronic acid. Therefore, the coupled reaction of TRAIL receptors and decoy receptors
may be decisive for the cell sensitivity to the zoledronic acid. The uncoupled DR4, DR5 and
DcRl, DcR2 in the sensitive cell line RPMI 8226 may be responsible for the drug sensitivity.
This suggest that TRAIL-induced apoptosis is not regulated simply through either the
competitive binding of TRAIL by DcRl and DcR2 or by the transduction of protective
signals mediated by either of these receptors. It does not preclude the possibility that changes
of surface expression of TRAIL receptor(s) in each particular cell lines may modulate its
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TRAIL sensitivity. On the other hand, it also suggests that zoledronic acid may act on the
myeloma cells partially by activating TRAIL and its receptor pathway.
Since myeloma cells are located in the bone marrow microenvironment, the cytokines
secreted by stromal cells in the vicinity should be considered. It was found that OPG, a
secreted homologue of the tumour necrosis factor receptor, represented a fifth TRAIL
receptor (Emery et a1.,1998). Therefore, it is possible that OPG could block the effect of
zoledronic acid on the sensitive myeloma cells since it has been reported that OPG could
inhibit TRAIL-induced apoptosis of Jurkat cells (Emery et al., 1998). Future studies
examining the role of OPG in blocking the effect of zoledronic acid would enable this
question to be addressed.
Taken together, our in vitro studies indicate that zoledronic acid might produce the
therapeutic action on myeloma cells (1) through direct anti-proliferative and apoptotic
effects, (2)bV inhibiting the mevalonate pathway, and (3) activating TRAIL and its receptor
pathway. The results shown here also highlight the potential clinical value of the recently
developed BP, zoledronic acid, which in combination with TRAIL may result in additive
anti-myeloma effects, and yield benefit in the treatment of MM. Further studies are required
to examine whether BPs with different chemical structure may have different effects on
myeloma cell growth and apoptosis.
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CHAPTER 4
IN WTRO STUDIES EXAMINING TIIE EFFECT OF THE NITROGEN
CONTAINING BISPHOSPHONATE, ZOLEDRONIC ACID, ON
OSTEOBLAST.LIKE CELLS
4.1 INTRODUCTION
It is widely believed that the increased bone mineral density in patients receiving BPs can be
attributed to decreased bone turnover (Balena et al., 1993; Chavassieux et al., 1'991; Storm e¡
al., 1993). This observed decrease in bone turnover appears to be due to BP-mediated
inhibition of proliferation and recruitment of OC precursors (Hughes et a|.,1989; Schmidt e/
al., 1996) as well as apoptosis of mature OC (Hughes et al., 1995; Murakami et a1.,7995;
Sato and Grasser, 1990; van Beek et a1.,1997).In recent years, it has been proposed that BPs
may also act indirectly by modulating the expression of osteoclastogenic factors synthesised
by OB (Derenne et al., 1999; Giuliani et al., 1998b; Nishikawa et al., 1996; Sahni et al.,
1993;Yitte et al.,1996). However few studies have been reported detailing the direct effects
of BPs on OB (Giuliani et al.,1998a; Reinholz et a1.,2000; Tenenbaum et al.,1992; Toolan
et al., f992; Tsuchimoto et al., 1994). Therefore, the increase in bone mass observed
following BP treatment may not be fully explained by the inhibition of bone resorption
(Pataki et a1.,1997),but may, in part, be due to increased bone formation by OB.
Osteoblasts play a pivotal role during the biological response of bone to agents including
hormones, polypeptide growth factors, and cytokines that stimulate bone resorption andlor
inhibit bone formation. The proliferation and differentiation of OB precursors (or
preosteoblasts) is an essential step in the bone formation process. It has been reported that
pamidronate and zoledronic acid decrease OB proliferation and enhance the differentiation
and bone-forming activities of OB (Reinholz et al., 2000). However, the underlying
mechanisms of action remain unclear. Therefore, to clarify why BPs inhibit OB proliferation
and stimulate the differentiation of these cells, could provide additional clues with respect to
the action and molecular targets of BPs.
Our understanding of OB differentiation and function has been hampered by a relative lack of
markers which identify the earliest cells of this lineage (Gronthos et a|.,1999). Despite this, a
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number of studies now demonstrate that the OB lineage shares a coÍlmon stromal cell
precursor with adipocytes, reticular cells, fibroblasts and chondrocytes (Gronthos et al',
lgg4). Moreover, a number of independent studies have shown that the OB lineage at
different stages of maturation can be separated, based on their expression of the stromal
precursor cell marker, STRO-1 and the osteoblastic marker, alkaline phosphatase (Gronthos
et al., 1999; Stewart et al., 1999). The majority of the NHBCs, which express the STRO-1-
/ALP+ and STRO-I-IALP- phenotypes, appear to represent fully differentiated OB. In
contrast, the cells that express STRO-I+/ALP* phenotype are considered to be representative
of osteoprogenitors, whilst the cells, which only express STRO-1 antigen, represent stromal
precursors
Zoledronic acid is a new generation, nitrogen-containing BP and the most potent inhibitor of
bone resorption currently available. In this study, we have investigated the effect of
zoledronic acid on cultures of human OB with respect to (a) its ability to regulate the
expression of molecules with roles in osteoclastogenesis and (b) its ability to promote bone
formation, using an established model of human OB differentiation and function.
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4.2 RESULTS
4.2.1 The Elþct of Zoledronic Acid on Osteobløst-Like Cell Proliferøtion and Survival
Osteoblast-like cells derived from 3 donors were cultured in increasing concentrations of
zoledronic acid. As shown in figure 4.1, zo\edronic acid induced a significant decrease in cell
number at concentrations of 0.05pM or greater at d3 in all three donors (p<0.05)'
Furthermore, zoledronic acid induced a decrease in cell number in a dose-dependent manner
at both d3 and d5. Surprisingly, a low concentration (0.05¡rM) of zoledronic acid was found
to increase cell number at d5, although there was no significant difference compared with
negative control (p>0.05).
The actual concentration range of BPs that OB are exposed to under pharmacological
conditions in vivo is unknown. Therefore, it is difficult to design in vitro experiments that can
be directly correlated to in vivo physiological conditions. Five ¡rM of zoledronic acid, a
concentration having an effect in terms of inducing measurable cellular responses, was
chosen for most of the experiments in this study. Osteoblast donor cells were cultured in the
presence of 5pM zoledronic acid and the cell number and viability was assessed at the
different time points using the colorimetric dye WST-I. Zoledronic acid was found to inhibit
cell proliferation and induce cell death in a proportion of the cells. At day 3, a significant
difference between negative control and zoledronic acid treatment goups was observed in
cells from all three donors (p<0.05). In this study, donor #1 responded to zoledronic acid with
the least sensitivity, whereas donor #3 responded to the drug with the most sensitivity (figure
4.2).
To differentiate between cytostatic and clotoxic effects of zoledronic acid, studies were
performed to examine if zoledronic acid induced apoptosis. Using the nuclear fluorochrome,
DAPI, morphological examination revealed that treatment of OB-like cells with zoledronic
acid led to morphological changes characteristic of apoptosis, including chromatin
condensation, nuclear fragmentation and the formation of dense, rounded apoptotic bodies
(figure 4.3). The proportion of apoptotic cells was low in all donor OB-like cell cultures and
it was donor dependent. Donor #3hadmore apoptotic nuclei compared with Donot #l and#2
(refer to figure 4.1). In contrast, analysis by gel electrophoresis showed that zoledronic acid
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Figure 4.I. The effect of increasing concentrations of zoledronic acid on the
proliferation of human OB-like cells. Osteoblast-like cells derived from three different
donors were seeded in 96-well plates at a cell density of 4000 cells/well. Cells were
cultured in media supplemented with zoledronic acid at the different concentrations.
Ce1l number and viability was quantitated at d3 and d5 using V/ST-I as described in
section 2.1.2.1and the results are presented as the mean percentage of negative control
t SEM (trþlicate cultures). Zoledronic acid induced a significant decrease of cell
number at a concentration of 0.05pM at d3 (A) in all three donors þ<0.05, /-test)'
Furthermore, zoledronic acid induced a cytoreductive effect in a dose-dependent
manner. A similar phenomenon was observed at d5 (B), however, zoledronic acid at a
concentration of 0.05pM was found to increase cell number at d5, although this was not
significantly different when compared with untreated cells (p>0.05, /-test). This study
also revealed that OB-like cells derived from donor #3 proliferated faster than those
































Figure 4.2. Effects of 5 pM zoledronic acid on the proliferation of OB-like cells.
Osteoblast-like cells derived from three different donors were seeded at a cell density of
4000 cells/well in 96-well plates using FACStaTPLUS cell sorter. Cells were cultured in
medium in the presence or absence of zoledronic acid for the period of 5 days. The cell
number and viability was assessed by WST-I as described in the methods, and the data
are presented as the mean absorbance of colorimetric reaction * SEM (triplicate
cultures). These studies demonstrate that zoledronic acid induces an anti-proliferative
effect at a concentration of 5 ¡rM in OB-like cells derived from all three donors. A
significant difference between negative control and zoledronic acid treated groups was
achieved at day 3 (p<0.01, /-test), and the sensitivity of OB-like cells to zoledronic acid
was donor dependent. In this study, donor #1 (A) responded to zoledronic acid with the
least sensitivity, whilst donor #3 (C) responded to the drug with the most sensitivity.





































Figure 4.3. Effect of zoledronic acid on apoptosis of OB-like cells in culture. The OB-
like cells were seeded in 8 chamber slides at a cell density of 7,500/we11 and cultured in
the presence of 5 pM of zoledronic acid for 72 hrs. Cells were stained with DAPI and
examined by fluorescence microscopy. Morphological changes characteristic of
apoptosis, including condensation and the formation of dense, rounded apoptotic bodies
were clearly evident in a small percentage of OB-like cells in all donor-derived cells (B,
D, F) when compared with untreated cells (4, C, E). Consistent with the cell
proliferation results (fig 4.114.2), fewer apoptotic nuclei were noted in donor #l (B) and
#2 (D) compared with donor #3 (F).







treatment failed to induce appreciable levels of apoptosis as evidenced by the lack of low
molecular weight DNA fragments in all donors (figure 4.4).
It has been demonstrated in other cell types that BP-induced apoptosis is proceeded by
activation of the caspase cascade (Benford et a\.,2001 Fromigue et a|.,2000;Hiraga et al.,
2001). To assess whether the cell death observed in OB-like cells might also be mediated by
caspase activation, we assessed caspase 3 activity in all 3 donor OB cultures following
zoledronic acid treatment (hgure 4.5). Using the fluorometric caspase 3 substrate DEVD as
described in the methods, it was clear that untreated OB-like cells possessed low caspase
activity compared with other cell types, such as the myeloma cell line RPMI 8226' However,
zoledronic acid did increase caspase activity in OB-like cells derived from all three donors.
The extent of this increase varied in different donors, with a significant increase of caspase
activity noted in donor #2 (p<0.001) and donor 3# (p<0.005).
4.2.2 Zoledronic Acid Mediates the Dffirentíation of Osteobløst-Like Cells
Using multi-parameter immunofluorescence and flow cflometry, cultured human OB-like
cells can be separated according to their stage of differentiation. Using monoclonal
antibodies (mAbs) STRO-I and B4-78 (anti-bone/liver/kidney isoenzyne of AP), the OB
lineage at different stages of maturation can be identified. Consistent with the previous
findings (Gronthos et al., 1999), the OB-like cell cultures were found to have a
heterogeneous but highly reproducible pattern of expression of both STRO-I and ALP
(figure 4.6). Notably, zoledronic acid was found to alter the proportion of cells expressing
STRO-1 and ALP cell surface markers when compared with the untreated control. There was
an inverse reciprocal relationship between the alteration of cell proportion of STRO-l*/AP-
and STRO-174P- subpopulations. Zoledronic acid increased the percentage of cells
expressing STRO-174P- phenotype, and decreased the percentage of cells expressing the
STRO-1 antigen. At dl there was a minor change in the relative proportion of STRO-l*/AP-
cells, whils t at d3, there was a significant decrease in the number of STRO-I* and AP* cells,
with a concomitant increase in the number of STRO-l-/AP- cells. At d5, the number of
STRO-I+ cells were found to increase, and assumed a phenotlrpe similar to the untreated
control. These observations were qualitatively similar in cells from each of four donors
(p<0.05), and the effect of zoledronic acid appeared partially reversible.
67
Figure 4.4. Zoledronic acid does not induce detectable levels of intranucleosomal
genomic DNA fragmentation. Osteoblast-like cells were treated for 72 hours with 5 prM
zoledronic acid, intranuclear and genomic DNA fragmentation was assessed as
described in the materials and methods (section 2.L5). No low-molecular weight DNA
fragments were observed in donor #1 (lanes 5-8), donor #2 (lanes 9-12) and donor #3
(lanes 13-16) either in the presence or absence of zoledronic acid. The murine cytokine-
dependent myeloid cell line, FDC-PI cells were used as a positive control as factor







lane 1,2: FDC-P1 without GM-CSF
lane 3,4: FDC-P1 with GM-CSF
lane 5,6: donor#1 w/o zole
lane 7,8: donor#1 zole (SpM)
lane 9,10: donor#2 w/o zole
lane 11,12: donor#2 zole (sPM)
lane 1 3,14: donor#3 wlo zole






















Figure 4.5. Zoledronic acid induces low levels of caspase activity in OB-like cells.
Osteoblast-like cells derived from three different donors were seeded in 24-well plates
with a cell density of 10,000 cells/well and cultured in the presence or absence of
zoledronic acid at a concentration of 5 pM. Caspase-3 activity was measured by
measuring the degradation of the fluorometric substrate DEVD as described in the
methods. Osteoblast-like cells displayed relatively low caspase activity compared with
the myeloma cell line RPMI 8226. Treatment resulted in an increase in caspase activity
in the OB-like cells derived from all three donors. Although relatively resistant to
zoledronic acid, cells from donor #l displayed a small but measurable (p<0.01, r-test)
increase in caspase activity. In comparision, caspase activity in donor #2 was increased
dramatically (p<0.001, /-test) whilst there was an intermediate increase (p<0.01, r-test)






























Figure 4.6. Modulation of STRO-I and ALP expression by OB-like cells treated with
zoledronic acid. A model of bone cell development has been previously described
where cultures of normal human bone cells can be separated on the basis of their
expression of the stromal precursor cell marker STRO-I and the osteoblastic marker,
alkaline phosphotase (AP). According to this model, cells with the surface phenotlpe
STRO-1"/Ap-, STRO-I*/AP*, STRO-174P* and STRO-174P- represent preosteoblasts,
committed OB, mature OB and osteocfes, respectively. Dual-colour
immunofluorescence and flow cytometric analysis was performed using OB-like cells
stained with the mAbs STRO-I (anti-stromal precursors marker) and 84-78 (anti-ALP
Ab). Immunoreactivity was revealed by incubation with an anti IgM-PE (y-axis) and
IgG-FITC (x-axis), as described in the methods. The dot plot histogram represents
10,000 events collected as listmode data. The quadrant lines were established with
reference to staining observed with isot),pe-matched control antibodies, 1B5 (FITC) and
l¡612 (PE), respectively. The results show that zoledronic acid alters the proportion of
cells expressing STRO-I and ALP cell surface markers. There was an inverse reciprocal
relationship between the alteration of cell proportion of STRO-l*/AP- and STRO-174P-
phenotype subpopulations. In briel zoledronic acid increased the percentage of cells
expressing STRO-174P- phenotype, and decreased the percentage of cells expressing
the STRO-I antigen. At dl there was a minor change in the relative proportion of
STRO-1*/AP- cells, whilst at d3, there was a significant decrease in the number of
STRO-I+ and AP* cells, with a concomitant increase in the number of STRO-174P-
cells. At d5, the number of STRO-I* cells increased compared with d3. As seen in
figure 4.6 (B), these observations were consistent in each of the four donors. The data
for donor #2 arc presented as a typical example of results obtained (A). The changes
that occurred at d3 are observed for all four donors. The percentage of cell






























































































Table 4.1. Summary of results of dual-colour immunofluorescence and flow cytometric
analysis of osteoblast-like cells derived from four different donors treated with zoledronic
acid. The percentages of osteoblast-like cells, which have the various phenotpes, are
displayed. Spearman Rank Correlation analysis revealed that there \Mas a negative
correlation between the alteration of STRO-l+/AP- and STRO-174P- subpopulation
induced by zoledronic acid (p<0.05), suggesting that zoledronic acid treatment mediates
differentiation of the osteoblast-like cells, or selectively affects the less mature cells.











Donor #1, d1 (o/o) 46.37 47.36 8.34 8.96 5.47 5.48 39.83 38'20
Donor #1, d3 (%) 49.06 40.01 5.40 5.14 4.38 3.84 41.16 51.01
Donor #1, dS (%) 50.66 42.26 6.21 5.11 4.78 4.47 38.35 48.15
Donor #2, d1 (o/o) 42.84 39.16 21.49 16.49 12.35 14.62 23'34 29-73
Donor #2, d3 (Yo) 49.71 19.14 15.63 9.59 9.43 20.85 25.22 50.42
Donor #2, d5 (yo) 41.79 31.06 12.14 9.45 12.07 13.06 34.00 46.43
Donor #3, d1 (%) 5.83 3.73 21.55 8.49 62.17 69.62 10.45 18.15
Donor #3, d3 (%) 7.90 5.00 25.07 12.85 55.13 54.75 11.90 27.40
Donor #3, d5 (%) 7.69 2.39 44.77 18.77 42.21 65.52 5.33 13.32
Donor #4, d1 (o/o) 55.03 50.98 12.68 11.81 6.37 7.19 25.92 30.01
Donor #4, d3 (Yo) 67.43 34.47 8.76 5.18 2.38 5.98 21'43 54.98
Donor #4, d5 (%) 38.95 35.51 2.74 8.53 2.51 5.86 55.79 50.10
4.2.3 STRO-/'ich'Osteobløst-Like Cetls Proliferate More Røpidly and Are More Sensitive
to Zoledronic Acid
To determine if a difference in the cell cycling status between different subpopulations may
play a role in the differential sensitivity of these cells to zoledronic acid, dual-colour FACS
analysis of OB-like cells was employed, examining the expression of STRO-I and the cell
cycle-specific antigen Ki-67. As seen in figure 4.7,the majority of the OB-like cells were
actively dividing, as indicated by their expression of the Ki-67 antigen. At dl, approximately
600/o of cells were found to express appreciable levels of the Ki-67 antigen, suggesting that
most of the cells were in either Gr, S or GzlM phase of the cell cycle, whilst the remainder
were in Gs phase. Consistent with the data in figure 4.6, zoledronic acid treatment resulted in
the diminution in STRO-I expression. The reduction in STRO-1 expression was associated
with the induction of quiescence in the STRO-lbricht population as evidenced by the
appearance of a STRO-1b'ieht/Ki-6Tnesarive population. The data also revealed that zoledronic
acid appeared to inhibit cell division when compared with the control. Moreover, following
exposure of the cells to zoledronic acid, a distinct population of STRO-lb'ieht cells, which
exhibited low forward and side scatter, were generated by d3, indicating that the STRO-lb'ich'
cells may be undergoing zoledronic acid-induced cell death.
To further clarify the effects of zoledronic acid on the different subpopulation of OB-like
cells, three-colour FACS analysis was employed using mAbs to STRO-1, ALP and the DNA
fluorochrome, 7-AAD. As seen in figure 4.8, the cell cycle status was not related to the extent
of ALP expression by the OB-like cells derived from donor #2. In contrast, the majority of
cells expressing STRO-I antigen at high levels were distributed in the S and Gzlld phase.
Consistent with previous findings, treatment of OB-like cells resulted in a time-dependent
increase in the apoptotic sub-Go/Gr peak, consistent with the onset of apoptosis.
To confirm whether zoledronic acid induced changes in STRO-I and ALP expression was
due to a difference in the rate of cell death in the different subpopulations, the STRo-lb'icht
and STRO-lnesative subpopulations of OB-like cells were sorted using the FACStaTPLUS cell
sorter and the cell proliferation rate assessed using WST-1. Although there was no significant
difference in the growth rate of STRO-lb'icht and STRO-ln"cuti" cells (figure 4.9), the STRO-
lb'isht cells were slightly more sensitive than STRO-lnesative cells to zoledronic acid (p<0.05).
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Figure 4.7. The cycling status of STRO-I* OB-like cells treated with zoledronic acid'
Osteoblast-like cells were cultured in the presence or absence of zoledronic acid over
the period of 5 days. The cells were harvested at different time points and stained with
the mAb STRO-I followed by IgM-PE, fixed in 70o/o cold ethanol on ice for l0 mins
and subsequently immunoreacted with the FITC conjugated mAb Ki-67. The samples
were analysed by dual-colour immunofluorescence and flow cytometry. The dot plot
represents 10,000 events collected as listmode data. The quad-stat markers were
established with reference to the reactivity obtained with the isotype-matched control
antibodies, IgGI(FITC, X axis) and LA6.I2(PE, Y axis). At d1, approximately 60Yo of
cells were found to express appreciable levels of the I<t-67 antigen, suggesting that most
of the cells were in either Gl, S or GzM of the cell cycle, whilst the remainder were in
G6 phase. Consistent with the data in figure 4.6, zoledronic acid treatment resulted in
the diminution in STRO-I expression. The reduction in STRO-I expression was
associated with the induction of quiescence in the STRO-lb'icht population as evidenced
by the appearance of STRO-lb"chtlKi-6Tnegative population (A). The data also revealed
that the STRo-lb'icht cells, in the presence of zoledronic acid, assume low forward and
side scatter (highlighted in red, on B and C) indicating that the STRO-lbdsht cells may












































































































Figure 4.8. Three-colour immunofluorescence and flow cytometric analysis reveals that
zoledronic acid induces S-phase arrest and cell death of the STRo-lb'icht OB-like cells.
Osteoblast-like cells derived from donor #2 were cultured in the presence or absence of
zoledronic acid for 72 hrs. The cells were stained with the mAbs STRO-I, B4-78
coupled to FITC, and the DNA fluorochrome, 7-AAD, as described in the methods. The
dot plot represents 10,000 events collected as listmode data. The auxiliary channel was
used to discriminate between single cells and cell doublets. The latter were excluded
and the single cells were gated in accordance to their stage of the cell cycle, including
hypo-diploid sub-Go/Gr, Go/Gr, S and GzlM. Cells expressing ALP antigen were
analysed with respect to their cell cycle status (FL4). Similarly, cells expressing STRO-
1 antigen were also analysed with respect to their cell cycle status (FL4). The results
suggest that cell cycle status was not related to the extent of ALP expression on the OB-
like cells derived from donor #2.In contrast, the majority of cells expressing STRO-I
antigen at high levels were distributed in the S and GzM phase. Consistent with
previous findings (refer to figure 4.2), treatment of OBJike cells resulted in a time-

































































Figure 4.9. The STRo-lb'icht population of OB-like cells is more sensitive to zoledronic
acid induced cytostasis and cell death. Osteoblast-like cells derived from donot #2 werc
sorted into STRO-lbrieht and STRO-lnesative subpopulations using FACStaTPLUS cell
sorter. The cells were seeded in 96-we11 plates at a concentration of 4000 cells/well.
Cells were cultured in the media in the presence or absence of zoledronic acid for the
period of 5 days. The cell proliferation rate was assessed using WST-I at different time
points as previously described. The results demonstrated that although both STRO-I
bright @) and STRo-ln"cutiu' (C) OB-like cells were sensitive to zoledronic acid
treatment (p<0.001 at d3 and d5, r-test), STRo-lb'icht cells were more sensitive than the




















































To further investigate differences in cell proliferation between STRo-lb'icht and STRO-
lnegative/dim cells, Carboxyfluorescein diacetate succinimidyl ester (CFSE) was used. CFSE is a
cell permeant fluorescein based dye and can be used for tracking cell division in vitro and in
vivo (Lyons, 1999; Lyons, 2000). Using two-colour flow cytometric analysis, we examined
the proliferative rate of the different subpopulations based on their expression of the STRO-1
and ALP cell surface markers. Unlike the cell proliferation results using WST-I, STRo-lb'icht
cells were found to have a significantly enhanced capacity to proliferate compared with the
STR6-ln"cative/dim population (figure 4.10). Furthermore, zoledronic acid inhibited cell
division in a dose dependent manner, and totally inhibited cell division at a concentration of 5
¡rM at dl and d3 (figure 4,11). Although the expression of STRO-1 was marginally increased
in the presence of 0.5 ¡rM of zoledronic acid, it dramatically decreased in the presence of 5
pM of zoledronic acid (figure 4.11). However, following 7 days culture in the present of 5
¡rM zoledronic acid, the cells began to divide and this was accompanied with re-expression of
STRO-I antigen at the cell surface. Therefore, the decrease in STRO-I expression may
correspond to the inhibition of cell division, suggesting that the STRO-I cell surface
molecule, is strongly associated with OB-like cells which are actively dividing.
4.2.4 Zoledronic Acid Reguløtes the Expression of Osteoclast und Osteoblast-Related
Genes
The alteration of gene expression was also detected in zoledronic acid-treated OB-like cells
utilising semi-quantitative RT-PCR (figure 4.12). The mRNA integrity in each of the groups
was confirmed by reproducible and consistent amplification of the "house keeping" gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Among the various genes
investigated in this study, TNF-c¿ and IL-IB were upregulated in donor #2 and donor #3 by
prolonged exposure to zoledronic acid (d3 and d5). TNF-cr gene expression increased 2-fold
at d3 in donor #2, and in donor #3, it was increased 5- and 22-fold at d3 and d5, respectively
(p<0.005). Similar effects on IL-1p gene expression were also noted (p<0.005). However,
zoledronic acid did not alter the expression of other OAFs, including IL-6 and M-CSF.
In addition, the expression of the TNF-family molecules RANKL and OPG, which play a
crucial role in osteoclastogenesis and bone resorption in normal bone remodelling, was also
examined. The expression of OPG was unaltered over treatment periods of 5 days. There was
no significant difference of the relative ratio of RANKL/OPG between the negative control
and the cells exposed to zoledronic acid (figure 4.13).
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Figure 4.10. The STROIb'icht fraction of OB-like cells have a gteater proliferative
capacity than the STRo-1n'cutiu' fraction. Osteoblast-like cells derived from donor #2
were labelled with CFSE as described in the methods. Osteoblast-like cells without
CFSE labelling were used to establish a negative control (auto-fluorescence).
Colchicine (100 nglml) was used to inhibit cell division and provided an input labelling
index to establish a positive control. Cells were subsequently stained with STRO-I-PE
as described above and the cell proliferation was analysed using the ModFit LT for win
32 (Version 2.0). The STRO-lbrieht ce[s (R1) were found to have a significantly
enhanced capacity to proliferate when compared with the STRO-ln"cative/dimpopulation
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Figure 4.11. Zoledronic acid inhibits the proliferation of OB-like cells in a dose-
dependent manner. Osteoblast-like cells derived from donor #2 were labelled with
CFSE as described in the methods. Cells were subsequently cultured in the presence of
zoledronic acid (0.5 & 5 ¡rM) for 3 (A), 5 (B) and 7 (C) days, stained with STRO-I and
analysed as above. Zoledronic acid was found to inhibit cell division in a dose-
dependent manner. In accordance with previous studies, zoledronic acid treatment
resulted in a decrease in STRO-I expression, which was reacquired upon cell division at
d7 (c).
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Figure 4.12. The effect of zoledronic acid on the temporal expression of OC-related
genes. Osteoblast-like cells derived from three different donors were seeded in 6-well
plates at a cell density of 1.5 x 10s cells/well and cultured in the presence/absence of
zoledronic acid. The cells were harvested at the five different time points, total RNA
was isolated, and semi-quantitative RT-PCR was performed examining the expression
of the OC-relatedmolecules TNF-a (A), IL-l8 (B), IL-6 (C), M-CSF (D), RANKL (E)
and OPG (F) as described in the methods. The house keeping gene, GAPDH was used
as an internal control for mRNA integrity and enabled relative gene expression to be
determined. PCR products were subjected to electrophoresis on 2o/o agarcse gel, stained
with SYBR gold, visualised using a Fluorimager. The product bands were semi-
quantitated and plotted as a histogram of the ratio of specific gene expression relative to
the expression of GAPDH. These data suggest that the gene expression of TNF-a
(p:0.005 in donor #2,p<0.005 in donor #3,'Wilcoxon test), L-18 (p<0.005 in donor #3,
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Figure 4.13. Zoledronic acid does not significantly alter the ratio of RANKL to OPG
expression in OB-like cells. Semi-quantitative gene expression of RANKL and OPG
was detected as described in figure 4.I2. The results here showed that the relative ratio
of RANKL/OPG, a key factor in OC formation, was not significantly altered in














































Exposure of OB-like cells to zoledronic acid also increased the expression of bone related
genes (figure 4.14). In donor #3,the expression of OCN increased 6-,Il- and 8-fold at dl,
d3 and d5, respectively. The expression of BSP was also found to be upregulated in donor #3.
However, the exposure of zoledronic acid did not alter the gene expression of OCN and BSP
in donor #l and donor #2, or of the core binding factor alpha-l (CBFA-l), a transcription
factor that plays an integral role in OB differentiation.
4.2.5 The Up Regalation in Gene Expression Mediated by Zoledtonic Acid Wøs Not
Reløted to the Proportional Alteration of Osteoblast-Like Cell Subpopuløtions
As previously described (figure 4.6), culture of OB-like cells in 5 pM zoledronic acid,
resulted in a decrease in the number of cells which expressed a preosteoblast phenotype
(STRO-1+/Ap-), with a concomitant increase in the number of cells with a mature OB
phenotype (STRO-174P-). This prompted us to examine if the alteration in gene expression
observed, was related to the inherent differences in the gene expression profile of the STRO-
lb'icht and STRO-1n'cuti"' subpopulations. In an attempt to answer this question, total RNA
was isolated from freshly sorted STRo-lb'icht and STRo-1n"cuti"" OB-like cells derived from
donor #3. Using semi-quantitative RT-PCR technique, gene expression was examined in both
subpopulations. Interestingly, the gene expression profile detected in these two populations
was comparable (figure 4.15). However, when the sorted cells were re-cultured either in the
presence or absence ofzoledronic acid for three days, significant changes in gene expresion
were noted. As shown in figure 4.16, STRg-lbriehtce[s expressed more IL-lp and TNF-a
than STRO-lnesative cells, whilst STRO-lb'isht cells express less OCN and BSP than STRO-
lnesative cells. Although zoledronic acid did not affect most of the genes expressed in STRO-
lb'ish'and STRO-ln'cu'iu" subpopulations, the expression of message for TNF-a was reduced
in STRO-lbricht 6g-like cells and increased in STRO-1""cutiu' cells when exposed to
zoledronic acid for three days. Furthermore, oCN gene expression in STRo-lb'icht cells was
also found to be upregulated.
4.2.6 Zoledronic Acid Decreased Protein Expression on the Osteoblast'Like Cells
The expression of cell surface protein STRO-I, RANKL and ALP is important for OB
maturation and function, therefore, these proteins were investigated using single-colour
immunofluorescence and flow cytometric analysis. Culture of OB-like cells in zoledronic
10
Figure 4.I4. The effect of zoledronic acid on the temporal expression of OB-related
genes. As described in fig 4.12, the expression of OB-related genes including CBFA-I
(Ð, BSP (B), and OCN (C) was examined by semi-quantitative RT-PCR. These data
suggest that although CBFA-I and BSP gene expression does not appear to be altered in
response to zoledronic acid, OCN gene expression is significantly (p:0.005 in donor #3,
Wilcoxon test) upregulated in OB-like cells, partially in donor #3. The arrow indicates
the position of an upper band for CBFA1.
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Figure 4.15. Freshly sorted STRo-lb'icht and STRO-lnesative cells do not differ with
respect to the expression of OC- and OB-related gene. Osteoblast-like cells derived
from donor #3 were sorted by FACStaTPLUS cell sorter into STRO-lbrieht and STRO-
lneeative populations as previously described (A). Total RNA was isolated from the both
populations, and gene was examined by semi-quantitative RT-PCR. The various
transcripts examined in this study included: TNF-u, IL-18, IL-6, RANKL, OPG, COX-
2, BSP and OCN (B). The product bands were semi-quantitated and plotted as a
histogram of the ratio of specific gene expression relative to the expression of GAPDH
(C). There \ryas no difference in the relative gene expression between two


































Figure 4.16. Gene expression in sorted STRO-lb'icht and STRo-lnesative subpopulations
of OB-like cells treated with zoledronic acid. Osteoblast-like cells derived from donor
#2were sorted using FACStaTPLUS cell sorter. Unsorted, STRo-1n'cutiu'thorizontal bar
A), STRo-lintermediate (horizontal bar B) and STRO-lbricht (horizontal bar C) cells were
sorted as described previously. The sorted cells were seeded in the 6-well plates (2.5
x 105 cells/well) and cultured for 72 hrs in the presence or absence of zoledronic acid.
The cells were harvested and total RNA isolated, semi-quantitative RT-PCR was
performed in order to detect any changes in gene expression. The product bands were
quantitated using ImageQuant and the results plotted out as a histogram of gene
expression relative to GAPDH. Interestingly, the expression of a majority of the genes
examined was substantially different between the STRO-lnesative, STRO-1int"*"diutt, and
STRO-1b'icht fractions when the cells were cultured for 3 days in the absence of
zoledronic acid. Of note, STRO-lbdsht cells expressed more IL-lB and TNFc¿ transcripts
than STRO-lnesative cells. In contrast, STRO-lb'icht cells expressed less OCN, COx-2
and BSP transcripts than STRO-1n'cutiu" cells. The STRO-lint"rmediate population
expressed very high levels of COX-2 transcript, which was reproducibly down regulated
following 3 days culture in zoledronic acid. Although zoledronic acid did not alter the
expression of most of the genes examined in STRO-lb'icht and STRo-1n"cutiu"
subpopulations, the expression of TNFcr was reproducibly down regulated in STRO-
lbrieht gB-like cells and upregulated in the STRO-1"'cutiu" fraction. In contrast, the








































































wlo zole zole (5 pM)
1 unsorted osteoblast-like cells: wlo zole
2 STRO-I intermediate : MO ZOle
3 STRO-I nesative : w/o zOle
4 STRO-1brisht. Mo zole
6 unsorted osteoblast-like cells: zole (S¡lM)
7 STRO-I intermediate : zole (SpM)
g STRO-I nesative : zole (SpM)
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acid for three days, resulted in a decrease in the expression of membrane protein expression
of STRO-I (figure 4.17) and RANKL (figure 4.18) on the OB-like cells. In contrast, when
cytoplasmic protein expression was examined, no significant changes were noted, suggesting
that membrane expression was regulated by mechanisms independent of gene expression
(figure 4.20). A comparable down regulation of ALP expression was observed for both
membrane and cytoplasmic expression of this protein (figure 4.19)'
4.2.7 Zoledronic Acid Upreguløted TACE Gene Expression
Our studies suggest that zoledronic acid regulates the membrane expression of RANKL
without demonstrably affecting the level of transcript expression. Recent reports suggest that
membrane-bound RANKL is able to be cleaved by a member of the metalloprotease-
disintegrin, TACE. In the absence of an antibody specific for TACE, we examined the
regulation of TACE expression using semi-quantitative RT-PCR. As seen in frgve 4.21,
zoledronic acid treatment resulted in an up regulation of TACE gene expression at d1 and d3
in donor #2, at d3 in donor #3. The up regulation in TACE expression coincided with a
reduction in RANKL and STRO-I expression. Moreover, TACE gene expression declined to
baseline levels at d5, temporally consistent with the re-expression of RANKL and STRO-I
expression.
4.2.8 TNF-a and IL-Ip Augmented STRO-I*/ALP* Subpopuløtion and Inueased Cell-
Dividing Potential of Osteobløst'Líke Cells
As described previously, zoledronic acid treatment resulted in the up regulation of TNF-c¿
and IL-lp in OB-like cells. To investigate whether TNF-cr and IL-lp expression can
overcome the cytostatic effects induced by zoledronic acid, OB-like cells were cultured with
recombinant human TNF-o or IL-lp and the cell phenotypes were assessed by dual-colour
immunofluorescence and flow clometric analysis. As seen in figure 4.22, cells cultured in
TNF-cr and IL-18 resulted in an increase in the number of STRO-l*/AP* cells.
Consistent with previous f,rndings, STRO-lbrieht and AlPb'isht cells possessed a greater
proliferation capacity than the cells expressing low levels of the STRO-1 and ALP antigens.
Of note, TNF-a had a greater capacity to increase the number of STRO-lbrieht cells, whilst
1L-1p had greater capacity to increase the number of AlPb'isht cells. Moreover, both TNF-o
7t
Figure 4.17. The zoledronic acid-mediated down regulation of STRO-I expression
occurs at the level of surface expression. Fluorescence histograms depicting the
expression of STRO-I protein at the surface (A) and within the cloplasm (B) of OB-
like cells derived from donor #2.The data is expressed as the relative cell count (y-axis)
versus the intensity of STRO-I expression (log scale). 10,000 events were collected as
listmode data. The horizontal bar (region M1) depicts the relative percentage of cells
expressing STRO-I antigen compared to the isotype matched negative control mAb,
1116.12, coupled to FITC. The mean fluorescence of STRO-I expression on the cell
membrane was decreased 3-fold when the cells were exposed to zoledronic acid (from
130.43 to 30.95). In contrast, no difference was noted in permeablised cell staining,





















































Figure 4.18. The zoledronic acid mediated down regulation of RANKL expression
occurs at the level of surface and cytoplasmic expression. Fluorescence histograms
depicting the expression of RANKL protein at the surface (A) and within the cytoplasm
(B) of OB-like cells derived from donor #2. The data is expressed as the relative cell
count (y-axis) versus the intensity of RANKI expression (log scale). 10,000 events
were collected as listmode data. The horizontal bar (region M1) depicts the relative
percentage of cells expressing RANKL antigen compared to the isotype matched
negative control mAb, 146.11 (for mAb TRANCE), or a-MAP (for anti-rabbit
RANKL), coupled to FITC. A decrease in mean fluorescence of RANKL expression
both in membrane and permeablised staining was observed when the cells were exposed
























































Figure 4.19. The zoledronic acid mediated down regulation of ALP expression occurs at
the level of both the cytoplasmic and membrane expression. Fluorescence histograms
depicting the expression of ALP protein at the surface (Ð and within the cytoplasm (B)
of OB-like cells derived from donor #2. The data is expressed as the relative cell count
(y-axis) versus the intensity of ALP expression (log scale). 10,000 events were collected
as listmode data. The horizontal bar (region M1) depicts the relative percentage of cells
expressing ALP antigen compared to the isotype matched negative control mAb, lB5,
coupled to FITC. A decrease of mean fluorescence of ALP expression both in






















































Figure 4.20. Summary of membrane and cytoplasmic protein expression by OB-like
cells treated with zoledronic acid. As described above, zoledronic acid mediated a
decrease in the expression of membrane protein expression (A) for STRO-I, RANKL
and ALP on the OB-like cells. This decrease was not as significant when cytoplasmic
expression was examined for both RANKI and STRO-I (B). Data are displayed as the
mean fluorescence of each protein from which the mean fluorescence value of the





















Figure 4.2I. Zoledronic acid upregulates TACE gene expression. As described in figure
4.12, the gene expression of TACE was examined by semi-quantitative RT-PCR. It can
be seen that zoledronic acid upregulates TACE gene expression at d3 in donor #2 (A),
and donor #3 (B).
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Figure 4.22. Recombinant human TNF-o and IL-IB increases the number of STRO-
l*/AP* osteoprogenitor-like cells. Osteoblast-like cells derived from donor #4 were
cultured in the T75 flasks and treated with TNF-o and IL-lp at concentrations of 5
nglml and l0 nglml, respectively. The cells were harvested at d6 and stained with
STRO-I and ALP as described in figure 4.\2. The results show that culture of OB-like


























































and IL-lB were found to significantly enhance the proliferative capacity of the OB-like cells
in culture (figure 4.23).
4.2.9 Minerølisøtion Potentiøl of Osteoblsst-Like Cells is Enhanced by Zoledronic Acid
Treatment
As demonstrated above, zoledronic acid treatment resulted in a decrease in the STRO-lb'icht
population of OB-like cells, which was due, in part, to the greater death rate of STRO-lb'ich'
cells compared to the STRO-lnegative population. It was also noted that zoledronic acid
treatment resulted in the inhibition of cell proliferation, which was accompanied by a
decrease in STRO-I antigen expression. One possibility of the loss of STRO-I expression
was that the STRO-lbrieht population differentiated into more mature OB-like cells. To
investigate this possibility, the ability of the OB-like cells to form a mineralised bone matrix
was assessed by culturing the cells in osteoinductive conditions in the presence of zoledronic
acid at different concentrations (figure 4.24A). The level of mineral formation by the OB-like
cells was dependent upon the concentrations of zoledronic acid used in cultures. Lower levels
of mineral deposition were evident in the OB cultures treated with zoledronic acid relative to
the negative controls before day 28.In contrast, at day 35 a significantly (p<0.05) higher
level of mineral formation was observed in the OB treated with zoledronic acid at a
concentration of 0.5 ¡rM in donor #1 and donor #2. However, the equivalent levels of mineral
deposition were noted at day 35 in donor #3 in the presence of 0.5 ¡rM of zoledronic acid.
The potential for mineral formation in OB-like cells was significantly reduced when the cells
were cultured with zoledronic acid at concentrations higher than 5 ¡.rM in all three donors. As
zoledronic acid treatment was shown to induce cell death of OB-like cells in a dose
dependent manner (please refer to hgure 4.1), we normalised the amount of calcium
phosphate produced per viable cells. As shown in figure 4.248, when cells were cultured in
zoledronic acid at a concentration of 0.5 pM, this resulted in a significant increase in mineral
formation in donor #1 and #2 (p<0.001).
We noted that the high concentration of zoledronic acid decreased mineral formation of OB-
like cells when treated with fresh drug at weekly intervals for the duration of the assay. To
reduce the cell death caused by constant drug exposure, single dose zoledronic acid was
administrated only at d0 of cultures and omitted in subsequent weekly feeding of the cultures.
As seen in figure 4.25, zoledronic acid at very low concentrations (0.05 and 0.5 ¡rM) did not
enhance the mineral formation in the OB-like cell cultures. However, when zoledronic acid
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Figure 4.23. TNF-o and IL-IP increases the proliferative potential of OB-like cells.
Osteoblast-like cells derived from donor #2 were labelled with CFSE as described in the
methods. Cells were subsequently cultured in the presence of TNF-a (5 nglml) and IL-
1B (10 nglml) for 3 and 5 days, stained with STRO-1 or ALP and analysed as above.
Consistent with previous findings, STRO-lb'isht and 4¡p bright ce[s had an enhanced
proliferative potential than cells expressing negative/dim STRO-I and ALP (A). Of
note, TNF-o(, was more effective augmenting the growth of STRO-lbdsht cells (B), whilst
IL-18 was more able to augment the growth of AlPb'icht cells (C). Both TNF-o¿ and IL-
1B were found to enhance cell division (D).
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Figure 4.24. Mineralisation potential of OB-like cells is enhanced by zoledronic acid
treatment. Osteoblast-like cells derived from three different donors were seeded in 96-
well plates at a cell density of 8,000 cells/well in triplicate, and cultured in
osteoinductive conditions, as described in the methods. The cells were treated with
zoledronic acid at different concentrations (from 0 to 50 pM) and cultures'were "fed"
weekly with fresh medium containing zoledronic acid at the noted concentrations. The
release of free calcium from the matrix was achieved by treating the adherent cell layers
under acidic condition as described in the methods. Samples then were reacted with o-
cresol-phthalein-complexon and the colorimetric reaction was read af 570 nm. The
absolute calcium concentration was determined according to a standard curve for
calcium. Results were confirmed by measuring calcium levels using AAnalyst 300
Atomic Absorption Spectrometer. The results showed that lower levels of mineral
deposition were evident in the OB-like cells treated with zoledronic acid compared to
the negative control before day 28.In contrast, at day 35 a significantly (p<0.05, Êtest)
higher level of mineral formation was observed in the OB-like cells treated with
zoledronic acid at a concentration of 0.5 ¡rM in donor #l and donor #2. However, the
equivalent levels of mineral deposition were noted at day 35 in donor #3 in the presence
of 0.5 ¡rM zoledronic acid. The potential for mineral formation in OB-like cells was
significantly reduced when cells were cultured with zoledronic acid at concentrations
greater than 5 ¡rM in all three donors. As zoledronic acid induced cell death of OB-like
cells in a dose-dependent manner, calcium levels were noÍnalised to viable cell number
(panel B), and showed that zoledronic acid at a concentration of 0.5 ¡rM significantly
increased mineral formation in donor #1 and #2 (p<0.001, r-test). The morphology of
cells in culture was assessed at d35, photographed, and represented as C (negative











































































































































was used at concentrations between 5 and 25 ¡t}d, this resulted in a significant increase in
mineral formation (p<0.05). V/hen the data vrere noÍnalised to viable cells, the difference
was even more significant (p<0.005) and the trend was the same in the all three donors. It
also shown that a concentration of 10 ¡rM of zoledronic acid is the most suitable
concentration to enhance mineral formation in vitro (p<0.05).
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Figure 4.25. A single high-dose treatment of zoledronic acid enhances mineral
formation of OB-like cells. Osteoblast-like cells were established as described in figure
4.24. Iî contrast, cells were only treated with zoledronic acid at d0 at different
concentrations. The results showed that zoledronic acid at very low concentrations (0.05
and 0.5 pM) did not affect the mineral formation of OB-like cells. Zoledronic acid at
concentrations ranging between 5 and 25 ¡rM significantly increased mineral formation
C)<0.05, Êtest). When the data were noÍnalised to viable cell number, the difference
was more significant (p<0.005, Êtest) and the trend was the same in the all three donors.
Zoledronic acid at a concentration of 10 ¡rM was found to be the optimal concentration
in augmenting mineral formation (p<0.05, Êtest). The typical data of donor #3 before















































To date, zoledronic acid represents the most potent BP in suppressing bone resorption and
normalising serum calcium in patients with metastatic bone disease (Berenson et al.,200lb;
Body et al., 1999; Major et a1.,2001). In animal model studies, zoledronic acidwas found
not only to mediate a dose-dependent suppression of cancellous bone tumover and
resorption, but also augmented cancellous bone formation (Pataki et al., 1997). Moreover,
zoledronic acid was recently shown to enhance bone formation on a calcium sulphate bone
graft substitutes in a rabbit model of tibial fracture repair (Sharpe et a|.,2002).
The zoledronic acid-mediated increase in bone formation seen in animals and humans could
be attributed to the establishment of a positive bone balance between osteoblastic bone
formation and osteoclastic bone resorption. This is thought to occur bV (1) the diminution of
bone resorption by the inhibition of OC recruitment, proliferation, differentiation and
maturation , (2) the newly formed bone would be less likely to be remodelled and therefore
have more time to complete mineralisation, and (3) if the decrease in resorption depth at
individual remodelling sites is not coupled by a decrease in formation, the local bone balance
will be positive. Despite this, the underlying molecular mechanism of this enhanced bone
formation at the level of the OB, is not clearly understood. As such, this study was designed
to explore the effect of zoledronic acid on cultures of human OB-like cells at both a
molecular and cellular level.
Ow in vitro s1¡idies show that zoledronic acid caused a dose and time-dependent decrease in
human OB-like cells (refer to figure 4.114.2). This observation is consistent with the work of
Reinholz and colleagues who demonstrated that zoledronic acid induced cell death and
cytostasis in the immortalised human fetal OB (hFOB) cells (Reinholz et al., 2000)'
Although our studies and studies by others (Reinholz et a1.,2000) show that BPs induce
clostasis and cell death, other studies have shown that BPs can inhibit apoptosis of murine
osteocytes and OB mediated by etoposide, TNF-u or glucocorticoid (Plotkin et al., 1999)'
Meaningful comparisons between these data are difficult, as the experimental systems used
here are dramatically different and as such these opposing effects may be, in part, due to
differences in the cell types, duration of treatment, the BP analogues, and the concentrations
of BPs used in these experiments.
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The zoledronic acid-induced reduction in OB-like cell number was due to the combination of
cytostasis (inhibition of proliferation) and cell death. Staining of nuclei with the nuclear
fluorescent stain DAPI, demonstrated morphological changes characteristic of apoptosis
including chromatin condensation, nuclear fragmentation and formation of dense, round
apoptotic bodies in a small number zoledronic acid treated OB-like cells (refer to figure 4.3).
Despite this, the reduction in cell number was mainly due to an inhibition of cell proliferation
(refer to figure 4.11). Assessment of the induction of intranucleosomal DNA fragmentation
as assessed by gel electrophoresis (refer to figure 4.4), supported this observation. In
addition, the induction of apoptosis in OB-like cells by zoledronic acid was assessed by
monitoring caspase-3 activity. Although the caspase activity was relatively low compared to
the other cell lines, zoledronic acid did significantly enhance caspase 3 activation (refer to
figure 4.5). Therefore, it is conceivable that the cell death in all OB tested may be a late event
following zoledronic acid treatment. Although it is established that caspase-regulated
apoptosis is at least one entity of programmed cell death (PCD), it has also been reported that
non-apoptotic PCD with necrotic-like cell appearance can be regulated independent of
caspases by c-Myc, dexamethasone and ceramide (Mochizuki et al., 2002). Therefore, it is
likely that zoledronic acid induces a combination of apoptosis, and non-apoptotic PCD in the
OB-like cells in vitro.
To date, numerous studies have failed to determine how BPs reach the OB in vivo. Although
BPs may come directly from the general circulation after their administration, they are also
released from bone into the microenvironment of OB, either by passive diffusion or
following resorption. In addition, under pharmacological conditions, the concentration of BPs
encountered by OB in vivo is unknown. As such, it is difficult to design in vitro experiments
that can directly correlate to physiological conditions. Using a mouse model, Sato et al
(1991) reported that half of the bone forming surface had a moderate deposition of BPs, with
one fifth the density compared to the BP deposition on the bone resorption surface (Sato e/
at., I99I). The high concentration of BPs in the space beneath resorbing OC, in vivo, is due
to OC-induced acidification of the bone surface. The high local concentration declines
immediately when the bone resorption is completed. Therefore, it is reasonable to assume
that the concentration of BPs to which OB are exposed would be lower than that encountered
by OC. In time, the BP containing bone will be "buried" under newly formed osteoid (Sato e/
al., I99l), supporting the notion that osteoblastic exposure to BPs will be limited. As such,
15
most of the studies detailed here, made use of a concentration of 5 pM zoledronic acid, as
this was shown to mediate a measurable effect on the OB phenotype.
Osteoblasts produce most of the bone matrix constituents and enhance new bone formation.
As we have shown before, zoledronic acid induced OB-like cell death in a dose-dependent
manner. Therefore, this decrease in OB cell number would conceivably result in a loss of
bone mass. On the other hand, the increase in bone mass and strength in an animal model
(Balena et al., 1993) and human systems (Rossini et al., 1994; Storm et al., 1993) led to the
assumption that BPs may enhance the maturity of OB, thereby increasing the bone density.
As described previously (refer to section 4.2.2), OB can be separated into four
subpopulations based on their stage of cellular differentiation. Using dual-colour
immunofluorescence and flow cytometric analysis, we examined the effect of zoledronic acid
on the differentiation of OB-like cells. Treatment of OB-like cells with 5 pM zoledronic acid
resulted in an increase in the number of STRO-174P- cells, with a concomitant decrease in
the number of STRO-l*/AP- cells in all cultures of OB-like cells tested (refer to figure 4.6).
This suggests that zoledronic acid may augment the maturation of OB-like cells by either
selectively inhibiting proliferation and inducing cell death in the OB precursor population
and/or by mediating the differentiation of the preosteoblast population. Although the
representation of each of the four subpopulations was found to be highly donor dependent,
this could not be attributed to the donor age or gender of the individual, from whom the cells
were derived. As described in the materials and methods, OB cultures from two donors were
from individuals diagnosed with osteoarthritis, whilst the remainder were from healthy,
young volunteers. Although there were differences in the response to zoledronic acid
treatment, these differences were restricted to the magnitude of the response but not in its
direction. These studies were confirmed by immunofluorescence and flow cytometric
analysis, which showed that zoledronic acid decreased both membrane and total cell ALP
protein expression (refer to figure 4.1,9). In addition, the dramatic decrease in cell surface
STRO-I expression following zoledronic acid treatment may be due to both a decrease in the
number of cells that express STRO-I andlor a decrease in the level of expression of this
protein at the cell membrane (refer to figure 4.I7).Interestingly, zoledronic acid did not alter
the total STRO-I protein expression in the cytoplasm, indicating that changes in membrane
protein expression may be due to enzymatic cleavage of STRO-I from the cell surface. In
support of this notion, examination of the expression of TACE (ADAM I7), a membrane
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metalloprotease, revealed that the loss of STRO-I protein from the cell membrane was
preceeded by an elevation in TACE expression (refer to figure 4.21). These data suggest that
STRO-I may represent a membrane protein belonging to a small cohort of proteins cleaved
by this eîzyme, which include TNF RI/II, IL-IRII, TNF-c, TGFa, amyloid-beta precursor
protein (APP) and RANKL.
In order to investigate whether the apparent selective reduction in the STRO-I population
seen following zoledronic acid treatment, was due to inherent difference in the sensitivity of
the STRO-lbrieht OB-like cells to this agent, dual colour immumofluorescence and flow
cytometric analysis was performed examining the expression of Ki-67 in combination with
STRO-I. The expression of the human Ki-67 protein is strictly associated with cell
proliferation, and during interphase the antigen can be exclusively detected within the
nucleus, whereas in mitosis most of the protein is relocated to the surface of the
chromosomes. Ki-67 can be used to analyse those cells which are in the so-called growth
fraction, as Ki-67 protein is present during all active phases of the cell cycle (Gr, S, Gz and
mitosis), but is absent from resting cells (Go, or so-called "quiescent" cells) (Scholzen and
Gerdes, 2000). Our data revealed that the majority of the OB-like cells were actively
dividing. 
.When 
compared with the control, zoledronic acid appeared to inhibit cell division,
and moreover resulted in the emergence of a population of cells with low forward and side
scatter in a time-dependent manner. These cells were found to express STRO-I antigen at
high levels and lacked measurable Ki-67 expression (refer to figure 4.7). This suggested that
cells that express STRO-I at high levels, may be more sensitive to zoledronic acid and the
Ki-67 negative cells in this case may represent quiescent cells or cells undergoing apoptosis.
This was further examined using three-colour flow cytometric analysis.
The human OB-like cells at different stages of the cell cycle were analysed using the nuclear
stain, 7-AAD. In combination with STRO-I and ALP, this enabled us to examine the cell
cycle status of the cells at different stages of osteoblastic maturation. One limitation
encountered in these studies, was the inability to resolve those cells in Go or G1, âS these cells
contain the same nuclear content. These studies revealed that zoledronic acid reduced the
number of cells in S and Gzllli4 phase, and the stage of cell cycle was not related to the extent
of ALP expression by the OB-like cells. In contrast, the majority of cells expressing STRO-1
antigen at high levels were distributed in the S and GzlM phases, suggesting that zoledronic
acid preferentially induced quiescence and cell death in these populations (refer to figure
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4.8). These data therefore suggest that STRO-lbricht cells are more susceptible to zoledroic
acid induced cell death due to their enhanced proliferative potential.
To further examine the preferential induction of cell death in the STRO-1b'icht population, the
STRO-lb'icht and STRO-ln"cutiu' subpopulations of OB-like cells were sorted by a
FACStaTPLUS cell sorter and the proliferative potential assessed using V/ST-1. As anticipated,
the STRO-lb'isht cells were more sensitive to zoledronic acid than STRO-lnesative cells (refer
to figure 4.9).
To further examine if the growth rate of cells contributed to their sensitivity to zoledronic
acid, OB-like cells were labelled with CFSE to track cell division over different periods of
culture. To our knowledge, we have shown here for the first time that STRo-lb'icht cells
possess a greater proliferative potential than the STRo-ln"cative/dim subpopulation (refer to
figure 4.10). These data confirmed our previous findings that the most STRO-lbricht cells had
a greatt proliferative potential and were mainly distributed in the S and Gzlll4 phase of the
cell cycle. Furthermore, zoledronic acid inhibited cell division in a dose-dependent manner,
accompanied by a dramatic decrease in STRO-I expression on the cell surface (refer to figure
4.ll). This reduction in STRO-1 expression may be due to the induction of quiescence. In
support of this notion, when the cell proliferation was inhibited with the spindle poison,
colchicine, the expression of STRO-I was also decreased. This suggests that the cells may
lose their STRO-I surface expression when cell division is inhibited. Our results suggest that
cel| division was totally inhibited by zoledronic acid a the concentration of 5 pM at d3 and
d5. Surprisingly, at d7, approximately l2Yo cells of these cells underwent their first division,
which was accompanied by the resumption of STRO-1 expression. This suggests that OB-
like cells may start to recover from the effect of zoledronic acid by either decreased drug
exposure due to drug consumption/breakdown or by up regulating the expression of
molecules, which are essential for cell proliferation and maturation.
For this reason, gene expression of both osteoclastogenesis and osteoblastogenesis-related
molecules were investigated in our studies (refer to figure 4.12). Our data revealed that the
expression of TNF-c and IL-l8 was decreased in the negative control in a time-dependent
manner. Interestingly, these genes were significantly upregulated in OB-like cells following
treatment with 5 pM zoledronic acid, particularly in donor #3, which was the most sensitive
donor. This increased expression of TNF-cr and IL-lÞ may be due to the zoledronic acid-
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induced decrease in cell density due to the induction of cytostasis and cell death. As
described in the chapter 3, TNF-ø is a multifunctional cytokine which can mediate apoptotic
cell death or induce cell proliferation depending on the cell cycle status (Baxter et a1.,1999).
Furthermore, TNF-o plays an essential and dual role in bone remodelling, both stimulating
the proliferation of OB or inducing OB apoptosis (Hill et al., 1997). The effects of TNF-o on
osteoclastic resorption of mineralised matrix are dependent on the stage of OC development
and the concentrations applied (van der Plurjm et a1.,1991). IL-l8 is a key proinflammatory
mediator implicated in the pathogenesis of various diseases associated with bone loss, such as
osteoporosis, tumour-associated osteolysis, and rheumatoid arthritis. IL-lB, a survial factor
for OC, acts through the release of soluble factors from OB and other marro\M cells. The
biological effect of IL-lp on bone, depends on complex interactions with many factors,
including IL-l receptor antagonist secreted by OB, and IL-l receptors expressed by OC
(Sunyer et al.,1999).
Although TNF-a and IL-lp have been shown to stimulate OC-like formation in human
maffow cultures (Lader and Flanagan, 1998), these cytokines are not capable of substituting
M-CSF in stimulating human OC formation (Fujikawa et a|.,2001). Hence, it is more likely
that these cytokines act in the marrow microenvironment to enhance M-CSF-stimulated OC
formation. Two recent reports demonstrating that TNF-c¿ was sufficient to stimulate cultures
of bone marrow macrophages to differentiate into OC independent of RANKL-RANK
interaction, frày be confounded by contamination with minute concentrations of RANKL
(Azumaet a1.,2000; Kobayashi et a1.,2000). In support of this, in stromal-free cultures of
maffow derived macrophage precursors in the presence of saturating concentration of OPG,
TNF-cr by itself, failed to induce differentiation of OC (Lam et a|.,2000). Although previous
studies have established the importance of OC activation by clokines including IL-lB, TNF-
cr and IL-6, the role of these cytokines on OB development of bone loss requires further
clarification.
In our studies, the roles of TNF-cr and IL-18 induced by zoledronic acid are more likely to
rescue OB and compensate for the decrease in cell number. Although some reports suggest
that TNF-c¿ directly mediates the apoptosis of murine OB (Kitajima et al.,l996a;Kitajima et
al., I996b), we could not detect any cell death in human OB-like cells after treatment with
IL-18 and TNF-cr, consistent with the findings of others (Kwon et al., 1998; Tsuboi et al.,
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1999). Furthermore, we found IL-lP and TNF-cr at a concentration of 10 nglml and 5 nglml,
respectively, gave rise to an increase in the STRO-I*/ALP* subpopulation (refer to figure
4.22), which we have shown previously to possess greater proliferative rate than other
subpopulations (refer to figure 4.23). This supported our hypothesis that the upregulation of
TNF-cr and IL-l8, induced by zoledronic acid represents a mechanism, by which OB-like
cells may overcome the growth suppression effects of zoledronic acid.
It is well known that OB control the recruitment and activity of OC under physiological and
pathological conditions. The inhibitory effect of BPs on osteoclastic bone resorption may be
mediated, at least in part, by the regulation of the production of cytokines synthesised by OB.
It was reported that BPs inhibit OC-stimulating factors such as IL-6 (Giuliani et a1.,1998b)
and induce Oc-inhibiting factors (Nishikawa et al., 7996; Yitte et al., 1996) released by the
OB. Under physiological or pathological conditions, IL-6 is released mainly in response to
stimulating factors, including IL-18 and TNF-cr. Although there was an apparent increase in
IL-1P and TNF-c¿ gene expression observed in our studies, there was no significant change
in IL-6 and M-CSF gene expression. It is important to consider that the studies reported here
only examined expression at the genetic level. Future studies examing IL-6 and M-CSF
protein expression are required and should provide us with a more complete understanding
about the regulation of IL-6 and M-CSF expression by zoledronic acid.
The RANKL/RANK/OPG system is considered to mediate the final common step in OC
formation. RANKL promotes the differentiation of OC precursor cells to OC through the
RANK receptor expressed on the OC precursor cells. OPG acts as a decoy receptor that
negatively regulates the signalling between RANKL and RANK. It was found that IL-lp and
TNF-cr, but not IL-6, could stimulate RANKL gene expression in human osteoblastic cells
(Hofbauer et al., 1999). Although zoledronic acid treatment led to an upregulation of IL-l8
and TNF-cr gene expression in our studies, we did not find a significant change in RANKL
and OPG expression at the transcriptional level (refer to figure 4.13). In contrast, at the
protein level, our data suggest that zoledronic acid treatment leads to a significant decrease in
the membrane expression of RANKL on human OB-like cells, without a commensurate
decrease in total protein expression (refer to figure 4.18). This is consistent with the findings
of Mackie and colleagues who demonstrated that RANKL mRNA was down-regulated by the
BP, pamidronate, in the rat osteosarcoma cell line UMR 106-01 (Mackie et a1.,2001). In
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agreement with their findings, we also did not detect any alteration in OPG gene expression.
Thus, we conclude that BPs also can exert an anti-resorptive effect via a decreased
RANKL/OPG ratio.
As discussed previously, RANKL is a type II membrane-anchored polypeptide, which is
released from the plasma membrane by tumour necrosis factor alpha converting eîzpe
(TACE) (Lum et al., 1999). Soluble and truncated RANKL arc important components in
pathological bone loss (Quinn et al., 1998; Udagawa et al., 1999). Although the decreased
RANKL expression in OB-like cell surface may due to the decreased sythesis of this protein,
it is also possible that zoledronic acid treatment leads to the upregulation of TACE
expression and activity leading to the loss of membrane RANKL expression. Examination of
the expression of TACE (ADAM 17) revealed that the loss of RANKL protein from the
membrane was preceeded by an elevation of TACE expression on dl, d3 following
zoledronic acid treatment (refer to figure 4.21). Similary, expression of STRO-I on the
membrane was also significantly down regulated following zoledronic acid treatment (refer
to figure 4.17). This was not associated with an alteration in total STRO-I protein expression
in the cytoplasm, indicating that like RANKL, changes in STRO-I membrane expression
may also be due to enzymatic cleavage. Interestingly, the resumption of STRO-I expression
at d5 and d7 following zoledronic acid treatment is correlated with a decrease in TACE
expression to baseline levels of TACE expression at d5.
The discovery of the DNA-binding protein CBFA1 has provided a marker of early osteogenic
commitment (Ducy et al., 1997; Komori et al., 1997; Rodan and Harada, 1997). CBFA1
belongs to the runt-domain gene family and has been specifically associated with
osteogenesis in rodents. The precise function of CBFA1 is unknown, but it is thought to
regulate the OB-specif,rc genes. Although our results indicated that BSP and OCN gene
expression v/as upregulated by zoledronic acid in the OB-like cells derived from donor #3,
there was no alteration in CBFA-I expression at the transcript level (refer to figure 4'14). At
the protein level, zoledronic acid was found to upregulate the expression of OCN at dl and
d3 at both the transcript and protein level (data not shown).
As discussed above, OB can be separated into four subpopulations based on the stage of
differentiation. Previous studies (Gronthos et al.,1999) have shown that OB at diffeent stages
of development exhibit differential gene expression. Our studies show that zoledronic acid
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dramatically alters the expression of a number of genes, especially in the zoledronic acid
sensitive donors. It was therefore thought that these large changes in gene expression may be
due to changes in the relative proportions of these subpopulations following zoledronic acid
treatment. To exclude this possibility, the STRo-lb'icht and STRo-1n"cutiu" cells were sorted
by FACStaTPLUS cell sorter and their incident gene expression profile was determined.
Interestingly, the gene expressions in these two subpopulations are similar (refer to figure
4.15). However, the difference between the two populations emerged when the cells were
cultured in the media for three days in the presence or absence of zoledronic acid (refer to
figure 4.16). As expected, the STRO-ln"cutiu' subpopulation was found to express more OCN
and BSP than the STRo-lb'icht subpopulation, consistent with their stage of differentiation.
Zoledronic acid increased OCN and BSP expression in STRO-lb'ish' cells indicating that
zoledronic acid may "drive" STRo-lb'icht cells to differentiate into more mature OB.
Furthermore, STRO-lb'ish'cells were found to express more IL-IP and TNF-a than the
STRO-1n"cuti"' subpopulation, suggesting that the upregulation of IL-18 and TNF-cr in the
whole population could not be attributed to a decrease in the proportion of STRO-1b'isht cells.
Of note, the middle population which display intermediate levels of STRO-1, express the
highest level of COX-2, whilst the STRO-lb'ishtcells express the least amount of COX-2.
Zoledronic acid only increased COX-2 expression in the STRO-lb'icht subpopulation, which
may facilitate the proliferation of STRO-lbrieht cells. As expected, there was no significant
difference in IL-6, M-CSF, OPG and CBFA-I expression among the different
subpopulations. In terms of RANKL, zoledronic acid increased RANKL expression in the
STRo-lb'icht subpopulation whilst it was decreased in the STRO-1"'su'u" subpopulation. It
should be noted that the results presented herein were generated from cells isolated by FACS
and cultured separately in the absence of cells at other stages of differentiation, which may
significantly alter the pattern of gene expression seen in a mixed culture.
A previous report suggests that zoledronic acid can enhance the rate of mineralisation of
viable immortalised human fetal OB (hFOB) cells (Reinholz et al., 2000). Consistent with
this finding, our data suggest that zoledronic acid at a concentration of 0.5 pM increases
mineral formation in OB-like cells at day 35. However, the potential for mineral formation in
OB-like cells was decreased when the cells were cultured with zoledronic acid at
concentrations exceeding 5 ¡rM. It should be noted that in these experiments, the cells were
subjected to fresh zoledronic acid every week for the entire 35 day period. As we discussed
previously, zoledronic acid induces cell death in a dose dependent manner, and therefore the
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cell number in the zoledronic acid treated groups was substantially lower than that in the
untreated control group. This suggests that the viable single cells have gteater potential for
mineral formation when cultured in the presence of zoledronic acid. When the data was
normalised to the viable cells number, there was a significant increase in mineral formation
when the cells were treated with 0.5 pM of zoledronic acid. The potential for mineral
formation in OB-like cells was decreased when the cells were cultured with zoledronic acid
at concentration exceeding 10 pM in all donors (refer to 4.24). However, when the cells were
only treated with zoledronic acid once during the whole period of the mineralisation assay, it
was evident that zoledronic acid at low concentrations (<0.5 ¡.rM) had no significant effect on
the mineral formation of human OB-like cells in vitro.In contrast, a significantly higher level
of mineral formation was observed in the OB-like cells treated with zoledronic acid at a
concentration between 5 pM and25 prM. Of note, 10 pM zoledronic acid was found to be the
optimal concentration which enhanced the mineral formation in the OB-like cells (refer to
4.25). Taken together, we can therefore conclude that zoledronic acid at concentrations
between 5 pM and 25 ¡rM can significantly augment mineral formation. It should be
emphasised that zoledronic acids inhibits cell proliferation and induces cell death in a
proportion of cells, therefore leading to the conclusion that the increased mineralisation
potential is due to an increase in the number of mature OB. This may clarify an additional
observation that BPs can mediate a biphasic effect on the formation of bone-like nodules,
with a dose-dependent stimulation at lower concentrations and an inhibitory effect at higher
concentrations (Giuliani et al., 1 998a).
Taken together, our studies show that in addition to its effects on OC, zoledronic acid also
has direct effects on the proliferation and survival of OB-like cells in vitro. Out observations
support the notion that zoledronic acid is anabolic in bone by increasing the proportion of
differentiated OB and enhancing the bone-forming activities of these cells.
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CONCLUSIONS
This thesis presents several novel observations of the molecular and cellular mechanisms of
the way in which zoledronic acid effects myeloma cells and osteoblasts.
The reaction of the human body to a drug is complicated by the fact that different cell types
have distinct responses based on the concentrations to which they aÍe exposed.
Bisphosphonates are uniquely distributed to the bone matrix, by virtue of their affinity for
hydroxyapatite. Only cells in close proximity to the bone matrix will be affected by these
compounds. Three major cell types, namely osteoclasts, myeloma cells and osteoblasts would
therefore be affected in MM patients receiving bisphosphonate treatment. Our studies
indicate that in addition to inhibiting bone resorption, zoledronic acid can enhance bone
formation (figure 5. 1).
Zoledronic acid induces apoptotic and non-apoptotic cell death in myeloma cells by inducing
S phase arrest in a time and dose dependent manner and inhibiting the mevalonate pathway.
In addition, zoledronic acid upregulates the expression of TRAIL in myeloma cells and
induces cell death by uncoupling the regulation of the TRAIL death receptors and decoy
receptors. The uncoupling of TRAIL receptors may ultimately determine the sensitivity of
myeloma cells to zoledronic acid. The in vitro studies suggest that zoledronic acid represents
a potent agenl to reduce bone loss in patients with MM by inducing cell death in myeloma
cells, a source of numerous osteoclast-activating factors'
Zoledronic acid induces cell death in the osteoblast-like cells in a dose dependent manner.
Compared to the other subpopulations, STRO-I bisht osteoblast-like cells have a greater
proliferative potential and this may account for a gteater sensitivity to zoledronic acid by
blocking cell replication in S and GzlMphase in a dose-dependent manner. Zoledronic acid aI
the concentration of 5 pM leads to an increase in the number of STRO-1-/AP- (mature
osteoblast/osteocyte-like) cells, with a concomitant decrease in the number of STRO-l*/AP-
(stromal precursors) cells. Based on the ability of osteoblast-like cells to form mineralised
bone matrix and their expression of bone-associated matrix proteins, we found that a
proportion of STRO-I b'isht osteoblast-like cells differentiate into maturing osteoblast in the
presence of zoledronic acid. This is thought to account for the enhanced bone formation
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Figure 5.1. Zoledronic acid augments bone formation by acting on three major cell
t1pes, namely osteoclasts, myeloma cells and osteoblasts in patients with MM.
Zoledronic acid inhibits bone resorption not only by inducing apoptosis of osteoclasts
but also by inhibiting osteoclast-activating factors s¡mthesised by myeloma cells and
osteoblasts. It also affects osteoblasts directly by expanding and maturing osteoblasts to






























observed. Our studies showed that zoledronic acid optimally increased bone formation at a
concentration of 10 ¡rM. We demonstrate that zoledronic acid is able to upregulate IL-l8 and
TNF-g expression in osteoblast-like cells. Culturing osteoblast-like cells in recombinant
human IL-1P and TNF-cr increase the number of STRO-1*/AP* osteoprogenitors, which in
the presence of zoledronic acid may also differentiate into maturing and functional
osteoblasts. Furthermore, zoledronic acid was found to decrease the expression of RANKL
on the osteoblast-like cell surface possibly by upregulating TACE expression, which may
also be responsible for the decrease in STRO-1 expression on the cell surface.
Taken together, zoledronic acid inhibits bone resorption not only by inducing apoptosis of
osteoclasts but also by inhibiting osteoclast-activating factors synthesised by myeloma cells
and osteoblasts. It also affects osteoblasts directly by expanding and maturing osteoblasts to
enhance osteoblastic bone formation. This represents the first study to provide evidence that
zoledronic acid directly augments bone formation in vitro'
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